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INTRODUCTION 
 
Glycogen synthase kinase-3 (GSK-3) has became one of the most attractive therapeutic targets for 
the treatment of diabetes,[1-4] inflammation,[5,6] multiple neurological diseases including 
Alzheimer,[7-10] amyotrophic lateral sclerosis (ALS),[11] Parkinson,[12,13] stroke,[14,15] bipolar 
disorders[16-18] and it is known as an important component of different signaling pathways involved 
in the regulation of cell fate, protein synthesis, cell mobility, proliferation and survival.[19-23] 
GSK-3 is a multifunctional serine / threonine (Ser / Thr) kinase, originally found in mammals, and 
homologues have been found in all eukaryotes. There are two mammalian GSK-3 isoforms, 
encoded by distinct genes: GSK-3α (51 kDa) and GSK-3β (46 kDa). The two isoforms are highly 
conserved within their kinase domain but greatly differ at the C-terminal domain (only 36% of 
identity), while the α isoform additionally contains an extension N-terminal glycine-rich. Despite 
the high degree of similarity (they share 85% overall sequence homology, including 98% amino 
acid sequence identity within their kinase domains),[24] the two isoforms of GSK-3 are not 
functionally identical and they have different substrate specificities in the brain and as well as in 
other tissues.[25] Several studies show that GSK-3β knock-out mice die around embryonic day 16 
due to liver degeneration caused by hepatocyte apoptosis.[26] Furthermore, GSK-3β activity was 
essential for NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation 
induced by TNF-α (tumor necrosis factor alpha) in hepatocytes. In contrast, GSK-3α knock-out 
mice are viable but exhibited enhanced glucose and insulin sensitivity and reduced fat mass. GSK-
3α knock-out mice elicited metabolic and neuronal developmental abnormalities,[27,28] also 
demonstrating the involvement of GSK-3α in age-related diseases and in promotion the production 
of β-amyloid peptide and formation of senile plaques in Alzheimer's disease models.[29] 
Thus, GSK-3 isoforms exhibit tissue-specific physiologically important functions which may not be 
overlapping and may be different. Most biochemical studies have focused on GSK-3β 
demonstrating its role in differentiation, cell growth, cell cycle progression and apoptosis. It is 
known, in fact, that the dysregulation of GSK-3β has been implicated in tumorigenesis and cancer 
progression.[30,31] 
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GSK-3β is composed of 12 exons in humans and 11 exons in mice with the ATG start codon 
located within exon 1 and the TAG stop codon found in the terminal exon. The gene product is a 
protein of 46 kDa consisting of 433 amino acids in the humans and 420 amino acids in the mice. 
GSK-3β is similar to other Ser / Thr kinases and consists of three distinct structural domains. The 
N-terminal domain is comprised of the first 134 amino acid residues and it forms a 7-strand β-barrel 
motif. A small linker region consists of the amino acid residues 135-151 and it connects the N-
terminal domain to the central α-helical domain, which in turn is composed of the amino acid 
residues 152-342. The ATP binding site lies at the interface of the N-terminal and the central α-
helical domains. The C-terminal domain consists of amino acid residues 343-433 and it is outside of 
the classical Ser / Thr kinase core fold; these amino acid residues form a helix-loop domain that 
interacts with the core α-helical domain. The p53 association region and the basic domain region 
are both located in the N-terminal domain (Figure 1).[32] 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of glycogen synthase kinase-3β. 
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A minor (~15% of total) splice variant of GSK-3β, termed GSK-3β2, has recently been identified, 
which contains a 13 amino acids insert within the kinase domain. An antibody selective for the 
novel splice insertion polypeptide revealed that GSK-3β2 is localized primarily to neuronal cell 
bodies, unlike unspliced GSK-3β that is also found in neuronal processes. Given the location of the 
insert within a highly conserved sequence, the splice-encoded peptide likely forms a loop / hook, it 
may allow differential binding of the splice variant to scaffolding proteins exposing the isoform to a 
distinct subset of target proteins.[33,34] However, GSK-3β1 and GSK-3β2 have regulation 
mechanisms and ATP binding properties similar, being both phosphorylated to a similar extent at 
the regulatory sites, serine 9 (Ser 9) and tyrosine 216 (Tyr 216), and showing identical sensitivities 
to the ATP-competitive inhibitors.[35] 
GSK-3β has traditionally been considered as a predominantly cytosolic protein, however, it was 
recently shown that smaller but much more active pools of GSK-3β are present in the nucleus and 
mitochondria,[36] as well as in other subcellular compartments, which its levels and / or activation 
state can be regulated by localized signaling activities. Unlike most protein kinases, GSK-3β is 
constitutively active in resting cells and undergoes a rapid and transient inhibition in response to a 
number of external signals. GSK-3β activity is regulated by site-specific phosphorylation: full 
activity of GSK-3β generally requires phosphorylation at Tyr 216 residue, located in the kinase 
domain, and conversely, phosphorylation at amino-terminal Ser 9 residue leads to its inactivation 
through proteosomal degradation. GSK-3β is subjected to multiple regulatory mechanisms and 
phosphorylation of Ser 9 is probably the most important. Several kinases are capable of mediating 
this modification, including p70 S6 kinase (p70S6K),[37] extracellular signal-regulated kinases 
(ERKs), p90Rsk (also called MAPKAP kinase-1), protein kinase B (also called Akt), certain 
isoforms of protein kinase C (PKC),[38] and cyclic AMP-dependent protein kinase (protein kinase 
A).[39,40].Insulin treatment inactivates GSK-3β, an effect that is associated with Ser 9 
phosphorylation, and Akt was identified as the major kinase mediating this response to insulin.[41] 
Akt is activated by a signaling cascade involving phosphatidylinositol-3-OH kinase (PI3K), 3-
phosphoinositide-dependent kinase-1, and likely other kinases as well, notably integrin-linked 
kinase that may also directly phosphorylate GSK-3β. Stimulation of certain receptors, such as the 
insulin receptor (insulin-like growth factor 1 receptor, IGF-IR), activates this signaling cascade 
leading to activation of Akt, which in turn, it phosphorylates Ser 9 of GSK-3β with inhibition of its 
activity. Some studies report that potential lethal stressors can cause failure of Akt activation with 
an increase in the active form of GSK-3β[11] which plays positive roles in cell proliferation and its 
aberrant expression promotes various tumor types including melanoma, glioblastoma, and lung, 
breast, ovarian, prostate, colon, liver, stomach and pancreatic tumors.[42-45]  
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Moreover, GSK-3β activity is often shut off after exposure to mitogenic / growth factors, in fact, 
epidermal growth factor (EGF), platelet derived growth factor (PDGF) and other growth factors 
also induce the phosphorylation of GSK-3β (Ser 9) through the PI3K pathway as well as through 
induction of the Raf-MEK-ERK-p90Rsk1 signaling pathway.[46] 
Elucidation of the crystal structure of GSK-3 has helped to reveal how the phosphorylation of GSK-
3β at Ser 9 results in its inhibition. When Ser 9 of GSK-3β is phosphorylated, a primed 
pseudosubstrate is created which folds and binds the positively-charged pocket of the kinase, 
formed by basic residues Arg 96 (R96), Arg 180 (R180) and Lys 205 (K205). This folding prevents 
the phosphorylation of substrates as the catalytic groove is blocked. This is a competitive 
mechanism of inhibition and if elevated concentrations of the primed substrates are present, they 
will out-compete the pseudosubstrate and the substrates will be phosphorylated.[47] Arg 96 of GSK-
3β is a critical component of the positive pocket which binds primed substrates. Mutation of Arg 96 
(R) to Ala 96 (A) (R96A) has consequences on the ability of GSK-3β to phosphorylate primed 
versus unprimed substrates. Priming of substrates usually occur N+4 from the site where GSK-3β 
phosphorylates the substrate. The R96A mutation disrupts the GSK-3β pocket of positive charge 
and prevents the phosphorylation of the primed substrates, that can not longer bind, resulting in the 
maintenance of enzyme activity and the phosphorylation of unprimed substrates even when GSK-
3β is phosphorylated at Ser 9.[25,48] 
In opposition to the inhibitory modulation of GSK-3β that occurs by serine phosphorylation, 
tyrosine phosphorylation of GSK-3β increases the enzymatic activity by providing access to the 
catalytic site of the protein.[49] Stimulation of GSK-3β (Tyr 216) is reported to be mediated by GSK-
3β itself (intramolecular autophosphorylation leads to the stabilization of the enzyme),[50,51] by 
proline-rich tyrosine kinase 2 (PYK2),[52] a calcium-dependent tyrosine kinase, and by Fyn, a 
member of the Src tyrosine family that regulates important processes of growth and cell motility.[53] 
PYK2 is a member of the focal adhesion kinase (FAK) family and it is most abundant in the central 
nervous system and hematopoietic cells; it is activated by intracellular calcium increases such as 
those induced by G-protein receptor activation, membrane depolarization, stress stimuli, and growth 
factors and it has been implicated in intracellular signaling events, in synaptic plasticity, neurite 
outgrowth and apoptosis.[52] PYK2 controls lysophosphatidic acid-induced activation of GSK-3β, 
which regulates the phosphorylation of microtubule-associated proteins with consequent regulation 
of the neuronal architecture. PYK2-mediated activation of GSK-3β is initiated by 
phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis and may serve to destabilize microtubules 
during actomyosin-driven neurite retraction, demonstrating the role of this kinase in neuronal 
development.[54]  
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In addition, PYK2 stabilizes the β-catenin by phosphorylation of GSK-3β (Tyr 216), and the 
dysregulation of expression of FAK / PYK2 causes increased activity of kinase with promotion of 
Wnt / β-catenin pathway, accumulation of β-catenin and intestinal tumorigenesis.[55] 
The Src family kinases (SFKs), which include Fyn, cSrc, Yes and Lyn, are also required for the 
phosphorylation of the Tyr 216 residue of GSK-3β and their dysregulation leads to increased kinase 
activity, found in highly aggressive prostate cancer cells. It has been demonstrated that the 
treatment with GSK-3β inhibitors decreases cell survival, proliferation, migration, invasion and 
micrometastasis of prostate cancer cells as well as of many other types of cancer, in which GSK-3β 
acts as a tumor promoter.[53] GSK-3β is also subjected to the regulation of mitogen-activated protein 
kinase like MEK 1/2, and to the regulation of different apoptotic stimuli (heat shock proteins and 
staurosporine). They induce Tyr 216 phosphorylation on GSK-3β with a dynamic increase of its 
nuclear levels, favoring in this manner the interaction with its nuclear substrates.[43] 
The activity of GSK-3β may also be regulated by phosphorylation of other amino acid residues that 
are part of the protein, for example, p38 mitogen-activated protein kinase (p38MAPK) 
phosphorylates the Thr 390 residue of the C-terminal domain reducing its activity as well as 
contributing to the canonical Wnt signaling and to the regulation of kinase substrates, such as β-
catenin. This is of particular interest because the Thr 390 amino acid residue is not conserved in 
GSK-3α and thus it provides a potential GSK-3β isoform specific regulation.[56,57] In addition, ERK 
phosphorylates the residue Thr 43 of GSK-3β, resulting in its subsequent phosphorylation at Ser 9 
by p90Rsk and in its inhibition.[58] Finally, protein phosphatases (eg, PP2A, PP1) have important 
roles in regulation of GSK-3β activity by removing the phosphate on Ser 9 as well as other 
regulatory residues.[59] 
The majority of GSK-3β substrates exhibit an absolute requirement for prior phosphorylation by 
another kinase at a “priming” residue, located at C-terminal level differing from the site of 
subsequent phosphorylation by GSK-3β. GSK-3β-catalyzed phosphorylation of these substrates 
occurs at the fourth serine or threonine residue N-terminal to the primed site (pS/T1-XXX-pS/T2), 
where the first pS/T1 (Ser or Thr) is the target residue, X is any amino acid (but often Pro), and the 
last pS/T2 is the site for priming phosphorylation. Thus, the primed Ser / Thr is recognized by the 
positively charged “binding pocket” on GSK-3β, formed by basic residues Arg 96 (R96), Arg 180 
(R180), and Lys 205 (K205), which facilitates the correct orientation of the substrate within the 
active site of the kinase (Figure 2).[23] 
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Figure 2. Regulation of GSK-3β. 
 
Several protein kinases have been shown to act as priming enzymes for GSK-3β phosphorylation, 
including cyclin-dependent kinase 5 (CDK-5), protease-activated receptor 1 (PAR-1), casein 
kinase-1 (CK1), casein kinase-2 (CK2), protein kinase C (PKC), 5’ adenosine monophosphate-
activated protein kinase (AMPK). In the case of several substrates, the residue phosphorylated by 
GSK-3β acts to prime an additional Ser / Thr residue N-terminal to it. This can lead to a zippering 
effect where multiple residues become phosphorylated by GSK-3β. However, not all substrates 
require prior phosphorylation for recognition by GSK-3β, including members of the myc family of 
transcription factors. This category of substrates can contain acidic residues or peptide 
conformations that may be recognized by GSK-3β, thus substituting for the effect of the priming 
phosphate.[46] 
More than forty proteins are substrates of GSK-3β, and these proteins have roles in a wide spectrum 
of cellular processes, including glycogen metabolism, transcription, translation, cytoskeletal 
regulation, cell differentiation, proliferation and apoptosis.  
GSK-3β plays an important role in the degradation of the cyclin D1 through phosphorylation of the 
Thr 286 residue and in the degradation of the cyclin E through phosphorylation of the Thr 380 
residue, thus promoting cell cycle progression. Cyclin D1 is synthesized early in G1 phase and it 
plays a key role in the initiation and progression of this phase, as well as, in the G1 / S transition of 
the cell cycle.[60] During G1 phase, cells need to make a decision whether advancing toward another 
division or withdrawing from the cell cycle into the quiescence phase (G0) in response to 
extracellular signals. The point at which this decision is made is called a restriction point. Cyclin D1 
acts as a mitogenic signal sensor and forces cells to enter the proliferative cycle from G0 phase. 
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Cyclin D1 forms a complex with the cyclin-dependent kinases (CDKs) 4 and 6 and functions as a 
regulatory subunit of them. The cyclin D1 / CDK4-6 complexes are phosphorylated by CDK-
activating kinase (CAK) leading to their activation and translocation to the nucleus. The main role 
of the cyclin D1 / CDK4-6 complexes in cell cycle control is the phosphorylation of retinoblastoma 
protein (Rb) mediation. Rb serves as a gatekeeper of the G1 phase, since Rb inhibits cell cycle 
progression through its ability to repress E2F transcriptional activity. Partially phosphorylated Rb 
still binds to E2F, but the transcription of some genes, such as cyclin E, induces its activation. 
Cyclin E binds to and activates CDK2, resulting in the phosphorylation and release of Rb from E2F, 
thereby E2F induces the expression of target genes whose functions are important for S phase entry 
and passage through the restriction point leads to DNA synthesis. When cells enter S phase, cyclin 
D1 is rapidly degraded by ubiquitin-proteasome-system and this proteolysis is triggered by 
phosphorylation made by GSK-3β, that leads to association of cyclin D1 with CRM1 
(Chromosomal Maintenance 1, also known as Exportin 1), a nuclear protein that mediates the 
export of proteins from nucleus to cytoplasm to initiate their proteasomal degradation.[61] 
In addition to phosphorylate cyclin D1 (Thr 286), GSK-3β collaborates with CDK2 to control the 
levels of cyclin E, because the regulation of cell cycle requires stringent controls on the amount and 
timing of cyclin E - CDK2 activity and hence on the amount and timing of cyclin E expression that 
it attains a maximum level in late G1 phase and a minimum in M and early G1 phases. GSK-3β and 
CDK2 kinases participate in cyclin E phosphorylation on Thr 380 and Ser 384, respectively, 
resulting in its nuclear export and degradation, so promoting the entry of the cell into S phase 
(Figure 3).[61,62] Thus, phosphorylation and proteolytic turnover of D1 and E cyclins and their 
subcellular localization during the cell division cycle are linked to the activity of GSK-3β,[63] whose 
aberrant expression with abnormalities in the regulation is involved in the development of 
cancer.[61,64] In particular, GSK-3β has been implicated to play roles in cancers which are resistant 
to chemo-, radio-, and targeted therapy.[65] Thus, targeting GSK-3β may be a means to overcome 
the resistance of these cancers to certain chemotherapeutic drugs, radiation and small molecule 
inhibitors.[30,31,66] 
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Figure 3. Schematic representation of the mammalian cell cycle and its regulatory molecules. The cell cycle 
progresses through four sequential phases, gap 1 (G1), synthesis (S), gap 2 (G2) and mitosis (M) phases. Passage 
through the cell cycle is controlled by cyclin / cyclin-dependent kinase (CDK) complexes and the timely activation of 
CDKs by the binding of partner cyclins is required. Cyclins are the regulatory subunits of CDKs, and each cyclin 
exhibits a characteristic pattern of expression and degradation. In lower panel, protein levels of cyclins throughout the 
progression of the cell cycle are shown. CDK, cyclin-dependent kinase; R, restriction point. 
 
 
In addition to the activity carried out on D1 and E cyclins, GSK-3β can also phosphorylate cyclin-
dependent kinase inhibitor p21 (Thr 57), resulting its proteasomal degradation.[67] p21 is a cell cycle 
regulatory protein that mediates various biological activities primarily by binding to and inhibiting 
the kinase activity of CDK2 and CDK1, leading to growth arrest at specific stages in the cell cycle. 
Furthermore, by binding to Proliferating Cell Nuclear Antigen (PCNA), p21 interferes with PCNA-
dependent DNA polymerase activity, thereby inhibiting DNA replication and modulating various 
PCNA-dependent DNA. Its expression is tightly controlled by the tumor suppressor protein p53, 
through which p21 mediates the p53-dependent cell cycle G1 phase arrest and might also promote 
apoptosis in response to a variety of stress stimuli.[68,69] 
GSK-3β has important regulatory roles on other transcription factors involved in cell cycle 
regulation, and the inhibition of this kinase causes cell cycle arrest at G1 phase with subsequent 
activation of cyclin-dependent kinase inhibitor p27,[70] a protein that prevents the activation of 
cyclin E - kinase 2 complex and regulates the passage of the G1 / S restriction point.
[71] 
Moreover, GSK-3β through cooperation with mTOR (mammalian target of rapamycin) positively 
regulates the activity of p70 S6 Kinase (p70S6K), a Ser / Thr kinase involved in cell survival, 
growth and proliferation by regulating protein synthesis, cell metabolism, glucose homeostasis, 
insulin sensitivity, cell cycle, and gene transcription.[72] 
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GSK-3β, together with the yeast protein Mck1, inhibits the activity of the major mitotic cyclin - 
kinase complex cyclin B - CDK 1, that accumulates before of the anaphase and once inhibited in 
telophase, cells can exit mitosis and enter into the next cell cycle.[73] GSK-3β is also involved in the 
regulation of Activator protein 1 (AP-1),[74] a heterodimeric transcription factor complex composed 
by a Jun family member and a FOS family member that it binds to the TRE DNA sequence (5′-
TGAGTCA-3′) and regulates gene expression in response to a variety of stimuli, including 
cytokines, growth factors, stress, bacterial and viral infections and it also controls a number of 
cellular processes including differentiation, proliferation, and apoptosis.[75] 
Moreover, GSK-3β has the ability to regulate c-Myc activity through phosphorylation at Thr 58 
residue, thereby regulating c-Myc rapid proteolysis by the ubiquitin pathway. The c-Myc protein is 
a basic / helix-loop-helix / leucine-zipper (bHLHZip) transcription factor that, together with its 
dimerization partner Max (also known as Myc-associated factor X), binds specific E-box sequences 
and exerts its oncogenic effects through regulation of genes involved with growth and proliferation 
cell. Thr 58 is a major phosphorylation site that strongly impacts on c-Myc functions and it is a 
mutational hotspot in Burkitt’s and other aggressive human lymphomas, indicating that Thr 58 
phosphorylation regulates the oncogenic potential of c-Myc. In addition to the effect on c-Myc 
proteolysis, phosphorylation induced by GSK-3β at Thr 58 alters the subnuclear localization of c-
Myc, enhancing its localization to discrete nuclear bodies. Thus, c-Myc functions are strictly 
dependent by GSK-3β activity[76] and a failure of the GSK-3β regulation results in a dysregulation 
of the c-Myc, frequently overexpressed in breast cancer,[77] as well as in a variety of human 
cancers.[78,79] 
GSK-3β positively regulates NFκB-mediated gene transcription and cell survival.[80] In a resting 
state, NFκB (p65 / p50) heterodimer is generally inactive and forms a complex with its inhibitory 
proteins IkBα (inhibitor kappa B-cells alpha) in the cytoplasm. GSK-3β regulates the activity of IkB 
kinase (IKK) and the activation of the latter leads to phosphorylation of IkBα, resulting in its 
proteasomal degradation, liberation and translocation of NF-kB into nucleus where it regulates gene 
expression involved in cell survival.[81] This explains the use of GSK-3β inhibitors in colon and 
pancreatic cancers, where it has been observed an uncontrolled activity by NF-kappa B,[82] whose 
role has been documented in the development of different solid malignancies and, considering its 
important role in immune cell function, hyperactive NF-κB is also frequently associated with the 
development of leukemia and lymphoma.[83] GSK-3β also regulates the activity of Snail, the 
transcription factor which represses E-cadherin transcription, a structural protein involved in the 
maintenance of the mechanical tissue balance. Phosphorylation of Snail made by GSK-3β leads to 
its cytoplasmic translocation with E-cadherin increased expression, generally found in oral 
10 
 
cancer.[84] In addition, stabilization of Snail protein, by increased GSK-3β phosphorylation, has also 
been observed during the epithelial-mesenchymal transition (EMT) in different types of solid 
tumors.[85,86] 
GSK-3β positively modulates Notch receptor signaling, through direct phosphorylation of its 
intracellular domain (NICD), protecting the latter from proteasome degradation.[87] Notch 
Intracellular Domain (NICD) not degraded, is activated and it translocates into the nucleus, thereby 
regulating the expression of genes involved in cell proliferation, differentiation and survival. 
Dysregulation of the Notch signaling pathway, due to an over-expression of GSK-3β, was found in 
various diseases, such as T-cell leukemia, breast, prostate, colorectal and lung cancers as well as 
central nervous system (CNS) malignancies.[88] 
Even if GSK-3β is a well-known downstream target of IGF-IR, throught PI3K-Akt pathway, as 
previously said, the same GSK-3β stimulates IGF-IR expression. This effect is due to the fact that 
GSK-3β activates the transactivation activity of O subfamily of forkhead / winged helix 
transcription factors (FOXO) that, in turn, directly bind to the IGF-IR promoter.[89] Once activated, 
phosphorylated IGF-1R recruits and activates signaling adaptor proteins, including IRS-1, IRS-2, 
and Shc. The first activates PI3K-Akt pathway, silencing GSK-3β and increasing anti-apoptotic 
effects; the last activates Ras-MAPK pathway, promoting gene expression and cell growth, events 
favored by GSK-3β. There is therefore a regulatory balance between GSK-3β and IGF-1R and the 
lack of this regulation causes tumorogenesis and tumoral progression. As a matter of fact, it has 
been demonstrated that IGF-1R is highly expressed in a wide variety of human cancers, and GSK-
3β knockdown or GSK-3β inhibitors lead to a decrease in cellular proliferation and suppress IGF-
IR-induced cell growth,[89] also bypassing in some cases the problem of the resistance to classic 
anticancer therapy.[90] GSK-3β stabilizes the expression of certain anti-apoptotic B-cell lymphoma-2 
(Bcl-2) family members, in fact, it regulates BCL2L12 anti-apoptotic signaling which is expressed 
at high levels in glioblastoma.[91]  
Glioblastoma is the most frequent malignant brain tumor that usually does not respond to currently 
available cancer treatments. The current standard therapy for newly diagnosed glioblastoma is the 
surgical resection of the tumor, followed by chemotherapy and radiation. However, it has been 
shown that pre-treatment with low doses of GSK-3β inhibitors potentiates the cytocidal effect of 
ionizing radiation in glioblastoma cells and at the same time protects normal hippocampal neurons 
from apoptosis induced by radiation. Therefore, inhibition of GSK-3β provides a double benefit for 
patients with glioblastoma treated with radiation, attenuating tumor proliferation and protecting 
brain tissue from decay and allowing its repair.[92]  
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Several data suggest that at the base of radioprotection mechanisms by GSK-3β inhibitors, there is 
the cytoplasmic MDM2 (Mouse double minute 2 homolog, also known as E3 ubiquitin-protein 
ligase Mdm2) accumulation, followed by MDM2-dependent p53 degradation, thus resulting in the 
regulation of p53 functions and p53-dependent cellular responses, with subsequently decrease of 
radiation-dependent apoptosis.[93] Moreover, GSK-3β binds directly to tumor suppressor protein, 
p53, a transcription factor that is activated by a wide variety of cellular stresses, notably including 
conditions that cause DNA damage. Important for GSK-3β-p53 binding appear to be two domains 
of p53, the basic domain (BD) and activation domain 1 (AD1), that have regulatory influences on 
its association with GSK-3β at the N-terminal domain. The activity of p53 is regulated both at the 
nuclear and mitochondrial levels by GSK-3β and inhibition of this kinase stabilizes its association 
with p53, thus contributing to the transcriptional and apoptotic actions of p53 and suggesting that 
mitochondrial GSK-3β is involved in the mitochondrial apoptotic signaling pathway.[94] 
Further, indirectly stimulating the transcription of Bcl-2-associated X protein (Bax), a key 
component of the intrinsic apoptotic cascade through the regulation of the p53 activity, GSK-3β can 
directly phosphorylate Bax on Ser 163, thus modulating Bax expression and function at the 
transcriptional and post-translational levels, respectively, to promote mitochondrial apoptosis.[95] 
GSK-3β also regulates the expression of the myeloblastosis transcription factor (c-Myb), which can 
form a complex with the lymphoid enhancer-binding factor 1 (LEF-1) transcription factor and binds 
the promoter regions of BCL2 and BIRC5 (survivin) genes which lead to the prevention of 
apoptosis. Therefore, GSK-3β inactivation reduces the expression of c-Myb by promoting its 
ubiquitination-mediated degradation, thereby inhibiting the expression of c-Myb-dependent anti-
apoptotic genes Bcl2 and survivin, with increase the levels of caspase-3 and promotion of 
apoptosis.[96]  
Another target of GSK-3β is the pro-apoptotic protein Bcl-2-like protein 11, commonly called Bim. 
Inhibition of GSK-3β activity, in this case, promotes an apoptotic response specifically in 
pancreatic cancer cells, induces an increase of Bim expression, caspase-3 and -7 activation as well 
as poly adenosine diphosphate ribose polymerase (PARP) cleavage through activation of the 
cascade c-Jun N-terminal kinase (JNK)-cJun, thus promoting the death ligand-induced apoptotic 
response.[21] 
GSK-3β activity on pro- and anti- apoptotic proteins leads to investigate how this target acts on 
regulation of apoptotic mechanisms. GSK-3β has paradoxical effects on apoptosis, as it promotes 
cell death caused by the intrinsic apoptotic pathway, but inhibits the death receptor-mediated 
extrinsic apoptotic pathway.[43]  
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Both apoptotic patways culminate in the activation of a family of intracellular cysteine proteases 
called caspase, that are classified as initiator caspases (caspases-8, -9, and -10) and effector 
caspases (caspases -3, -6, and -7), which can disrupt entire cells within a few minutes of their 
activation, leading to collapse and to cell death (Figure 4).[97] 
 
 
 
Figure 4. Intrinsic and Extrinsic Apoptocic Signaling Pathways and GSK-3β Activity. 
 
The intrinsic apoptotic signaling pathway causes the disruption of mitochondria, leading to cell 
destruction and can be induced by numerous stimuli that cause cell damage, such as DNA damage, 
oxidative stress and endoplasmic reticulum (ER) stress. GSK-3β promotes this cascade by 
facilitating signals that cause disruption of mitochondria and by regulating transcription factors that 
control the expression of proteins involved in apoptotic signaling.[43] 
The extrinsic apoptotic pathway, conversely, is mediated by the activation of cell-surface death 
domain-containing receptors (DRs) and initiates apoptosis by activating caspase-8. DRs belong to 
the tumor necrosis factor (TNF) family of receptors that contain conserved intracellular death 
domains that are critical for the initiation of extrinsic apoptotic signaling. Among the most well-
known death receptors are TNF receptor 1 (TNF-R1), Fas (also called CD95 or Apol), death 
receptor 4 (DR4) and DR5. The activated death receptors bind to the cytoplasmic proteins FADD 
(Fas-associated death domain protein) and procaspase-8 (or procaspase-10) to form a complex 
known as the death-inducing signaling complex (DISC). DISC formation can allow autoactivation 
of caspase-8, which then leads to the activation of effector caspases and thereby triggering entrinsic 
apoptosis (Figure 4).[97] 
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GSK-3β inhibits the death receptor-mediated extrinsic apoptotis pathway by preventing activation 
of the initiator caspase-8, and this upstream anti-apoptotic site of GSK-3β action thwarts its pro-
apoptotic actions, that are targeted downstream at the level of the mitochondria by blocking the 
signal from reaching that stage of the apoptosis cascade.[43] The caspase-8, generally, is not involved 
in intrinsic apoptotic signaling, so its inhibition by GSK-3β does not influence the intrinsic 
apoptotic cascade. Thus there is a clear segregation of the actions of GSK-3β on these two apoptotic 
signaling cascades, which allows GSK-3β to effectively regulate each pathway individually and in 
opposite directions. Intrinsic and extrinsic apoptotic signaling are normal mechanisms used to rid 
organisms of unwanted cells, the former in response to cell damage and the latter in response to 
external signals. Aberrant apoptosis can occur in association with a wide variety of diseases, 
especially well-documented for abnormally high apoptosis in neurodegenerative diseases and 
deficient apoptosis in cancer. Thus, since GSK-3β is an important component of both apoptotic 
pathway, GSK-3β-regulating drugs may provide a powerful approach to attenuate apoptosis in 
neurodegenerative diseases or to eliminate proliferative cancer cells. GSK-3β inhibitors may be 
useful in cancer therapies, also in conjunction with agents that activate death receptors, since the 
latter are preferentially expressed in cancer cells, so this combination may prove to be particularly 
efficient for killing tumor cells.[23,43,49,97] 
GSK-3β is also an important regulator of the Wnt / β-catenin signaling pathway, since it regulates 
the levels of β-catenin, a key molecule involved in cell normal development as well as cancer 
progression. Different pools of β-catenin exist at various subcellular locations, for example one pool 
of β-catenin is associated with cadherins at the cell-cell junctions while another pool is free and 
localized in the cytosol and nucleus where it plays important roles in regulating gene expression. 
Normally, this pool of free β-catenin is maintained at a low level through the rapid turnover by 
GSK-3β. The Wnts are a family of secreted, cysteine-rich and glycosylated protein ligands that 
signal by activating the Frizzled family of membrane-bound receptors. Wnt signal transduction 
causes nuclear translocation of β-catenin and ultimately results in the activation of genes 
regulated by the T-cell factor (TCF) / lymphoid enhancer factor (LEF) family of transcription 
factors. In the absence of Wnt signals, free cytoplasmic β-catenin is incorporated into a 
cytoplasmic complex that includes adenomatous polyposis coli (APC), axin / conductin, casein 
kinase-1α (CK1α) and GSK-3β. These kinases phosphorylate specific amino terminal residues of 
the β-catenin (Ser 45 phosphorylated by CK1α that primes β-catenin for subsequent 
phosphorylation by GSK-3β at Ser 33, Ser 37, Thr 41), causing its ubiquitination and subsequent 
degradation by the proteasome.  
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In the presence of Wnt ligand, it interacts with the transmembrane receptor Frizzled (Fz) and its co-
receptor LRP5 or LRP6 (low-density lipoprotein receptor-related protein 5 or 6) and the formation 
of Wnt-Fz-LRP5 / 6 complex along with the recruitment of scaffolding proteins Dishevelled (Dvl) 
results in phosphorylation of LRP5 / 6 by the GSK-3β; axin binds to the cytoplasmic portion of 
LRP5 / 6 leading to inhibition of the multiprotein complex which it is part of and preventing the 
phosphorylation of β-catenin by GSK-3β (GSK-3β-binding protein (GBP), also known as, 
frequently rearranged in advanced T-cell lymphomas (FRAT), may regulate the binding of GSK-3β 
to axin), in turn also inactivated through Wnt / Dvl signal transduction. This leads to the 
stabilization of β-catenin that not being degraded it translocates to the nucleus and interacts with 
many transcription factors including those of family TCF / LEF, leading to activate the responsive 
genes of the Wnt pathway (Figure 5).[98,99] 
 
 
 
Figure 5. Wnt / β-catenin signaling pathway. 
 
GSK-3β has two roles in the regulation of Wnt / β-catenin signaling. GSK-3β, on the one hand, 
phosphorylates β-catenin leading to its degradation, and on the other hand, phosphorylating the 
LRP5 / 6 co-receptor, it leads to the stabilization and activation of β-catenin with growth 
mechanisms and resistance to apoptosis by activating c-myc and cyclin D1 genes. Since GSK-3β is 
a kinase with a specific recognition motif present in substrate proteins that it phosphorylates, 
mutations can occur in certain genes which prevent GSK-3β-mediated phosphorylation of the 
proteins they encode. The mutant proteins may have altered half-lifes as compared to the WT 
proteins as they may not be subject to proteasomal degradation.  
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Genetic mutations changing the GSK-3β phosphorylation sites Ser 33, Ser 37, Ser 45 and Thr 41 
present in β-catenin prevent the ability of GSK-3β to phosphorylate β-catenin and inhibit its 
proteasomal degradation. Likewise mutations at Ser 45 of β-catenin prevent CK1α from performing 
the priming phosphorylation, thus GSK-3β is unable to phosphorylate the other residues of β-
catenin. Thus mutations at GSK-3β phosphorylation sites and its dysregulation lead to the 
promotion of tumor processes.[99] This explains the use of GSK-3β inhibitors in regulating the levels 
of β-catenin, since an increase of the same is often seen in basal cell carcinoma, in colorectal cancer 
and in leukemia.[100-102] 
 
Many efforts have been made in the discovery and development of GSK-3β inhibitors in the last 
years as it is a very active field of research for academic centres and pharmaceutical companies. 
Some GSK-3β inhibitors have synthetic origin, others derive directly or indirectly from small 
molecules of natural origin. However, pharmacological inhibitors of GSK-3β can be classified into 
following three categories[103]:  
 Non-ATP-competitive inhibitors 
 ATP-competitive inhibitors 
 Substrate competitive GSK-3β inhibitors 
Small heterocyclic thiadiazolidinones (TDZD) were the first family of compounds reported as non-
ATP-competitive GSK-3β inhibitors, including compound 1 and 2 with IC50 = 2.0 μM and 1.1 μM, 
respectively. TDZD also showed activity against various kinases including PKA, PKC, CK-2, and 
CDK1 / cyclin B.[103] 
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Halomethylketone (HMK) derivatives recently revealed as the first irreversible inhibitors of the 
second family of non-ATP-competitive GSK-3β inhibitors. In this case, inactivation of the enzyme 
is due to the formation of an irreversible covalent sulphurcarbon bond between the key Cys 199 
located at the entrance of the ATP site of GSK-3β and the HMK moiety. Various HMK's 3 were 
used as pharmacological tools for the study of GSK-3 physiology and pathology in different cell 
models.[103] 
S
R1
R2
R
O
Cl
3  
Palinurin 4 and tricantin 5 metabolites also belong to the class of non-ATP-competitive GSK-3β 
inhibitors and were mainly isolated from the Mediterranean sponges Ircinia dendroides. Palinurin 4 
showed inhibitory activity against GSK-3β with an IC50 value of 4.5 μM and Tricantin 5 has been 
found to inhibit recombinant human GSK-3β with an IC50 value of 7.5 μM.[103] 
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Benzothiazepinones (BTZs), others non-ATP-competitive GSK-3β inhibitors, include compound 6 
and 7, that were found to exhibit inhibitory activity against GSK-3β with IC50 values of 25 μM and 
8.0 μM, respectively.[103] 
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The category of ATP-competitive inhibitors consists of small metal cations, as lithium, that was the 
first “natural” GSK-3 inhibitor discovered. Lithium is a mood stabilizer, which has been used in the 
treatment of bipolar disorders. Lithium inhibits GSK-3β directly by competition with magnesium 
ions and indirectly via enhanced serine phosphorylation and autoregulation. Numerous studies have 
investigated therapeutic activity of lithium in various neuronal systems and verified its profound 
effect in neuroprotection against a variety of insults in apoptotic and brain injury paradigms.[103] 
Paullones, particularly alsterpaullone 8 and kenpaullone 9, the benzazepinone derivatives are potent 
ATP-competitive inhibitors of GSK-3β, with IC50 values within nanomolar range. The in silico 
interactions of alsterpaullone 8 and GSK-3β include two hydrogen bonds with Val 135 and one 
interaction between the nitro group and the side chain amino group of Lys 85.[104]  
Kenpaullone 9 with a 9-halogen substitution pattern was reported to display improved inhibitory 
activity toward GSK-3β, considering paullones as selective and potent GSK-3β inhibitors.[103] 
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Indirubines are bis-indole compounds found in a variety of natural sources. The most well-known 
compound of this family is indirubin 10, identified initially for the treatment of leukemia, and is a 
potent dual inhibitor of both CDKs (50-100 nM) and GSK-3β (5-50 nM), through an ATP-
competitive mechanism. Also compounds 11-13 displayed remarkable inhibition against GSK-3β 
within the low nanomolar range. In particular, the introduction of bromine in compound 13 
improved the activity for GSK-3β inhibition.[103] 
N
H
10 R = O, R1 = R2 = CH  
11 R = NOH, R1 = I, R2 = CH
12 R = NOH, R1 = R2 = Cl
13 R = NOH, R1 = CH, R2 = Br
R
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Triazole derivatives are part of ATP-competitive GSK-3β inhibitors. In particular, compounds 14 
and 15 showed inhibitor activity against GSK-3β with IC50 values of 0.28 μM and 0.111 μM, 
respectively.[103] 
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Oxadiazole derivatives also have been reported as ATP-competitive GSK-3β inhibitors. In fact, 
1,3,4-oxadiazoles conjugated with fused heterocyclic ring such as benzodioxole, benzofuran, 
benzimidazole, benzothiazole, imidazopyridine and indazole have been found to exhibit potential 
GSK-3β inhibition. Among these, the compounds 16-18 showed inhibitor activity against GSK-3β 
with IC50 values in the range of nanomolar.
[103] 
 
 
N N
OS
N
N
NCCF3
16
N N
O
S
17
F
F
O
O
O
18
S
O
CH3
O
N
N
CH3
 
 
 
 
 
19 
 
Furthermore, the category of ATP-competitive inhibitors includes also other potent GSK-3β 
inhibitors based on purine or pyrimidine motif, as the compounds 19,20, which inhibit GSK-3β 
within the nanomolar concentration range.[103] 
 
 
N
N
CH3
O
N
N
H
O
19
N
N
CH3
O
N
N
20
F
O
F
 
 
 
 
The thiazole AR-A014418 21 is a selective ATP binding site competitor and showed inhibitor 
activity against GSK-3β with IC50 values in the nanomolar range.[103] It induces mitotic spindle 
dysfunction and chromosomal instability, resulting in the mitotic catastrophe, that is an alternative 
mechanism for the anticancer effects of GSK-3β inhibitors in cancer cells resistant to apoptosis.[105] 
 
 
S
N
O2N
N
H
N
H
O
O
CH3
21  
 
 
 
 
 
 
 
 
 
 
 
20 
 
However, although in the literature there are numerous compounds with documented inhibitory 
activity against GSK-3β, maleimide derivatives 22-25 having different alkyl, aminoalkyl and 
hydroxyalkyl chains on the indole, 7-azaindazole and 7-azaindole portions, represent an interesting 
class of potent and highly selective ATP-competitive GSK-3β inhibitors, with IC50 values from 
micro to nanomolar range.[82,103,104,106-108] 
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R1 = -CH3, -(CH2)8CHOH, -(CH2)8O2NC2H5
R2 = -(CH2)8CHOH, -(CH2)8O2NC2H5, -(CH2)9O2NCH3
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Moreover, the compound 26-28, isolated from marine sponges, represent an other interesting class 
of ATP-competitive GSK-3β inhibitors and exhibit their activity also towards other protein kinases. 
In particular, compound 28 prevents cell proliferation and induces apoptosis, demonstrating its 
ability to enter cells and to interfere with the activity of kinases important for cell division and cell 
death.[103] 
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Manzamine alkaloids are β-carboline polycyclic compounds coming from Indo-Pacific sponges 
with potential therapeutic interest in CNS disorders. Manzamine A 29, is a substrate competitive 
inhibitor of GSK-3β and CDK5 with IC50 values of 10 and 1.5 μM, respectively.[103] 
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A plethora of GSK-3β inhibitors have been discovered in recent years and most of these, besides to 
inhibiting the GSK-3β, showed inhibitory activity against other kinases. Therefore, the discovery of 
new, selective and non-toxic GSK-3β inhibitors remains a challenge for pharmaceutical chemistry. 
Marine organisms are a highly valuable resource for pharmacologically active compounds, 
especially of kinase inhibitors and therefore possess a potential role in the discovery and 
development of new drugs suitable for the treatment of human diseases. In particular, marine 
alkaloids with the bis-indole structure have received a considerable attention because of their potent 
biological activity such as antitumor, antiviral, antimicrobial and anti-inflammatory agents.[109-112] 
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Nortopsentins A-C 30-32, group of bis-indole alkaloids having an imidazole as spacer, were the 
first isolated by Howard from Spongosorites ruetzleri and Halichondria. The subsequent catalytic 
hydrogenation of nortopsentin A-C 30-32 led to nortopsentin D 33, while the methylation of 
nortopsentin B 31 with dimethyl sulfate in the presence of potassium carbonate in acetone afforded 
trimethyl and tetramethyl nortopsentins B 34,35, as MeSO4
- salt. Nortopsentins A-C 30-32 
exhibited in vitro cytotoxicity against P388 leukemia cells with GI50 values of 7.6, 7.8, 1.7, g/ml, 
respectively. They also showed antifungal activity against Candida albicans (MIC 3.1, 6.2, 12.5 
g/ml). The N-methylated derivatives of nortopsentin B 34,35 showed in vitro a significant 
improvement in the citotoxycity against P388 cells compared to that showed by the parent 
compound (0.9 and 0.34 g/ml respectively).[113-115] 
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30 Nortopsentin A R = R1 = Br
31 Nortopsentin B R = Br, R1 = H
32 Nortopsentin C   R = H, R1 = Br
33 Nortopsentin D   R = R1 = H
R R1
N N
N
N
CH3 R
34 R = H
35 R = CH3
CH3SO4
CH3
Br
H3C
 
Due to the considerable biological activities shown and its low availability, nortopsentin has 
become an interesting "lead compound" for the search of new compounds of pharmaceutical 
interest. Among the several analogues reported in the literature, significant is the cytotoxic activity 
showed by 2,4-bis(3’-indolil)thiazoles 36-46 in which the imidazole central ring of the natural 
compound was replaced by a thiazole one. These compounds, tested by the National Cancer 
Institute (NCI, Bethesda MD) showed cytotoxic activity against a wide number of human cancer 
cell lines, as shown in table 1.[114-115] 
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R      R1      R2
36  H      H      H
37  H    6-Br    H
38  6-Br   H     H
39  6-Br 6-Br   H
40  H    5-Br    H
R         R1        R2
41  5-Br    5-Br       H
42  6-Br   6-OCH3  H
43   6-Br   5-Br       H
44   6-OCH3 6-Br   H
45   5-Br     6-Br     H
46    H         H        CH3 
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Table 1. Cancer cell growth inhibitory activity of compounds 36-46 in vitro. 
Cell line Cytotoxicity (GI50 in μM) 
 36 37 38 39 40 41 42 43 44 45 46 
Leukemia            
CCRF-CEM ND 14.6 10.9 10.1 2.11 2.40 27.7 2.58 2.66 2.99 >100 
HL-60(TB) ND ND ND 0.95 2.43 2.76 ND 3.76 4.13 3.86 >100 
K-562 3.27 18.8 5.61 4.69 1.96 1.94 15.2 2.13 1.74 2.25 11.2 
MOLT-4 5.31 19.9 31.2 5.80 1.41 1.75 23.0 1.55 2.95 2.26 14.1 
RPMI82226 ND 19.4 12.2 11.4 1.97 1.95 27.1 2.24 2.03 1.84 20.8 
Non-Small Cell 
Lung Cancer 
           
NCI-226 >100 14.4 24.4 3.3 2.10 3.14 45.4 2.48 2.24 7.23 32.2 
NCIH322M >100 16.7 18.9 18.4 2.01 1.99 70.8 2.51 3.09 2.99 24.5 
NCI-H460 >100 16.1 7.31 16.4 2.55 1.93 23.2 2.31 1.58 2.00 26.5 
EKVX >100 15.6 29.5 28.6 ND ND 32.1 0.48 0.29 0.55 ND 
Colon Cancer            
HCT-15 >100 15.2 17.8 8.50 1.81 2.51 7.54 2.70 0.81 2.84 >100 
SW-620 >100 16.5 25.6 12.5 1.52 2.14 7.00 3.57 5.50 2.89 59.4 
CNS Cancer            
SF-295 33.6 14.6 9.23 4.81 1.98 2.71 73.5 4.56 ND ND 23.5 
SF-268 ND 18.3 32.1 ND 1.52 2.44 26.0 2.69 13.8 1.80 58.2 
SNB-19 >100 17.8 41.8 17.2 2.11 3.75 >100 2.60 10.5 3.34 42.6 
U21 >100 17.9 28.1 15.3 2.10 2.30 25.0 3.34 5.07 3.00 32.4 
Ovarian Cancer            
IGROV1 8.14 13.0 30.5 14.4 1.85 1.70 81.5 2.96 4.61 2.43 27.0 
OVCAR-5 >100 16.1 37.1 23.6 1.96 2.14 42.7 2.16 3.44 2.35 95.9 
Renal Cancer            
786-0 >100 18.0 19.9 15.9 2.28 1.95 27.4 1.50 3.89 2.21 17.2 
A498 >100 17.0 25.7 23.2 1.92 2.48 89.4 2.19 7.43 2.40 12.6 
RXF 393 ND 22.4 7.62 18.4 1.81 1.69 11.9 2.42 2.03 1.66 14.1 
Prostate Cancer            
PC-3 >100 15.6 16.9 15.3 2.02 2.57 10.4 4.16 3.49 2.81 21.9 
DU-145 >100 18.8 14.9 18.4 2.29 2.61 >100 3.74 5.46 2.03 42.9 
Breast Cancer            
MCF7 >100 16.7 27.2 6.46 2.13 2.70 54.1 0.88 4.36 3.82 45.5 
MDAMB435 33.1 14.9 25.6 4.34 2.53 2.27 7.70 4.54 14.6 3.97 26.4 
MDA-N 83.0 19.2 31.5 2.94 1.88 2.09 8.27 2.86 6.84 3.77 24.9 
T-47D >100 24.8 23.9 16.2 3.27 2.90 59.3 3.33 4.12 1.76 28.1 
BT-549 >100 18.3 73.8 41.1 2.71 10.6 67.3 1.24 1.46 1.41 56.3 
Melanoma            
LOX IWVI 21.8 15.5 6.55 11.3 1.97 1.69 64.1 2.32 2.41 1.87 36.4 
MALME3M >100 16.9 >100 ND 1.28 1.72 1.72 1.45 1.50 2.83 19.0 
M14 >100 14.2 32.4 10.6 1.61 1.63 >100 2.86 5.49 2.77 26.7 
SKMEL2 >100 ND 37.5 68.8 1.81 1.98 19.1 3.25 7.30 2.91 38.8 
SKMEL28 >100 14.2 7.74 32.0 3.02 3.05 >100 9.84 1.36 4.96 61.5 
SKMEL5 ND 14.9 23.7 28.5 1.76 1.63 >100 2.82 5.13 3.36 26.9 
ND= Not Determined 
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In the research lab where I carried out my PhD thesis, different analogues of nortopsentin has been 
synthesized, in which the imidazole ring of the natural compound was replaced by other five-
membered heterocycles, such as thiophene 47,[116] pyrazole 48,[117] furan 49,[118] isoxazole 50,[118] 
and pyrrole 51[119] (Figure 6). Some of them showed remarkable antiproliferative activity in cancer 
cells, often with GI50 values at submicromolar level.  
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Figure 6. Nortopsentin Analogues. 
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Considering the interesting antitumor activity of 2,4-bis(3’-indolil)thiazoles 36-46 reported, the 
attention was also focused on the synthesis of indolyl-7-azaindolyl thiazoles 52a-n, 53a-j, 54a-j 
(Table 2) in order to verify whether the introduction of a nitrogen atom in the 7 position on the 
indole portion led to an increase of the antitumor activity.[120] 
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3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl)-1H-7-azaindoles
52a-n, 53a-j, 54a-j
 
Table 2. 3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-b]pyridines 52a-n, 53a-j, 54a-j. 
Compd R R1 R2 Yields Compd R R1 R2 Yields 
52a H CH3 H 85% 53d Cl Boc H 90% 
52b CH3 CH3 H 70% 53e Br Boc H 80% 
52c OCH3 CH3 H 90% 53f H Boc CH3 92% 
52d Cl CH3 H 78% 53g CH3 Boc CH3 53% 
52e Br CH3 H 60% 53h OCH3 Boc CH3 90% 
52f F CH3 H 95% 53i Cl Boc CH3 90% 
52g H CH3 CH3 75% 53j Br Boc CH3 72% 
52h CH3 CH3 CH3 60% 54a H H H 99% 
52i OCH3 CH3 CH3 85% 54b CH3 H H 95% 
52j Cl CH3 CH3 57% 54c OCH3 H H 99% 
52k Br CH3 CH3 55% 54d Cl H H 99% 
52l F CH3 CH3 91% 54e Br H H 54% 
52m F H H 87% 54f H H CH3 71% 
52n F H CH3 60% 54g CH3 H CH3 99% 
53a H Boc H 85% 54h OCH3 H CH3 90% 
53b CH3 Boc H 60% 54i Cl H CH3 99% 
53c OCH3 Boc H 90% 54j Br H CH3 90% 
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All the synthesized indolyl-azaindolyl thiazoles 52a-n, 53a-j and 54a-j were submitted to the NCI 
in order to evaluate their biological activity as antitumor agents. Biological screening were 
performed according to the NCI protocol, at the 10-5 M dose for the in vitro disease-oriented 
antitumor screenings against a panel of about 60 human tumor cell lines. Compounds 52a, 52d, 52f, 
52g, 52l-n, 53f, 54b-f were selected by the NCI for full evaluation at five concentration levels (10-4-
10-8 M), and showed antiproliferative activity with GI50 values from micro to sub-micromolar range 
(Table 3).[120] 
 
Table 3. In vitro inhibition of cancer cell lines growth by compounds 52a, 52d, 52f, 52g, 52l-n, 53f, 
54b-f. 
Compd N° of cell 
line tested 
N° of active 
cell lines 
GI50 (µM) 
RangeMG_MID 
52a 59 56 0.84-0.60 0.70 
52d 59 59 0.85-0.66 0.73 
52f 60 60 0.87-0.72 0.75 
52g 59 59 0.83-0.72 0.76 
52l 55 55 0.82-0.72 0.77 
52m 23 14 0.80-0.69 0.69 
52n 58 58 0.82-0.63 0.75 
53f 59 59 0.78-0.68 0.72 
54b 48 3 0.82-0.74 0.61 
54c 58 58 0.79-0.62 0.73 
54d 59 59 0.77-0.71 0.74 
54e 59 59 0.77-0.70 0.74 
54f 60 60 0.86-0.70 0.79 
 
The five most active compounds, 52f, 54f, 52g, 52l, and 52n, were further tested by Istituto 
Nazionale dei Tumori (Fondazione IRCCS, Milano) against two additional cell lines, STO and 
MesoII, derived from human Diffuse Malignant Peritoneal Mesothelioma (DMPM), a tumor type 
not included in the NCI panel. After seventy-two hours of exposure to increasing concentrations of 
each compound, compounds 52f, 54f, and 52l showed a dose-dependent inhibition of cell 
proliferation in both cellular models and they did not interfere with the proliferation of normal cells 
(W138) (Table 4).[120] 
 
 
 
27 
 
Table 4. Cytotoxic activity of compounds 52f, 54f, 52g, 52l, 52n, in DMPM and normal cells. 
Compd  
STO 
GI50 (M)a 
MesoII            WI38 
52f 0.49±0.07 25.12±3.06 >100 
54f 0.33±0.07 4.11±0.22 >100 
52g 0.61±0.14 16.77±1.99 18.76±3.21 
52l 0.43±0.11 4.85±0.64 >100 
52n 0.54±0.09 13.27±0.74 15.44±3.87 
a
Data are reported as GI
50
 values (concentration of drug required to inhibit growth by 50%) determined by MTS assay 
after 72 h of continuous exposure to each compound. The data represents mean values ± SD of at least three 
independent experiments. 
 
As many nortopsentin analogues exhibited the cellular effects by inhibiting of kinase activity, in 
order to study the mechanism of action, compounds 52f, 54f and 52l were tested on several protein 
kinases (CDK1, CDK5, EGFR, FGFR1, RET, MET, KIT, JAK2, PKCA, PKCB, CHKI, MAPK12, 
GSK, PKA, GSK-3, GSK-3). Results showed that those compounds markedly repressed CDK1 
activity with GI50 values (0.89±0.07, 0.86±0.04, 0.75±0.03) comparable to those reported for two 
well-known CDK1 inhibitors, roscovitine and purvalanol A (0.73±0.06, and 0.59±0.08, 
respectively) and they decreased CDK1 activity in a time-dependent way. These compounds were 
also active against GSK-3 protein, but at higher concentrations (Table 5).[120] 
 
 
Table 5. In vitro Kinase inhibitory activity of derivatives 52f, 54f, 52l. 
GI50 (M)a 
Protein kinase 52f 54f 52l Roscovitine Purvalanol A 
CDK1 0.89±0.07 0.86±0.04 0.75±0.03 0.73±0.06 0.59±0.08 
GSK-3 42.18±3.28 35.68±1.69 40.18±2.94 >50 >50 
a
Concentration of drug required to inhibit by 50% (GI
50
) the activity of CDK1 e GSK-3β. Values represent the mean 
values ± SD of three independent experiments. 
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Moreover, it has been assessed the phosphorylation status of histone H1, a specific substrate for 
CDK1, in STO cell lines, in order to confirm the ability of these three derivatives to inhibit CDK1 
activity in living cells; the obtained results showed a substantial and time dependent reduction of 
kinase activity (Figure 7 A-B).[120] 
 
Figure 7. Effect of 52f, 54f, and 52l derivatives on CDK1 kinase activity in DMPM cells. (A) Representative kinase 
assay illustrating the CDK1 activity in STO cells at different intervals after exposure to 1% (v/v) DMSO (control cells; 
C) or to derivative 54f (GI50; T). (B) Densitometric quantification of CDK1 activity in STO cells exposed to derivatives 
52f, 54f, and 52l for 24, 48, and 72 h. CDK1 activity was achieved by immunoprecipitation. Data are reported as the 
percentage of CDK1 activity in cells exposed to derivatives 52f, 54f, and 52l (gray column) compared with DMSO-
treated cells (black column) and represent the mean values ± SD of at least three independent experiments. ***p 
<0.001, **p < 0.01, *p < 0.05. 
These compounds were also tested in STO and MesoII cells to observe the importance of 
nortopsentin analogue treatment on cell cycle progression. Compound 52f, 54f, 52l induced a time-
dependent accumulation of cells in the G2 / M phase, and a concomitant decrease of the percentage 
of cells in the G1 phase. It was also observed a marched growth in the number of cells with 
apoptotic morphology (in terms of chromatin condensation and DNA fragmentation) and a 
significant increase in the activity of caspase -9 and -3 (Figure 8).[120] 
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Figure 8. Effect of 52f, 54f, and 52l derivatives on cell-cycle progression and apoptosis induction. (A) STO and 
MesoII cells were exposed to 1% (v/v) DMSO (control cells; C) or to derivatives 52f, 54f, and 52l (GI50) for 48 and 72 
h. Data are reported as the percentage of cells in sub-G1 (dark gray), G1 (light gray), S (black), and G2 / M (white) 
phases and represent the mean values of three independent experiments; SDs were always within 5%. (B) The 
percentage of cells with apoptotic morphology was assessed by fluorescence microscopy after exposure of DMPM cells 
to 1% (v/v) DMSO (control cells; C) or to derivatives 52f, 54f, and 52l at 48 h (black column) and 72 h (gray column) 
after treatment. Data are expressed as mean values ± SD of at least three independent experiments. **p < 0.001, *p < 
0.01. (C) The catalytic activity of caspases was assessed after 72 h of exposure of the DMPM cells to 1% (v/v) DMSO 
(control cells; C) or to derivatives 52f, 54f, and 52l. Caspase-9 (black column) and caspase-3 (gray column) catalytic 
activity was determined in vitro by hydrolysis of the fluorogenic substrates (LEHD-pNA and DEVD-pNA, 
respectively). Data are expressed as mean values ± SD of at least three independent experiments. ***p < 0.001, **p < 
0.01, *p < 0.02. 
 
It was previously demonstrated that DMPM chemoresistance was principally caused by the 
dysregulation of apoptotic pathway, through the over-expression of members of the inhibitors of 
apoptosis protein family (IAP), such as survivin,[121] a multifunctional protein involved in cell 
division and apoptosis and selectively overexpressed in most human cancers.[122] It has been 
demonstrated that to exert its functions, survivin needs to be physically associated with CDK1 and 
phosphorylated on the Thr 34 residue by CDK1 / Cyclin B1 complex.[122] 
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It was investigated the effect of these compounds on survivin activation. Immunoblotting 
experiments demonstrated that 1H-pyrrolo[2,3-b]pyridine derivatives induced apoptosis in DMPM 
cells through a relevant and time-dependent decrease of levels of the active form of survivin, 
phosphorylated in Thr 34 (Figure 9).[120] 
 
 
Figure 9. Effect of 52f, 54f, and 52l derivatives on survivin phosphorylation. (A) Representative Western blotting 
illustrating the survivin phosphorylation status in STO cells after exposure to 1% (v/v) DMSO (control cells; C) or to 
derivative 54f, (GI50; T). (B) Densitometric quantification of surviving phosphorylation levels in STO cells exposed to 
52f, 54f, and 52l for 24, 48, and 72 h. The phosphorylation of survivin on the Thr 34 residue was evaluated on STO 
cells treated with 1% (v/v) DMSO (control cells; black column) or to derivatives 52f, 54f, and 52l (IC50; gray column) 
by Western immunoblotting. Survivin was immunoprecipitated using the antihuman survivin antibody and analyzed 
with the antibody to phosphorylated Thr 34. Data are expressed as mean values ± SD of at least three independent 
experiments. ***p < 0.001, **p < 0.01, *p < 0.05. 
 
The cytotoxic effect of the most active compound 54f was also investigated in DMPM cells alone or 
in combination with the taxan paclitaxel. At the beginning STO and MesoII cells were treated only 
with the taxan for 24 hours, and then they were also exposed for 72 hours to derivative 54f. At all 
concentrations, it was observed a synergistic cytotoxic effect to inhibit DMPM cell survival. After 
the combination of two drugs, an inhibition of cell proliferation bigger than that estimated by simple 
addition / amount of the effects of the two agents it was detected (Figure 10A).  
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A higher catalytic activity of caspase-3 was identified in cells treated with the two compounds than 
in those exposed to each single agent (Figure 10B).[120] 
 
 
 
Figure 10. Cytotoxic effect of 54f derivative in combination with paclitaxel in DMPM cells. (A) The cytotoxic effect 
of paclitaxel and 54f derivative, alone or in combination, was assessed by MTS assay. The dashed lines represent the 
expected additive effect of the combination, calculated as the product of the effects of the individual drugs. Data are 
expressed as mean values ± SD of at least three independent experiments. CI was calculated according to Chou and 
Talalay.[123] (B) Caspase-3 catalytic activity was determined in vitro by the hydrolysis of the specific fluorogenic 
substrate (DEVD-pNA). Data are expressed as mean values ± SD of at least three independent experiments. *p < 0.001. 
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The antitumoral activity of 52f, 54f, and 52l derivatives was then investigated on STO cells 
xenotransplanted in athymic nude mice and after the treatment with each compound it was possible 
to observe a marked tumor growth inhibition (Figure 11).[120] 
 
Figure 11. Activity of 52f, 54f, and 52l derivatives on STO cells xenotransplanted on athymic 
mice. Drugs were administered ip at 25 (52f and 52l) or 50 (54f) mg/kg qd×4−5/w×3w, starting 
from the day after the injection. **p < 0.01, *p < 0.05. 
In particular, at the end of the experiment, a statistically significant tumor volume inhibition (TVI) 
compared with the control (73%, 58% and 75%, for 52f, 54f and 52l derivatives, respectively) was 
observed (Table 6). In addition, two complete responses were observed in each treatment group, 
with the disappearance of tumor induced by treatment. Moreover, the compounds were well 
tolerated without any appreciable sign of toxicity (Table 6).[120] 
 
Table 6. Activity of derivatives 52f, 54f and 52l, on STO cells xenotransplanted in athymic nude 
mice. 
Compd TVI (%)a CRb BWL (%)c TOXd 
52f 
54f 
73* 
58* 
2/8 
2/8 
4 
7 
0/8 
0/8 
52l 75** 2/8 1 0/8 
aTumor volume inhibition (%) in treated vs control mice, determined 17 days after the end of drug treatment (day 35). 
bComplete response, disappearance of tumor induced by treatment. cBWL, body weight loss induced by treatment (%). 
dToxic death on treated animals. **p <0.01, *p < 0.05. 
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AIM OF THE WORK  
 
Considering the interesting biological results shown by indolyl-7-azaindolyl thiazoles of type 52-
54, and considering the importance of alkyl, aminoalkyl and hydroxyalkyl chains of maleimide 
derivatives 22-25 against GSK-3β, the aim of my PhD project was the synthesis of new analogues 
7-azaindolyl thiazoles, characterized by the presence of different chains on the indole ring, and the 
evaluation of their potential cytotoxic activity and possible selectivity against GSK-3β. 
In particular, seven new series have been synthesized:  
 
 2-{3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanols 55a-h 
 3-{2-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 56a-h 
 3-{2-[1-(3-Morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 57a-h 
 3-{2-[1-(4-Morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 58a-h 
 3-{2-[1-(2-Piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 59a-h 
 3-{2-[1-(3-Piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 60a-h 
 3-{2-[1-(4-Piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 61a-h 
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RESULTS AND DISCUSSIONS: CHEMISTRY 
 
The synthetic pathway of new 7-azaindolyl thiazoles 55a-h, 56a-h, 57a-h, 58a-h, 59a-h, 60a-h, 
61a-h (Tables 7-13), involves an Hantzsch reaction between two key intermediates: 
carbothioamides 62a-d, 75a-d, 79a-d, 84a-d, 88a-d, 92a-d, 95a-d, and 3-bromoacetyl-7-azaindoles 
63a,b (Schemes 1, 6, 8, 10, 12, 14, 16). 
In particular, 2-{3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanols 
55a-h were prepared from reaction of carbothioamides 62a-d and 3-bromoacetyl compounds 63a,b. 
These key intermediates, reacted in ethanol under reflux from 30 minutes to 2 hours, gave after 
crystallization, the desired 7-azaindolyl thiazoles 55a-h (Scheme 1), in excellent yields (90-98%) 
(Table 7). 
Scheme 1. 
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N
N
62a-d 63a,b 55a-h
R R
CH2CH2OH R1 R1CH2CH2OH
+
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a R1 = H
b R1 = CH3
EtOH, 
S
NH2
 
 
Table 7. 2-{3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanols 55a-h. 
 
Compd R R1 Yield % 
55a H H 98 
55b H CH3 98 
55c Br H 90 
55d Br CH3 90 
55e F H 98 
55f F CH3 98 
55g OCH3 H 98 
55h OCH3 CH3 98 
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For the synthesis of carbothioamides of type 62 it was initially proceeded reacting indole 64a with 
1-bromo-2-trityloxy-ethane 65[124], in the presence of sodium hydride (NaH) as a base and 
dimethylformamide (DMF) as reaction solvent, to get derivative 66a. The reaction was heated to 60 
°C for 3 hours to obtain derivative 66a in excellent yield (98%). This latter was then dissolved in 
acetonitrile and reacted with chlorosulfonyl isocyanate (CSI), at room temperature for 30 minutes. 
The resulting intermediate, treated with a solution of acetone and water and subsequent basification 
with potassium hydroxide solution (10% KOH), afforded derivative 67a (70%) in which 
deprotection and carbamoylation of the side chain occurred, leading to introduction of the amide 
function also in position 3 of the indole. Despite the original purpose, the obtained intermediate was 
used and reacted with 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide 
(Lawesson's reagent), in toluene under reflux. The reaction gave carbothioamide 68a, which was 
reacted with 3-bromoacetyl-7-azaindoles 63a,b in ethanol under reflux, affording thiazoles 69a,b 
(Scheme 2). 
 
Scheme 2. 
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In order to achieve our original goal, thiazoles 69a,b were subjected to hydrolysis using both basic 
and acid conditions to obtain the desired thiazoles of the type 55. Unfortunately, these reactions 
showed only negative results (Scheme 3).  
 
Scheme 3. 
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On this basis, it was decided to change the synthetic strategy as shown in the scheme 4. The 
commercially available indole derivatives 64a-d were reacted with CSI and DMF in acetonitrile at 0 
°C, leading to the cyano derivatives 70a-d in excellent yields (90-98%). Then, these latter were 
reacted with 2-bromoethanol 71, using NaH as a base and DMF as reaction solvent. The reaction 
mixture was heated at 80 °C affording derivatives 72a-d (62-75%), which were then reacted with 
phosphorus pentasulfide (P4S10) in ethanol. The reaction was conducted at room temperature 
allowing the synthesis of the desired key intermediate carbothioamides 62a-d (70-80%). 
 
Scheme 4. 
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The 3-bromoacetyl-7-azaindole intermediates 63a,b were synthesized in excellent yields (86-92%), 
starting from the commercial available 7-azaindole 73 and its methyl derivative 74 by acylation 
reaction with bromoacetyl bromide in the presence of aluminum chloride in dichloromethane 
(DCM) under reflux. The derivative 74 was obtained in good yield (96%) through the methylation 
of the 7-azaindole 73, using potassium t-butoxide as a base, tris[2-(2-methoxyethoxy)ethyl]amine 
(TDA-1) (1 or 2 drops) as phase transfer catalyst and methyl iodide (CH3I) as methylating agent in 
toluene at room temperature (Scheme 5).[125] 
 
 
Scheme 5. 
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3-{2-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 56a-h were synthesized from carbothioamides 75a-d and 3-bromoacetyl compounds 
63a,b. The key intermediates were reacted in ethanol for 30 minutes under reflux. After 
crystallization with ethanol, the desired 7-azaindolyl thiazoles 56a-h were isolated as hydrobromide 
salts (Scheme 6) in excellent yields (70-98%) (Table 8).  
 
Scheme 6. 
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Table 8. 3-{2-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 56a-h. 
 
Compd R R1 Yield % 
56a H H 70 
56b H CH3 80 
56c Br H 81 
56d Br CH3 98 
56e F H 95 
56f F CH3 98 
56g OCH3 H 92 
56h OCH3 CH3 93 
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In this case carbothioamides 75a-d were prepared as shown in the scheme 7.  
Once synthesized derivatives 70a-d were reacted with 4-(2-chloroethyl)morpholine 77[126], which 
was synthesized in excellent yield (98%) from the commercially available 4-(2-
chloroethyl)morpholine hydrochloride 76. The latter was solubilized in distilled water and treated 
with an aqueous solution of sodium hydroxide (NaOH) at 5%. Reaction between compounds 70a-d 
and 77 performed at 50 °C, using NaH as a base and DMF as reaction solvent, led to the synthesis 
of intermediates 78a-d (88-95%) which were then reacted with P4S10 in ethanol under reflux 
affording carbothioamides 75a-d (73-81%). 
 
 
Scheme 7. 
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3-{2-[1-(3-Morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 57a-h were synthesized from carbothioamides 79a-d and 3-bromoacetyl compounds 
63a,b, reacted in ethanol under reflux (30 minutes - 1 hour). Also in this case the desired 7-
azaindolyl thiazoles 57a-h were isolated as hydrobromide salts (Scheme 8) in excellent yields (80-
98%) (Table 9).  
 
Scheme 8. 
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Table 9. 3-{2-[1-(3-Morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromides 57a-h. 
 
Compd R R1 Yield % 
57a H H 80 
57b H CH3 80 
57c Br H 87 
57d Br CH3 90 
57e F H 85 
57f F CH3 98 
57g OCH3 H 98 
57h OCH3 CH3 98 
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Carbothioamides 79a-d were also obtained from derivatives 70a-d, which were reacted in this case 
with 1,3 dibromopropane 80. The reaction, carried out at room temperature, afforded derivatives 
81a-d (70-80%), which were subsequently solubilized in DMF and treated with morpholine 82 and 
K2CO3. The reaction heated at 50 °C led to the synthesis of derivatives 83a-d in excellent yields 
(90-98%). These intermediates were then converted in the desired carbothioamides 79a-d (60-72%) 
using the same synthetic procedure previously described (Scheme 9). 
 
 
Scheme 9. 
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3-{2-[1-(4-Morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 58a-h (70-95%) (Table 10) were obtained from reaction of carbothioamides 84a-d 
and 3-bromoacetyl compounds 63a,b performed in ethanol at room temperature for 24 hours 
(Scheme 10). 
Scheme 10. 
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Table 10. 3-{2-[1-(4-Morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromides 58a-h. 
 
Compd R R1 Yield % 
58a H H 82 
58b H CH3 72 
58c Br H 70 
58d Br CH3 74 
58e F H 92 
58f F CH3 95 
58g OCH3 H 76 
58h OCH3 CH3 88 
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Carbothioamides 84a-d were obtained in good yields (84-91%) using the same route described for 
the synthesis of carbothioamides of type 79. In this case derivatives 70a-d were reacted with 1,4 
dibromobutane 85 affording derivatives 86a-d in good yields (80-86%). These latter were then 
dissolved in DMF and treated with morpholine 82 giving derivatives 87a-d (90-92%) which were 
finally reacted with P4S10 in ethanol (Scheme 11). 
 
Scheme 11. 
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3-{2-[1-(2-Piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 59a-h were prepared from key intermediates 88a-d and 63a,b. Reaction of 
carbothioamides 88a-d and 3-bromoacetyl-7-azaindole compounds 63a,b in ethanol under reflux 
for 30 minutes gave, after crystallization, the desired 7-azaindolyl thiazoles 59a-h as hydrobromide 
salts (Scheme 12) in very good yields (70-91%) (Table 11).  
 
Scheme 12. 
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Table 11. 3-{2-[1-(2-Piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 59a-h. 
 
Compd R R1 Yield % 
59a H H 86 
59b H CH3 70 
59c Br H 71 
59d Br CH3 78 
59e F H 86 
59f F CH3 91 
59g OCH3 H 80 
59h OCH3 CH3 91 
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Carbothioamides 88a-d were obtained starting the synthesis from reaction of derivatives 70a-d and 
90 which gave derivatives 91a-d in excellent yields (90-98%). Compound 90[127] (87%) synthesized 
from the commercially available 1-(2-chloroethyl)piperidine hydrochloride 89, which was 
solubilized in distilled water and treated with an aqueous solution of sodium hydroxide (NaOH) at 
5%. Once obtained, derivatives 91a-d were reacted with P4S10 in ethanol under reflux affording the 
desired key intermediates 88a-d (67-72%) (Scheme 13). 
 
 
Scheme 13. 
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3-{2-[1-(3-Piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 60a-h (56-98%) (Table 12) were synthesized from carbothioamides 92a-d and 3-
bromoacetyl compounds 63a,b, reacted in ethanol under reflux for 30 minutes (Scheme 14).  
 
Scheme 14. 
 
 
N
R
CH2
92a-d
CH2
CH2
NH2
S
NN
O
Br
N
N
S
N
N
63a,b
R
R1 R1CH2
+
a R = H
b R = Br
c R = F
d R = OCH3
a R1 = H
b R1 = CH3
CH2
CH2 HBr
N N
60a-h
EtOH, 
 
 
 
 
Table 12. 3-{2-[1-(3-Piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromides 60a-h. 
 
Compd R R1 Yield % 
60a H H 64 
60b H CH3 56 
60c Br H 66 
60d Br CH3 68 
60e F H 87 
60f F CH3 98 
60g OCH3 H 82 
60h OCH3 CH3 65 
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The key intermediates 92a-d were synthesized starting from derivatives 81a-d, whose synthesis was 
previously described in scheme 9. These latter were reacted with piperidine 93 affording derivatives 
94a-d in good yields (70-93%). The subsequent reaction of these intermediates with P4S10 in 
ethanol under reflux gave the desired carbothioamides 92a-d (80-88%) (Scheme 15). 
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3-{2-[1-(4-Piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 61a-h were synthesized from carbothioamides 95a-d and 3-bromoacetyl-7-
azaindoles 63a,b. The reaction, performed in ethanol, was heated under reflux for 30 minutes 
giving, after crystallization, the desired 7-azaindolyl thiazoles 61a-h as hydrobromide salts (Scheme 
16) in good yields (57-83%) (Table 13).  
Scheme 16. 
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Table 13. 3-{2-[1-(4-Piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromides 61a-h. 
 
Compd R R1 Yield % 
61a H H 74 
61b H CH3 57 
61c Br H 65 
61d Br CH3 83 
61e F H 70 
61f F CH3 57 
61g OCH3 H 74 
61h OCH3 CH3 76 
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The key intermediates 95a-d were synthesized from derivatives 86a-d, whose synthesis has been 
previously reported in the scheme 11. In this case derivatives 86a-d were reacted with piperidine 93 
and led to the synthesis of derivatives 96a-d in excellent yields (82-96%).  
Treatment of these latter with P4S10 in ethanol under reflux afforded the desired carbothioamides 
95a-d (56-75%) (Scheme 17). 
 
 
Scheme 17. 
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RESULTS AND DISCUSSIONS:BIOLOGY 
 
All synthesized thiazoles 55a-h, 56a-h, 57a-h, 58a-h, 59a-h, 60a-h, 61a-h and 69a,b (Tables 7-13) 
were submitted to the National Cancer Institute (NCI, Bethesda MD) in order to evaluate their 
antitumor activity. 
Derivatives 55a, 55e-h, 57a,b, 57e-g, 58a, 58f-h, 69a,b were selected, according to the NCI 
protocol, for the in vitro disease-oriented antitumor one dose screening (10-5 M) against a panel of 
about 60 human tumor cell lines derived from 9 human cancer cell types, grouped in disease sub-
panel including leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, 
melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer cell lines (Tables 14-17). 
Among thiazoles bearing the hydroxyethyl chain (55a, 55e-h, Table 14), compounds 55f and 55g 
showed the best results with a mean growth percent value of 52.05 and 48.81 respectively. Both 
compounds were selective against the breast cancer subpanel with a mean growth percent value of 
36.44 and 28.96 respectively, with significant antiproliferative effect against MDA-MB-468 (-16.49 
for 55f and 1.57 for 55g) for which also derivatives 55a, 55e and 55h showed the lowest growth 
percent values (4.37, -11.08 and -16.84 respectively). Moreover compound 55g resulted selective 
against the renal cancer subpanel (mean growth percent value of 36.14) showing the best result 
against A498 cell line (mean growth percent value of -0.47) 
Thiazoles bearing on the indole nitrogen the morpholine propyl chain (57a,b,e-g, Table 15), showed 
significant antiproliferative effect against the leukemia subpanel for which the best mean growth 
percent values were shown (16.39 for 57a, 56.20 for 57b, 19.85 for 57e, 37.01 for 57f and 5.27 for 
57g) if compared to those obtained for other subpanels. The most promising compound was 
derivative 57g with a mean growth percent value of 23.90 and showing significant antiproliferative 
effect in a wide range of human tumor cell lines with different negative growth percent values (e.g. 
-54.15 for SK-MEL-28 of the melanoma subpanel and -38.46 for COLO-205 of colon cancer 
subpanel). 
Also thiazoles bearing on the indole nitrogen the morpholine butyl chain (58a,f-h, Table 16) 
showed significant antiproliferative effect against the leukemia subpanel for which negative growth 
percent values were recorded for several cell lines. The mean growth percent values were -10.21 for 
compound 58a, 16.6 for 58f, -18.35 for compound 58g and -8.95 for compound 58h. Moreover they 
resulted active against melanoma subpanel with mean growth percent values of 19.44 for 58a, 0.99 
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for 58f, -12.15 for 58g and -26.26 for 58h. The most sensitive cell line of this subpanel was SK-
MEL-28 in which the lower growth percent values were reached (-71.09, -87.10, -90.30, -93.55 for 
compounds 58a, 58f, 58g, 58h respectively). Compounds 58a, 58g and 58h resulted also significant 
active against the colon cancer subpanel with mean growth percent values of 3.21, -29.07 and -
14.55 respectively. The most active compound of this series was 58h that also showed good results 
against the CNS cancer subpanel (mean growth percent values of 9.75). 
Table 14. Mean Growth Percent of compounds 55a, 55e-h. 
Cell line Growth Percent  
 55a 55e 55f 55g    55h 
Leukemia      
CCRF-CEM 84.83 55.96 44.39        41.27    43.33 
             HL-60(TB) 79.15 60.30 50.19 57.95 82.42 
K-562 54.21 21.52 18.07 43.53 25.19 
MOLT-4 71.22 54.54 46.70 54.99 58.24 
RPMI-8226 57.82 53.59 62.58 39.90 50.54 
SR 53.52 22.02 20.68 37.80 58.21 
Non-Small Cell Lung 
Cancer 
     
A549/ATCC 77.52 62.98 49.82 66.94 79.82 
EKVX 31.97 37.21 57.39 34.94 67.48 
HOP-62 74.66 71.90 52.56 53.72 81.17 
HOP-92 57.96 52.34 64.83 48.59 70.38 
NCI-H226 58.02 48.45 76.00 36.54 70.08 
NCI-H23 71.85 76.24 74.14 62.51 89.42 
NCI-H322M 74.83 66.32 79.14 47.56 77.68 
NCI-H460 78.63 65.73 27.05 46.34 74.87 
NCI-H522 58.57 45.48 10.05 36.85 60.52 
Colon Cancer       
COLO-205 85.90 66.44 46.03 56.94 81.17 
HCC-2998 51.97 65.25 64.10 58.93 95.10 
HCT-116 85.20 62.42 35.81 50.88 74.16 
HCT-15 55.93 41.55 41.53 31.95 61.08 
HT29 95.02 46.78 18.17 54.51 75.26 
KM12 47.97 28.35 30.63 20.67 49.46 
SW-620 91.50 57.93 29.76 63.07 93.58 
CNS Cancer      
SF-268 84.12 77.02 77.60 66.57 91.11 
SF-295 81.09 72.08 52.31 57.87 74.12 
SF-539 88.45 81.46 69.94 49.99 75.02 
SNB-19 88.11 79.45 69.62 82.36 90.18 
SNB-75 55.18 72.48 46.39 31.73 91.34 
U251 78.90 62.89 49.29 53.21 78.50 
Melanoma      
LOX IMVI 77.72 65.50 44.78 42.77 59.29 
MALME-3M 115.31 84.92 72.82 75.87 110.27 
M14 97.75 63.84 35.74 59.33 75.10 
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MDA-MB-435 52.14 5.03 1.70 66.48 86.53 
SK-MEL-2 98.57 66.20 52.17 48.68 92.99 
SK-MEL-28 103.64 89.81 74.35 78.53 85.97 
SK-MEL-5 77.50 63.04 62.89 58.43 74.18 
UACC-257 93.05 87.81 77.37 91.02 92.45 
UACC-62 69.91 63.27 52.39 58.44 80.45 
Ovarian Cancer       
IGROV1 56.06 44.74 51.91 43.42 85.16 
OVCAR-3 81.72 81.00 49.69 78.73 99.08 
OVCAR-4 51.66 52.35 35.97 42.13 45.54 
OVCAR-5 90.49 84.34 65.58 68.17 75.99 
OVCAR-8 90.45 80.18 75.86 56.23 73.03 
NCI/ADR-RES  94.60 82.57 45.45 76.04 90.04 
SK-OV-3 70.16 70.10 73.03 30.01 89.77 
Renal Cancer      
786-0 95.08 81.93 73.32 59.49 79.98 
A498 34.69 22.98 45.35 -0.47 49.34 
ACHN 69.30 65.80 69.49 26.66 72.10 
CAKI-1 73.74 70.74 78.44 35.50 88.75 
RXF 393 82.39 51.09 69.68 30.14 84.63 
SN12C 80.02 80.34 73.19 63.51 86.11 
TK-10 82.50 62.06 47.68 58.30 82.97 
UO-31 37.83 39.36 70.72 16.06 67.69 
Prostate Cancer      
PC-3 61.81 48.74 44.63 48.97 69.10 
DU-145 93.48 83.68 95.38 56.48 90.94 
Breast Cancer      
MCF7 32.92 48.11 34.86 20.06 12.04 
MDA-MB-231/ATCC 66.42 64.47 57.93 51.51 56.96 
HS 578T 71.29 70.93 79.85 33.51 80.94 
BT-549 76.05 68.74 52.77 41.74 76.92 
T-47D 37.25 35.17 9.75 23.37 10.12 
MDA-MB-468 
 
4.37 
 
-11.08 
 
-16.49 
 
1.57 
 
-16.84 
 
MEAN 71.57 59.61 52.05 48.81 72.12 
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Table 15. Mean Growth Percent of compounds 57a,b,e-g. 
Cell line                          Growth Percent  
 57a 57b 57e 57f 57g 
Leukemia      
CCRF-CEM 17.37 61.99 21.82      36.37    13.08 
              HL-60(TB) 35.82 70.87 21.94 69.93 17.38 
K-562 1.22 26.24 1.71 0.48 -5.12 
MOLT-4 16.58 59.70 24.79 32.14 -1.04 
RPMI-8226 24.42 59.46 36.64 34.76 0.66 
SR 2.93 58.94 12.05 48.37 6.64 
Non-Small Cell Lung 
Cancer 
     
A549/ATCC 54.36 79.29 42.57 66.12 42.02 
EKVX 47.89 86.74 55.89 63.03 57.79 
HOP-62 48.69 97.37 49.87 71.71 28.86 
HOP-92 12.00 67.73 23.52 40.78 27.92 
NCI-H226 61.48 75.71 59.29 51.90 45.41 
NCI-H23 68.07 88.33 76.03 63.75 56.63 
NCI-H322M 80.19 95.59 80.89 78.98 42.07 
NCI-H460 45.44 88.52 37.80 41.00 25.70 
NCI-H522 56.88 67.86 41.25 49.55 26.28 
Colon Cancer       
COLO-205 31.23 73.92 18.08 51.26 -38.46 
HCC-2998 58.63 92.88 74.26 65.42 65.52 
HCT-116 29.79 84.38 40.44 72.31 25.28 
HCT-15 13.98 55.53 24.47 27.08 13.73 
HT29 7.69 32.87 12.87 1.97 -12.94 
KM12 28.13 85.41 22.50 34.29 17.01 
SW-620 39.48 94.62 24.95 61.03 21.22 
CNS Cancer      
SF-268 52.34 91.69 50.78 66.61 43.86 
SF-295 16.71 79.49 27.54 11.21 -34.44 
SF-539 52.87 89.41 67.35 57.57 33.56 
SNB-19 56.82 90.84 62.75 77.12 54.40 
SNB-75 20.15 82.60 41.24 87.14 21.35 
U251 32.94 64.25 30.35 51.05 16.32 
Melanoma      
LOX IMVI 30.62 79.04 33.07 26.64 17.02 
MALME-3M 61.14 107.68 59.21 87.38 5.55 
M14 14.52 83.58 34.67 46.22 10.02 
MDA-MB-435 6.18 91.58 -17.10 65.35 46.96 
SK-MEL-2 82.63 91.75 60.49 86.29 11.35 
SK-MEL-28 65.30 88.64 75.37 77.55 -54.15 
SK-MEL-5 38.03 64.56 43.73 25.11 31.61 
UACC-257 85.05 89.28 82.95 78.50 49.86 
UACC-62 65.45 92.47 69.46 72.22 44.12 
Ovarian Cancer       
IGROV1 35.27 98.56 38.63 76.25 22.87 
OVCAR-3 64.40 96.32 59.80 77.57 44.02 
OVCAR-4 45.12 97.79 56.22 56.59 41.53 
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OVCAR-5 62.12 84.72 82.28 72.99 68.08 
OVCAR-8 62.43 82.60 59.72 47.59 25.31 
NCI/ADR-RES  60.09 91.03 59.24 53.78 43.42 
SK-OV-3 73.40 101.93 81.63 80.02 51.85 
Renal Cancer      
786-0 28.39 74.44 57.29 57.43 -24.31 
A498 53.86 55.20 50.99 36.14 27.80 
ACHN 32.81 93.66 42.23 63.78 14.53 
CAKI-1 47.46 92.03 56.15 78.99 28.83 
RXF 393 24.87 65.74 39.51 36.07 -9.75 
SN12C 64.49 87.16 73.90 78.48 52.65 
TK-10 69.59 86.85 66.89 75.05 51.47 
UO-31 23.03 70.98 31.54 50.24 11.87 
Prostate Cancer      
PC-3 19.59 67.97 31.93 29.63 18.25 
DU-145 82.03 97.89 79.79 80.30 41.48 
Breast Cancer      
MCF7 28.62 85.65 22.00 34.09 13.30 
MDA-MB-231/ATCC 27.10 76.52 36.04 25.09 9.85 
HS 578T 28.47 87.98 38.31 46.61 2.12 
BT-549 50.28 88.71 69.46 71.63 52.16 
T-47D 27.08 62.10 38.14 41.15 31.70 
MDA-MB-468 
 
26.19 
 
65.12 
 
18.29 49.32 
 
41.99 
 
MEAN 41.66 80.03 45.26 54.95 23.90 
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Table 16. Mean Growth Percent of compounds 58a,f-h.  
Cell line Growth Percent 
 58a 58f 58g 58h 
Leukemia     
CCRF-CEM 10.12 -59.55 -8.39        2.06 
           HL-60(TB) -58.24 76.21 7.66 24.65 
K-562 -38.72 -49.74 -65.23 -41.02 
MOLT-4 13.10 46.68 -21.00 -15.65 
RPMI-8226 32.60 49.01 -5.60 -18.11 
SR -20.13 36.99 -17.53 -5.63 
Non-Small Cell Lung 
Cancer 
    
A549/ATCC 56.90 75.11 49.70 48.31 
EKVX 64.03 72.68 68.39 60.22 
HOP-62 52.81 85.65 37.11 30.92 
HOP-92 31.99 52.76 43.00 47.86 
NCI-H226 72.43 60.21 70.25 70.13 
NCI-H23 81.08 80.34 69.92 78.41 
NCI-H322M 78.98 84.33 57.23 65.88 
NCI-H460 31.44 93.47 4.29 -31.92 
NCI-H522 49.07 57.18 39.91 3.68 
Colon Cancer      
COLO-205 -77.55 65.94 -100.00 91.73 
HCC-2998 56.87 92.42 26.72 7.68 
HCT-116 40.32 83.00 32.53 11.37 
HCT-15 5.17 61.67 -31.70 -42.12 
HT29 -44.59 -64.03 -84.42 -87.82 
KM12 24.13 52.48 16.39 -5.62 
SW-620 18.09 19.68 -63.03 -77.06 
CNS Cancer     
SF-268 49.73 63.04 52.37 52.79 
SF-295 53.93 50.80 13.11 -48.46 
SF-539 80.75 69.69 49.34 30.77 
SNB-19 57.53 88.19 52.44 35.14 
SNB-75 35.43 61.94 40.11 43.61 
U251 20.05 67.27 4.84 -55.35 
Melanoma     
LOX IMVI 20.76 67.61 -34.71 -78.84 
MALME-3M -24.96 -60.28 -66.68 -59.54 
M14 -49.93 -53.87 -53.54 -66.87 
MDA-MB-435 24.36 38.13 -59.02 -83.43 
SK-MEL-2 87.77 78.72 68.98 64.35 
SK-MEL-28 -71.09 -87.10 -90.30 -93.55 
SK-MEL-5 51.25 48.10 25.97 14.46 
UACC-257 67.84 -45.12 79.50 63.45 
UACC-62 68.93 22.77 20.41 3.59 
Ovarian Cancer      
IGROV1 34.89 65.37 36.07 67.80 
OVCAR-3 59.85 89.99 58.26 50.81 
OVCAR-4 74.82 84.55 50.78 60.17 
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OVCAR-5 72.49 79.47 58.31 56.86 
OVCAR-8 60.59 81.26 55.65 48.51 
NCI/ADR-RES  69.40 76.81 63.33 59.59 
SK-OV-3 81.14 83.97 78.20 79.71 
Renal Cancer     
786-0 53.95 63.16 -43.75 -71.67 
A498 56.81 46.69 92.30 58.14 
ACHN 32.35 86.29 17.11 32.00 
CAKI-1 44.28 76.10 37.46 41.38 
RXF 393 53.71 16.25 31.90 0.73 
SN12C 66.97 72.16 61.90 67.98 
TK-10 64.41 75.37 64.45 69.88 
UO-31 25.40 44.41 22.75 33.97 
Prostate Cancer     
PC-3 25.88 49.30 30.11 31.33 
DU-145 70.03 100.06 48.85 46.77 
Breast Cancer     
MCF7 25.14 78.36 18.08 15.10 
MDA-MB-231/ATCC 32.80 35.20 23.36 5.75 
HS 578T 54.86 41.06 44.77 18.76 
BT-549 79.64 65.25 84.19 76.80 
T-47D 36.13 76.87 47.97 64.50 
MDA-MB-468 
 
35.05 
 
65.01 
 
39.27 
 
34.99 
 
MEAN 36.05 50.59 20.84 13.44 
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Thiazoles 69a and 69b, bearing on the indole ring the ethyl carbamic chain, also showed inhibitory 
activity against several tumor cell lines (Table 17). In particular derivative 69a showed the best 
mean growth percent value (33.31) with selectivity against leukemia, colon cancer and melanoma 
with mean growth percent values for these subpanels of 18.06, 24.98 and 21.92 respectively. 
Table 17. Mean Growth Percent of compounds 69a and 69b. 
Cell line Growth Percent  Growth Percent  
 69a 69b  69a 69b  
Leukemia   Melanoma    
CCRF-CEM 21.73 73.88 LOX IMVI 30.07 79.02  
HL-60(TB) 6.14 86.87 MALME-3M 62.40 66.40  
K-562 11.77 27.31 M14 11.83 71.12  
MOLT-4 19.56 69.10 MDA-MB-435 -33.36 8.15  
RPMI-8226 24.94 74.08 SK-MEL-2 2.38 84.85  
SR 24.20 20.26 SK-MEL-28 61.66 92.51  
Non-Small Cell 
Lung Cancer 
  SK-MEL-5 18.49 71.87  
A549/ATCC 36.87 67.44 UACC-257 60.54 87.95  
EKVX 42.11 68.74 UACC-62 32.91 72.20  
HOP-62 39.17 74.46 Ovarian 
Cancer 
   
HOP-92 49.11 83.12 IGROV1 41.28 77.68  
NCI-H226 53.00 86.41 OVCAR-3 27.93 94.94  
NCI-H23 63.27 81.22 OVCAR-4 71.72 101.74  
NCI-H322M 65.91 90.80 OVCAR-5 58.25 104.16  
NCI-H460 17.82 82.36 OVCAR-8 41.57 89.35  
NCI-H522 5.49 24.21 NCI/ADR-RES 38.11 82.90  
Colon Cancer   SK-OV-3 41.64 95.18  
COLO 205 4.32 77.56 Renal Cancer    
HCC-2998 71.67 90.44 786-0 42.87 87.36  
HCT-116 30.79 86.50 A498 -11.71 19.02  
HCT-15 28.04 63.95 ACHN 38.02 96.99  
HT29 8.34 47.64 CAKI-1 34.47 88.24  
KM12 23.03 67.04 RXF 393 46.30 91.38  
SW-620 8.68 67.87 SN12C 49.10 88.32  
CNS Cancer   TK-10 62.30 82.56  
SF-268 50.00 95.79 UO-31 34.11 79.58  
SF-295 25.51 86.25 Prostate 
Cancer 
   
SF-539 33.76 92.69 PC-3 33.22 63.56  
SNB-19 42.23 78.64 DU-145 64.92 103.20  
SNB-75 10.57 80.75 Breast 
Cancer 
   
U251 20.01 77.77 MCF7 18.26 58.18  
   MDA-MB-
231/ATCC 
49.72 80.37  
   HS 578T 41.41 92.58  
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   BT-549 32.84 79.46  
   T-47D 44.70 45.80  
  MDA-MB-468 12.45 16.23  
MEAN 69a: 33.31  
69b: 74.60 
    
 
On the basis of the obtained results, compounds 57g, 58a, 58g, 58h, and 69a, satisfying the criteria 
set by the NCI for activity, were selected for further screenings at 5 concentrations at 10-fold 
dilution (10-4-10-8 M) on the full panel (Table 18). The antitumor activity of compounds was given 
by three parameters for each cell line: GI50 (GI50 is the molar concentration of the compound that 
inhibits 50% net cell growth), TGI (TGI is the molar concentration of the compound leading to total 
inhibition of net cell growth), and LC50 (LC50 is the molar concentration of the compound that 
induces 50% net cell death). The average values of mean graph midpoint (MG_MID) were 
calculated for each of these parameters.  
Table 18. In vitro inhibition of cancer cell line growth by compounds 57g, 58a, 58g, 58h, 69a 
(M)a. 
Cell line GI50 (M)  
 57g 58a 58g 58h 69a 
Leukemia      
CCRF-CEM 2.76 1.98 2.12         0.45    2.65 
             HL-60(TB) 2.11 1.96 1.93 1.67 2.12 
K-562 2.08 2.02 1.95 0.24 1.55 
MOLT-4 1.85 1.81 1.86 0.60 2.19 
RPMI-8226 1.92 1.83 1.99 0.77 2.04 
SR 2.30 1.91 2.01 0.27 1.08 
Non-Small Cell Lung 
Cancer 
     
A549/ATCC 4.04 1.89 2.23 1.41 2.34 
EKVX 3.01 2.07 2.66 1.50 1.30 
HOP-62 2.24 1.70 1.91 1.72 1.07 
HOP-92 2.42 1.43 1.67 0.52 0.67 
NCI-H226 3.10 2.29 2.46 2.56 1.68 
NCI-H23 2.68 2.04 2.15 2.02 2.02 
NCI-H322M 1.96 1.79 1.82 1.63 1.95 
NCI-H460 2.54 1.88 1.99 0.77 2.46 
NCI-H522 2.07 1.95 2.34 1.64 1.49 
Colon Cancer       
COLO-205 1.82 1.73 1.85 1.49 2.06 
HCC-2998 2.04 1.74 1.91 1.47 1.99 
HCT-116 1.85 1.65 1.78 0.28 1.72 
HCT-15 2.32 1.81 1.96 0.24 1.92 
HT29 2.22 2.10 2.18 0.31 1.77 
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KM12 2.41 1.72 1.93 1.09 1.44 
SW-620 2.26 1.77 1.99 0.31 1.30 
CNS Cancer      
SF-268 2.69 1.76 1.80 1.34 1.48 
SF-295 1.91 1.92 1.93 1.53 2.29 
SF-539 1.74 1.71 1.67 1.34 1.61 
SNB-19 2.86 1.76 1.91 1.49 2.57 
SNB-75 1.27 1.19 1.31 0.52 NDb 
U251 2.25 1.81 1.73 0.81 1.91 
Melanoma      
LOX IMVI 1.74 1.74 1.71 1.04 1.55 
MALME-3M 1.39 1.32 1.55 1.59 NDb 
M14 1.77 1.78 1.81 0.19 1.33 
MDA-MB-435 1.75 1.72 1.70 0.76 NDb 
SK-MEL-2 1.88 1.95 1.97 2.05 1.52 
SK-MEL-28 1.95 1.81 1.85 1.32 2.05 
SK-MEL-5 1.83 1.73 1.75 1.59 1.41 
UACC-257 2.04 1.84 2.18 1.49 2.08 
UACC-62 1.97 1.79 1.87 1.48 1.57 
Ovarian Cancer       
IGROV1 2.09 1.43 2.48 3.43 0.14 
OVCAR-3 2.57 1.64 1.87 1.46 1.27 
OVCAR-4 2.14 2.06 2.21 1.48 1.78 
OVCAR-5 2.60 1.82 1.99 2.03 2.21 
NCI/ADR-RES  3.02 2.04 2.34 1.56 2.82 
SK-OV-3 2.83 2.34 2.37 5.78 1.54 
Renal Cancer      
786-0 1.74 1.85 1.78 0.42 2.38 
A498 0.48 NDb 0.22 0.02 0.91 
ACHN 2.50 1.79 1.79 1.50 2.05 
CAKI-1 1.88 1.74 1.80 1.39 2.42 
RXF 393 2.09 1.67 1.73 0.93 1.78 
SN12C 3.16 2.98 1.91 6.05 2.46 
TK-10 3.48 2.77 5.25 4.25 2.24 
UO-31 1.37 1.15 1.43 1.11 0.62 
Prostate Cancer      
PC-3 2.48 1.59 1.75 0.73 1.87 
DU-145 3.15 2.12 3.07 1.44 3.07 
Breast Cancer      
MCF7 1.43 1.56 1.56 1.65 0.99 
MDA-MB-231/ATCC 1.86 1.58 1.70 0.52 1.10 
HS 578T 2.08 1.77 2.05 0.77 1.07 
BT-549 2.00 2.13 3.74 2.97 1.50 
T-47D 2.07 1.33 2.12 12.00 NDb 
MDA-MB-468 
 
2.52 2.07 
 
1.95 0.97 1.33 
a Data obtained from NCI’s in vitro disease-oriented tumor cells screen 
b ND = Not Determined  
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An evaluation of the data reported in table 19 pointed out that all derivatives resulted active from 
micromolar to nanomolar concentration, against most of tested cell lines, as it has been confirmed 
by the range of GI50 value of 4.04-0.48, 2.98-1.15, 5.25-0.22, 12.00-0.02, 3.07-0.14 M, 
respectively for compounds 57g, 58a, 58g, 58h, and 69a. 
Compound 58h, resulted more active than thiazoles 57g, 58a, 58g, and 69a in terms either of GI50 
(mean value 1.59, 2.21, 1.83, 2.01 and 1.82 µM, respectively) and percentage of sensitive cell lines 
out of the total number of cell lines investigated (100%, 100%, 98%, 100%, and 93% respectively). 
It showed a remarkable inhibitory activity against a wide range of tumor cell lines. The leukemia 
subpanel resulted the most sensitive, showing a range of concentrations from micromolar to 
submicromolar (1.67-0.24 µM) followed by the colon cancer with a range from 1.49 to 0.24 µM. 
 
 
Table 19. Overview of compounds 57g, 58a, 58g, 58h, 69a. 
Compd N° of cell 
line tested 
N° of active 
cell lines 
GI50 (µM) 
Range MG_MID 
57g 59 59 4.04-0.48 2.21 
58a 59 58 2.98-1.15 1.83 
58g 59 59 5.25-0.22 2.01 
58h 59 59 12.00-0.02 1.59 
69a 59 55 3.07-0.14 1.82 
 
However studies on the potential cytotoxic activity of the other thiazoles synthesized 56a-h, 59a-h, 
60a-h, 61a-h are in progress, as well as the evaluation of the selectivity of all the compounds 55a-h, 
56a-h, 57a-h, 58a-h, 59a-h, 60a-h, 61a-h against GSK-3β target. 
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DOCKING STUDIES 
 
GSK-3β has the typical two-domain kinase fold[128-129] with a β-strand domain (residues 25-138, 
blue in Figure 12) at the N-terminal end and an α-helical domain at the C-terminal end (residues 
139-343, magenta in Figure 12). The ATP-binding site is at the interface of the α-helical and β-
strand domain and is bordered by the glycine-rich loop and the hinge. The activation loop (residues 
200-226) runs along the surface of the substrate binding groove. The C-terminal 39 residues 
(residues 344-382) are outside the core kinase fold and form a small domain that packs against the 
α-helical domain.  
 
Figure 12. Structure of GSK-3β. 
The β-strand domain consists of seven antiparallel β-strands: strands 2-6 form a β-barrel that is 
interrupted between strand 4 and 5 by a short helix (residue 96-102) that packs against the β-barrel. 
This helix is conserved in all kinases, and two of its residues play key roles in the catalytic activity 
of the enzyme. Arg 96 (R96, Figure 13) is involved in the alignment of the two domains. Glu 97 is 
positioned in the active site and forms a salt bridge with Lys 85, a key residue in catalysis. GSK-3β 
has two phosphorylation sites that influence the catalytic activity of the protein. Ser 9 is the 
phosphorylation site for Akt, and the phosphorylation of this residue inactivates GSK-3β. Tyr 216 
(Y216, Figure 13), located on the activation loop, plays an important key role in the opening and 
closing of the substrate binding site.[130] 
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Figure 13. Activation loop of GSK-3β. 
Different X-ray crystallographic structures of GSK-3β were published providing further information 
about its regulation mechanism, its kinase activity and its preference for pre-phosphorylated 
substrates.  
In the crystal structure with pdb 1Q3D[131], GSK-3β is in complex with Staurosporine, a potent non-
selective inhibitor for which is reported a IC50 value of 15 nM.
[132]  
 
This structure reveals how the inhibitor binds the ATP-binding site. It utilizes a water network to 
bind the enzyme in a unique manner. Staurosporine infact, interacts through hydrogen bonds 
between its N1 and Asp 133 carbonyl oxygen of the hinge, and its O5 and the backbone nitrogen of 
Val 135. Moreover it establishes a water-polar-mediated interaction between the methylamino 
nitrogen (N4) of the glycosidic ring and the carbonyl oxygen of Gln 185. In the staurosporine 
complex, this water molecule is part of a hydrogen-bonding network that starts with Oɤ of Thr 138, 
passes through four water molecules and ends with the carbonyl oxygen of Val 135 (Figure 14). 
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Figure 14. Staurosporine-GSK-3β complex in 1Q3D crystal structure. 
In the crystal structure with pdb 1Q4I[131], indirubin-3’-monoxime, an extremely potent GSK-3β 
inhibitor (IC50 = 22 nM), is co-crystallized with GSK-3β.  
The structure reveals a donor-acceptor-donor series of hydrogen bonds between the ligand and the 
hinge residues of GSK-3β. The N1 and O2 atoms form hydrogen bonds with the carbonyl oxygen of 
Asp 133 and the backbone nitrogen of Val 135, respectively (Figure 15).  
 
 
 
 
Figure 15. Indirubin-3’-monoxime-GSK3β complex in 1Q4I crystal structure. 
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The co-crystal structure 1Q3W[131], shows alsterpaullone bound in the GSK-3β active site (Figure 
16). Alsterpaullone interact with the hinge area through two direct hydrogen bonds with Val 135 and 
one water mediated interaction with Asp 133. Moreover the N5 and carbonyl oxygen atoms of 
alsterpaullone make a pair of hydrogen bonds with the backbone nitrogen and carbonyl oxygen of 
Val 135, respectively, and the water molecule bridges between the carbonyl oxygen atoms of 
alsterpaullone and Asp 133. In addition to the hinge interactions, alsterpaullone also makes polar 
interactions between the nitro group in position 9 and the side-chain amino group of Lys 85. One 
feature that makes alsterpaullone unique is the positioning of its coupled ring systems.  
 
Figure 16. Alsterpaullone-GSK-3β complex in 1Q3W crystal structure. 
In the complex with GSK-3β, the inhibitor’s seven membered ring is situated slightly below the 
adenine-binding pocket and the pucker of ring B directs the attached ring. Ring A extends 
downward, following the path of the hinge towards the guanidine group of Arg 141. Rings C and D 
extend away from the hinge, passing through the ribose pocket and up towards the side-chain amino 
group of Lys 85. The shape of alsterpaullone also allows it to bury itself in the GSK-3β active site.  
The X-ray crystal structure 2OW3[133], shows a bis-indolyl maleimidic derivative (BIM) complexed 
to GSK-3β in the ATP binding pocket (Figure 17). The maleimide portion makes key hydrogen 
bonding contacts with residues Asp 133 (amide CO) and Val 135 (Nα). The other maleimide CO 
hydrogen bonds with a water molecule that bridges to Asp 200 (Nα). BIM ligand makes also 
hydrophobic contacts with the side chains of Ile 62, Phe 67, Thr 138, Leu 188, and Cys 199. 
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Figure 17. a) BIM-GSK-3β complex in 1Q3W crystal structure; b) two views of the complexed 
ligand, rotated 90° relative to each other. 
The analysis of the interactions between GSK-3β structures and different inhibitors reveals how the 
enzyme can accommodate a number of diverse molecular scaffolds. The comparison of all these 
structures shows that the interaction of selective, and nonselective, inhibitors with GSK-3β usually 
involves key hydrogen bonding of the inhibitor ligand with Asp 133 and Val 135, which reside at 
the ‘hinge region’ of the ATP binding site. 
In order to verify if the synthesized compounds are able to potentially interact with GSK-3β by 
forming the key hydrogen bonds observed for known inhibitors, docking studies were performed on 
this target. 
For this purpose, different structures were preliminary used. All X-ray structures were downloaded 
from the Protein Data Bank (http://www.rcsb.org) and prepared using Schrodinger’s Protein 
Preparation Wizard of Prime module[134] for protein structure refinement, through which the subunit 
B and its co-crystallized ligand were removed. 
Ligands were prepared considering their protonated forms at physiological pH. Docking studies 
were performed using Extra Precision mode (XP) of Glide module of Schrodinger.[135] In order to 
evaluate the reliability of Glide protocol, the re-docking of the co-crystallized ligand was performed 
and its pose was compared to that of the crystallographic structure. 
Considering the better results obtained in re-docking and docking procedures, the X-ray structure 
with pdb 1Q3D was selected for our studies. 
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All compounds bind GSK-3β similarly to Staurosporine. In table 20 are shown the docking score 
results and the key H-bond interactions for the synthesized compounds. The best results were 
obtained for derivatives bearing the free nitrogen on the azaindole moiety that is responsible for 
interaction with the key residues Asp 133 and Val 135 (Figure 18), as observed for the known 
inhibitors previously mentioned. The importance of the free nitrogen seems to be confirmed by the 
preliminary biological results obtained. Among the five most active compounds, selected for the 
five doses NCI screening, four compounds bear a free nitrogen in the azaindole portion. Moreover, 
all synthesized compounds bearing the unsubstituted azaindole moiety bind, through their chains, 
Asp 200 that seems to be a key residue for the new compounds (Figure 18, Table 20). No 
differences were observed on the basis of the inserted chains in terms of docking scores and binding 
poses probably due to the presence in all chains of an H-bond donor group that is able to bind Asp 
200 residue. 
 
 
Figure 18. Docking poses of compounds 69a, 55a, 56g, 57a, 58a, 59a, 60e and 61g. 
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Table 20. Docking score results of compounds 69a,b, 55a-h, 56a-h, 57a-h, 58a-h, 59a-h, 60a-h, 
61a-h. 
Compound D. Score H-bond interaction 
residues 
Compound D. Score H-bond interaction 
residues 
69a -9.323 ASP133, VAL135, 
ASP181, ASP200 
58d 
58e 
-6.680 
-9.665 
LYS85 
ASP133, VAL135, 
ASP200 
69b -7.045 LYS85, HOH609 58f -6.650 LYS85, HOH609 
55a 
 
55b 
55c 
 
55d 
55e 
55f 
-9.468 
 
-6.817 
-8.411 
 
-7.044 
-8.363 
-7.277 
ASP133, VAL135, 
ASP200, LYS183 
LYS85 
ASP133, VAL135, 
LYS183 
PRO136, LYS85 
PRO136 
PRO136, LYS85 
58g 
 
58h 
59a 
 
59b 
59c 
 
59d 
-9.920 
 
-7.219 
-9.504 
 
-6.719 
-9.225 
 
-6.460 
ASP133, VAL135, 
ASP200 
HOH589 
ASP133, VAL135, 
ASP200 
ASP200 
ASP133, VAL135, 
ASP200 
LYS85 
55g -9.056 ASP133, VAL135, 
ASP200, LYS183 
59e -9.015 ASP133, VAL135, 
ASP200 
55h 
56a 
 
56b 
56c 
 
56d 
56e 
 
-6.837 
-7.426 
 
-4.270 
-6.734 
 
-4.720 
-7.348 
 
HOH589 
ASP133, VAL135, 
ASP200, SER203 
LYS85 
ASP133, VAL135, 
ASP200, SER203 
LYS85 
ASP133, VAL135, 
ASP200, SER203 
59f 
59g 
 
59h 
60a 
 
60b 
60c 
 
6.353 
-9.437 
 
-5.581 
-9.873 
 
-6.273 
-9.765 
LYS85 
ASP133, VAL135, 
ASP200 
PRO136 
ASP133, VAL135, 
ASP200 
LYS85 
ASP133, VAL135, 
ASP200 
56f 
56g 
-4.977 
-7.909 
PRO136, LYS85 
ASP133, VAL135, 
ASP200, SER203 
60d -6.072 PRO136 
56h -4.023 ASP200 60e -10.174 ASP133, VAL135, 
ASP200 
57a 
 
57a 
57b 
57c 
-9.586 
 
-8.250 
-6.805 
-9.289 
ASP133, VAL135, 
ASP200 
ASP133, VAL135 
ASP200 
ASP133, VAL135, 
ASP200 
60f 
 
60g 
 
60h 
-6.589 
 
-9.708 
 
-6.671 
ASP200 
 
ASP133, VAL135, 
ASP200 
HOH589 
57d -6.097 ASP200 61a -9.628 ASP133, VAL135, 
ASP200 
57e -8.941 ASP133, VAL135, 
ASP200 
61b -5.929 HOH589, ASP200 
57f -6.377 LYS85, HOH609 61c -9.680 ASP133, VAL135, 
ASP200 
57g -8.958 ASP133, VAL135, 
ASP200 
61d -6.057 LYS85, PRO136 
57h -6.457 HOH589 61e -9.623 ASP133, VAL135, 
ASP200 
58a -10.009 ASP133, VAL135, 
ASP200 
61f -5.895 LYS85, TYR134 
58b -6.086 LYS85, LYS60 61g -9.913 ASP133, VAL135, 
ASP200 
58c -9.665 ASP133, VAL135, 
ASP200 
61h -7.029 HOH589, ASP200 
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EXPERIMENTAL SECTION 
 
CHEMISTRY 
General methods 
All melting points were taken on a Buchi-Tottoly capillary apparatus and were uncorrected. IR 
spectra were determined in bromoform with a Shimadzu FT / IR 8400S spectrophotometer. 1H and 
13C NMR spectra were measured at 200 and 50 MHz, respectively, on DMSO-d6 or CDCl3 solution, 
using a Bruker Avance II series 200 MHz spectrometer. Chromatography column was performed 
with MERK silica gel 230-400 mesh ASTM or FLASH40i Biotage chromatography or with Buchi 
Sepacore chromatography module (prepacked cartridge reference). Elementar analyses (C, H, N) 
were within ± 0.4% of the theoretical values. Compounds 55e, 55g, 60h were characterized only by 
1H NMR spectra, for their poor solubility the 13C spectra were not performed. 
General procedure for the synthesis of 1-(2-trityloxy-ethyl)-1H-indole (66a) 
To a solution of indole 64a (0.20 g, 1.71 mmol) in dry DMF (5 mL), cooled with an ice bath, was 
slowly added sodium hydride 60% dispersion in mineral oil (NaH) (0.06 g, 2.56 mmol). After 30 
minutes stirring at 0-5 °C, the compound 1-bromo-2-trityloxy-ethane 65[124] (0.75 g, 2.05 mmol) 
was added in one portion. The reaction mixture was then heated to 60 °C for 3 hours. After that, the 
mixture was poured into water and ice and the obtained precipitate was filtered off, dried, to give 
the desired derivative 66a. 
N
CH2CH2O
Ph
Ph
Ph
 
Yield: 98%, white solid; mp: 131-132 °C; 1H NMR (200 MHz, DMSO-d6) 3.21 ( 2H, t, J = 4.8 
Hz, CH2), 4.40 (2H, t, J = 4.8 Hz, CH2), 6.54 (1H, d, J = 3.0 Hz, H-3), 7.01-7.19 (15H, m, 3 × 5 H-
Ph), 7.27-7.44 (3H, m, H-4, H-5 and H-6), 7.50 (1H, d, J = 3.0 Hz, H-2), 7.63 (1H, d, J = 7.1 Hz, H-
7); 13C NMR (50 MHz, DMSO-d6) 45.7 (t), 62.8 (t), 86.0 (s), 100.5 (d), 110.1 (d), 118.9 (d), 
120.3 (d), 120.9 (d), 126.9 (3 × d), 127.7 (6 × d), 128.1 (6 × d), 128.2 (s), 129.5 (d), 135.9 (s), 143.4 
(3 × s); Anal. Calculated for C29H25NO (MW: 403.51) : C, 86.32; H, 6.24; N, 3.47%. Found: C, 
86.14; H, 6.07; N, 3.82%.
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General procedure for the synthesis of carbamic acid 2-(3-carbamoyl-indol-1-yl)-ethyl ester 
(67a) 
To a solution of the indole 66a (0.30 g, 0.74 mmol), in anhydrous acetonitrile (2.5 mL) was added 
dropwise at 0 °C chlorosulfonyl isocyanate (CSI) (0.2 mL, 2.23 mmol). The reaction mixture was 
warmed to room temperature and stirred for 30 minutes. A solution of acetone (8 mL) and water (1 
mL) was added and the mixture was basified using 10% aqueous solution of potassium hydroxide 
(KOH). The mixture was extracted with ethyl acetate (3 × 20 mL), dried (Na2SO4) and the solvent 
evaporated under reduced pressure. The obtained crude product was crystallized with 
dichloromethane to afford compound 67a. 
N
CH2CH2OCONH2
O
NH2
 
Yield: 70%, yellow solid; mp: 151-152 °C; IR: 3451, 3404 (NH2), 1696 (CO) cm
-1; 1H NMR (200 
MHz, DMSO-d6) 4.26 (2H, t, J = 4.5 Hz, CH2), 4.42 (2H, t, J = 4.5 Hz, CH2), 6.58 (2H, bs, NH2), 
6.91-7.37 (4H, m, NH2, H-5 and H-6), 7.55 (1H, d, J = 8.2 Hz, H-7), 8.04 (1H, s, H-2), 8.17 (1H, 
dd, J = 7.1, 1.8 Hz, H-4); 13C NMR (50 MHz, DMSO-d6) 45.4 (t), 62.0 (t), 110.0 (s), 110.2 (d), 
120.6 (d), 121.2 (d), 121.9 (d), 126.6 (s), 131.7 (d), 136.2 (s), 156.3 (s), 166.1 (s); Anal. Calculated 
for C12H13N3O3 (MW: 247.25) : C, 58.29; H, 5.30; N, 16.99%. Found: C, 58.10; H, 5.19; N, 
17.29%.
General procedure for the synthesis of carbamic acid 2-(3-thiocarbamoyl-indol-1-yl)-ethyl 
ester (68a) 
Lawesson’s reagent (0.49 g, 1.21 mmol) was added to a suspension of derivative 67a (0.30 g, 1.21 
mmol) in anhydrous toluene (15 mL). The mixture was heated at reflux for 1 h. After cooling the 
solvent was evaporated under reduced pressure and the residue was purified by column 
chromatography using dichloromethane:methanol (98:2) as eluent. 
N
CH2CH2OCONH2
S
NH2
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Yield: 45%, orange solid; mp: 149-150 °C; IR: 3404, 3309 (NH2), 1684 (CO), 1646 (CS) cm
-1; 1H 
NMR (200 MHz, DMSO-d6) 4.26 (2H, t, J = 4.9 Hz, CH2), 4.44 (2H, t, J = 4.7 Hz, CH2), 6.59 
(2H, bs, NH2), 7.15-7.28 (2H, m, H-5 and H-6), 7.58 (1H, dd, J = 6.4, 1.7 Hz, H-7), 8.10 (1H, s, H-
2), 8.59 (1H, dd, J = 7.1, 1.9 H-4), 8.81 (1H, s, SH), 9.04 (1H, s, NH); 13C NMR (50 MHz, DMSO-
d6) 45.5 (t), 61.9 (t), 110.4 (d), 115.8 (s), 121.1 (d), 121.9 (d), 122.2 (d), 126.1 (s), 131.5 (d), 
136.7 (s), 156.2 (s), 193.1 (s); Anal. Calculated for C12H13N3O2S (MW: 263.32) : C, 54.74; H, 4.98; 
N, 15.96%. Found: C, 54.87; H, 5.09; N, 15.72%.
Synthesis of 1-methyl-7-azaindole (74)[125] 
Potassium t-butoxide (t-BuOK) (1.3g, 11.51 mmol) and tris[2-(2-methoxyethoxy)ethyl]amine 
(TDA-1) (1-2 drops) were added at 0 °C to a cold solution of derivative 73 (1.0 g, 8.46 mmol) in 
anhydrous toluene (85 mL). The reaction mixture was stirred at room temperature for 3 hours, and 
then methyl iodide (CH3I) (0.7 mL, 8.46 mmol) was added at 0 °C. TLC analysis 
(dichloromethane:ethyl acetate 9:1) revealed that methylation was complete after 1 hour. The 
solvent was evaporated under reduced pressure. The residue was treated with water, extracted with 
dichloromethane (2 × 20 mL), dried (Na2SO4), evaporated and purified by column chromatography 
using dichloromethane:ethyl acetate (9:1) as eluent. 
1-Methyl-1H-pyrrolo[2,3-b]pyridine (74) 
N N
CH3 
Yield: 96%, yellow oil; 1H NMR (200 MHz, CDCl3) 3.87 (3H, s, CH3), 6.43 (1H, d, J = 3.4 Hz, 
H-3), 7.03 (1H, dd, J = 7.8, 4.8 Hz, H-5), 7.15 (1H, d, J = 3.4 Hz, H-2), 7.88 (1H, dd, J = 7.8, 1.5 
Hz, H-4), 8.33 (1H, d, J = 4.8 Hz, H-6); 13C NMR (50 MHz, CDCl3) 31.1 (q), 99.1 (d), 115.3 (d), 
120.4 (s), 128.6 (d), 128.9 (d + s), 142.6 (d); Anal. Calculated for C8H8N2 (MW: 132.16) : C, 72.70; 
H, 6.10; N, 21.20%. Found: C, 72.60; H, 6.00; N, 21.40%. 
Synthesis of 2-bromo-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)-ethanones (63a,b)[125] 
Anhydrous aluminum chloride (AlCl3) (4.0 g, 29.99 mmol) was slowly added to a solution of the 
proper derivative 73,74 (8.46 mmol) in anhydrous dichloromethane (34 mL). The reaction mixture 
was heated under reflux and a solution of bromoacetyl bromide (0.7 mL, 8.46 mmol) in anhydrous 
dichlorometane (7 mL) was added dropwise. The resulting solution was allowed to stir under reflux 
for 40 minutes. After cooling, water and ice were slowly added and the obtained precipitate (for 
derivative 63a) was filtered off or the oil residue (for derivative 63b) was extracted with 
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dichloromethane (3 × 20 mL), dried (Na2SO4), evaporated and purified by column chromatography 
using dichloromethane:ethyl acetate (9:1) as eluent. 
2-Bromo-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)-ethanone (63a)  
N N
H
O
Br
 
Yield: 92%, white solid; mp: 280-281 °C; IR: 3556 (NH), 1678 (CO) cm-1; 1H NMR (200 MHz, 
DMSO-d6) H, s, CH2), 7.30 (1H, dd, J = 7.8, 4.7 Hz, H-5), 8.37 (1H, d, J = 4.7 Hz, H-6), 
8.47 (1H, d, J = 7.8 Hz, H-4), 8.65 (1H, s, H-2), 12.7 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6) 
46.3 (t), 112.3 (s), 117.7 (s), 118.4 (d), 129.5 (d), 135.1 (d), 144.6 (d), 149.0 (s), 186.4 (s); Anal. 
Calculated for C9H7BrN2O (MW: 239.06): C, 45.22; H, 2.95; N, 11.72%. Found: C, 45.42; H, 2.85; 
N, 11.62%. 
2-Bromo-1-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-ethanone (63b)  
N N
O
Br
CH3  
Yield: 86%, white solid; mp: 116-117 °C; IR: 1650 (CO) cm-1; 1H NMR (200 MHz, DMSO-d6) 
3.91 (3H, s, CH3), 4.65 (2H, s, CH2), 7.34 (1H, dd, J = 7.6, 4.7 Hz, H-5), 8.40-8.48 (2H, m, H-4 
and H-6), 8.70 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6) 31.7 (q), 32.9 (t), 110.8 (s), 118.1 
(d), 118.7 (s), 129.8 (d), 138.7 (d), 144.4 (d), 148.1 (s), 186.1 (s); Anal. Calculated for C10H9BrN2O 
(MW: 253.10) : C, 47.46; H, 3.58; N, 11.07%. Found: C, 47.56; H, 3.78; N, 10.77%. 
General procedure for the synthesis of carbamic acid 2-{3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-
thiazol-2-yl]-indol-1-yl}-ethyl esters (69a,b)  
A suspension of the appropriate carbothioamide 68a, (0.2 g, 0.67 mmol) and 2-bromo-1-(1H-
pyrrolo[2,3-b]pyridin-3-yl)-ethanones 63a,b (0.17 g, 0.67 mmol) in anhydrous ethanol (3 mL) was 
heated under reflux from 30 minutes to 1 hour. The precipitate, obtained after cooling, was filtered 
off, dried, and crystallized with ethanol to afford the desired final products. 
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Carbamic acid 2-{3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethyl ester 
(69a) 
N
N
S
N
H
N
CH2
CH2
OCONH2  
Conditions: 1 hour at reflux. Yield: 87%, orange solid; mp: 244-245 °C; IR: 3378, 3314 (NH2), 
3182 (NH), 1728 (CO), cm-1; 1H NMR (200 MHz, DMSO-d6) 4.34-4.36 (2H, m, CH2), 4.50-4.53 
(2H, m, CH2), 6.58 (2H, bs, NH2),7.29-7.34 (2H, m, H-5’ and H-6’), 7.40-7.47 (1H, m, H-5’’), 
7.64-7.68 (1H, m, H-7’), 7.84 (1H, s, H-2’), 8.23-8.35 (3H, m, H-2’’, H-4’ and H-5), 8.45 (1H, d, J 
= 5.0 Hz, H-6’’), 8.92 (1H, d, J = 7.7 Hz, H-4’’), 12.46 (1H, bs, NH); 13C NMR (50 MHz, DMSO-
d6) 45.4 (t), 62.2 (t), 108.1 (d), 109.5 (s), 110.0 (s), 110.8 (d), 116.2 (d), 120.4 (d), 121.2 (d), 
121.4 (s), 122.6 (d), 124.4 (s), 124.6 (s), 126.0 (d), 129.9 (d), 132.9 (d), 136.6 (s), 139.0 (d), 148.8 
(s), 156.3 (s), 161.9 (s); Anal. Calculated for C21H17N5O2S (MW: 403.46) : C, 62.52; H, 4.25; N, 
17.36%. Found: C, 62.30; H, 4.12; N, 17.71%.
Carbamic acid 2-{3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethyl 
ester (69b) 
N
N
S
N
N
CH2
CH2
OCONH2
CH3
 
Conditions: 30 minutes at reflux. Yield: 88%, orange solid; mp: 234-235 °C; IR: 3346, 3255 (NH2), 
1710 (CO), cm-1; 1H NMR (200 MHz, DMSO-d6) 3.96 (3H, s, CH3), 4.33-4.36 (2H, m, CH2), 
4.51-4.55 (2H, m, CH2), 6.60 (2H, bs, NH2), 7.29-7.38 (3H, m, H-5’, H-5’’ and H-6’), 7.66 (1H, d, 
J = 8.8 Hz, H-4’), 7.77 (1H, s, H-2’), 8.21 (1H, s, H-2’’), 8.25 (1H, s, H-5), 8.34-8.44 (2H, m, H-6’’ 
and H-7’), 8.74 (1H, d, J = 7.5 Hz, H-4’’); 13C NMR (50 MHz, DMSO-d6) 31.8 (q), 45.4 (t), 
62.2 (t), 107.8 (d), 109.5 (s), 109.9 (s), 110.7 (d), 116.1 (d), 119.0 (s), 120.5 (d), 121.2 (d), 122.6 
(d), 124.6 (s), 129.7 (d), 129.9 (d), 131.2 (d), 136.6 (s), 140.3 (d), 148.3 (s), 148.4 (s), 156.3 (s), 
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162.0 (s); Anal. Calculated for C22H19N5O2S (MW: 417.48) : C, 63.29; H, 4.59; N, 16.78%. Found: 
C, 63.13; H, 4.42; N, 17.11%.
General procedure for the synthesis of 1H-indol-3-carbonitriles (70a-d) 
To a solution of the appropriate indole 64a-d (1.0 g, 5.10 mmol) in anhydrous acetonitrile (4.5 mL) 
was added dropwise at 0 °C chlorosulfonyl isocyanate (CSI) (0.44 mL, 5.10 mmol). The reaction 
mixture was stirred at 0 °C for 2 hours. After that, it was added dropwise anhydrous 
dimethylformamide (DMF) (2.8 mL, 36.39 mmol) and the reaction mixture was stirred at 0 °C for 1 
hour and 30 minutes. The mixture was poured into water and ice and the obtained precipitate was 
filtered off, dried, to give the desired derivatives 70a-d. 
1H-indole-3-carbonitrile (70a) 
N
H
CN
 
Yield: 90%, light orange solid; mp: 178-179 °C; IR: 3442 (NH), 2224 (CN) cm-1; 1H NMR (200 
MHz, DMSO-d6)  7.20-7.34 (2H, m, H-5 and H-6), 7.52-7.69 (2H, m, H-4 and H-7), 8.26 (1H, d, 
J = 3.0 Hz, H-2), 12.21 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6) 84.2 (s), 112.9 (d), 116.5 
(s), 118.4 (d), 121.6 (d), 123.3 (d), 126.7 (s), 134.4 (d), 135.2 (s); Anal. Calculated for C9H6N2 
(MW: 142.16) : C, 76.04; H, 4.25; N, 19.71%. Found: C, 75.87; H, 4.03; N, 20.10%. 
5-Bromo-1H-indole-3-carbonitrile (70b) 
N
H
Br CN
 
Yield: 98%, white solid; mp: 194-195 °C; IR: 3442 (NH), 2221 (CN) cm-1; 1H NMR (200 MHz, 
DMSO-d6)  7.41 (1H, d, J = 8.4 Hz, H-6), 7.54 (1H, d, J = 8.4 Hz, H-7), 7.80 (1H, s, H-4), 8.32 
(1H, s, H-2), 12.41 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6 ) 83.9 (s), 114.3 (s), 114.9 (d), 
115.6 (s), 120.6 (d), 126.0 (d), 128.3 (s), 133.9 (s), d); Anal. Calculated for C9H5BrN2 (MW: 
221.05) : C, 48.90; H, 2.28; N, 12.67%. Found: C, 49.23; H, 2.15; N, 12.47%. 
5-Fluoro-1H-indole-3-carbonitrile (70c) 
N
H
F CN
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Yield: 90%, light brown solid; mp: 176-177 °C; IR: 3443 (NH), 2231 (CN) cm-1; 1H NMR (200 
MHz, DMSO-d6) 7.15 (1H, td, J = 11.7, 9.3, 2.5 Hz, H-6), 7.42 (1H, dd, J = 9.2, 2.5 Hz, H-7), 
7.54-7.61 (1H, m, H-4), 8.33 (1H, d, J = 3.1 Hz, H-2), 12.33 (1H, bs, NH); 13C NMR (50 MHz, 
DMSO-d6) 84.5 (d, JC7a-F = 4.5 Hz), 103.6 (d, JC4-F = 24.8 Hz), 111.8 (d, JC6-F = 26.2 Hz), 114.3 
(d, JC7-F = 9.6 Hz), 115.9 (s), 127.2 (d, JC3a-F = 10.9 Hz), 131.8 (s), 136.2 (d), 158.3 (d, JC5-F = 236.1 
Hz); Anal. Calculated for C9H5FN2 (MW: 160.15) : C, 67.50; H, 3.15; N, 17.49%. Found: C, 67.60; 
H, 3.25; N, 17.29%. 
5-Methoxy-1H-indole-3-carbonitrile (70d) 
N
H
H3CO
CN
 
Yield: 90%, light brown solid; mp: 157-158 °C; IR: 3427 (NH), 2234 (CN) cm-1; 1H NMR (200 
MHz, DMSO-d6) 3.81 (3H, s, CH3), 6.90 (1H, dd, J = 8.5, 2.4 Hz, H-6), 7.08 (1H, d, J = 2.4 Hz, 
H-4), 7.44 (1H, d, J = 8.5 Hz, H-7), 8.17 (1H, d, J = 3.1 Hz, H-2), 12.07 (1H, bs, NH); 13C NMR 
(50 MHz, DMSO-d6) 55.3 (q), 83.9 (s), 99.6 (d), 113.8 (2 × d), 116.6 (s), 127.5 (s), 129.9 (s), 
134.3 (d), 155.2 (s); Anal. Calculated for C10H8N2O (MW: 172.18) : C, 69.76; H, 4.68; N, 16.27%. 
Found: C, 69.47; H, 4.57; N, 16.67% 
General procedure for the synthesis of 1-(2-hydroxy-ethyl)-1H-indole-3-carbonitriles (72a-d) 
To a solution of the appropriate indole carbonitrile 70a-d (0.5 g, 3.52 mmol) in dry DMF (10 mL), 
was slowly added at 0-5 °C, sodium hydride 60% dispersion in mineral oil (NaH) (0.13 g, 5.28 
mmol) and the reaction mixture was stirred at room temperature for 30 minutes. After that, it was 
added dropwise 2-bromoethanol 71 (0.50 mL, 7.04 mmol) and the reaction mixture was heated at 
80 °C for 24 hours. After cooling, the mixture was poured into water and ice and extracted with 
ethyl acetate (3 × 20 mL), dried (Na2SO4), and the solvent evaporated under reduced pressure. The 
residue was purified by column chromatography using dichloromethane:ethyl acetate (9:1) as 
eluent. 
1-(2-Hydroxy-ethyl)-1H-indole-3-carbonitrile (72a) 
N
CN
CH2CH2OH 
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Yield: 65%, light orange solid; mp: 94-95 °C; IR: 3428 (OH), 2219 (CN) cm-1; 1H NMR (200 MHz, 
DMSO-d6) 3.75 ( 2H, q, J = 5.3 Hz, CH2), 4.32 (2H, t, J = 5.2 Hz, CH2), 5.01 (1H, t, J = 5.3 Hz, 
OH), 7.24-7.38 (2H, m, H-5 and H-6), 7.64-7.71 (2H, m, H-4 and H-7), 8.26 (1H, s, H-2); 13C NMR 
(50 MHz, DMSO-d6) 49.0 (t), 59.6 (t), 83.1 (s), 111.7 (d), 116.1 (s), 118.6 (d), 121.8 (d), 123.1 
(d), 127.1 (s), 135.3 (s), 137.5 (d); Anal. Calculated for C11H10N2O (MW: 186.21) : C, 70.95; H, 
5.41; N, 15.04%. Found : C, 71.05; H, 5.51; N, 14.84%. 
5-Bromo-1-(2-hydroxy-ethyl)-1H-indole-3-carbonitrile (72b) 
N
Br CN
CH2CH2OH 
Yield: 70%, white solid; mp: 348-349 °C; IR: 3448 (OH), 2218 (CN) cm-1; 1H NMR (200 MHz, 
DMSO-d6) 3.72 (2H, q, J = 5.3 Hz, CH2), 4.32 (2H, t, J = 5.1 Hz, CH2), 4.98 (1H, t, J = 5.3 Hz, 
OH), 7.46 (1H, dd, J = 8.8, 1.9 Hz, H-6), 7.70 (1H, d, J = 8.8 Hz, H-7), 7.81 (1H, d, J = 1.9 Hz, H-
4), H, s, H-2); 13C NMR (50 MHz, DMSO-d6 ) 49.3 (t), 59.6 (t), 82.9 (s), 114.0 (d), 114.6 
(s), 115.4 (s), 120.8 (d), 125.9 (d), 128.7 (s), 134.3 (s), d); Anal. Calculated for C11H9BrN2O 
(MW: 265.11) : C, 49.84; H, 3.42; N, 10.57%. Found: C, 49.96; H, 3.55; N, 10.32%. 
5-Fluoro-1-(2-hydroxy-ethyl)-1H-indole-3-carbonitrile (72c) 
N
F CN
CH2CH2OH 
Yield: 75%, white solid; mp: 91-92 °C; IR: 3384 (OH), 2226 (CN) cm-1; 1H NMR (200 MHz, 
DMSO-d6) 3.73 (2H, q, J = 5.3 Hz, CH2), 4.32 (2H, t, J = 5.1 Hz, CH2), 4.98 (1H, t, J = 5.3 Hz, 
OH), 7.20 (1H, td, J = 11.8, 9.3, 2.5 Hz, H-6), 7.43 (1H, dd, J = 9.3, 2.5 Hz, H-7), 7.71-7.77 (1H, m, 
H-4), 8.31 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6) 49.4 (t), 59.7 (t), 83.4 (d, JC7a-F = 4.6 
Hz), 103.8 (d, JC4-F = 24.9 Hz), 111.6 (d, JC6-F = 26.1 Hz), 113.4 (d, JC7-F = 9.8 Hz), 115.7 (s), 127.6 
(d, JC3a-F = 10.8 Hz), 132.2 (s), 139.0 (d), 158.4 (d, JC5-F = 239.5 Hz); Anal. Calculated for 
C11H9FN2O (MW: 204.20) : C, 64.70; H, 4.44; N, 13.72%. Found: C, 64.94; H, 4.59; N, 13.33%. 
1-(2-Hydroxy-ethyl)-5-methoxy-1H-indole-3-carbonitrile (72d) 
N
H3CO
CN
CH2CH2OH 
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Yield: 62%, white solid; mp: 89-90 °C; IR: 3384 (OH), 2224 (CN) cm-1; 1H NMR (200 MHz, 
DMSO-d6) 3.71 (2H, q, J = 5.3 Hz, CH2), 3.82 (3H, s, CH3), 4.27 (2H, t, J = 5.2 Hz, CH2), 4.97 
(1H, t, J = 5.2 Hz, OH), 6.94 (1H, dd, J = 9.0, 2.4 Hz, H-6), 7.08 (1H, d, J = 2.4 Hz, H-4), 7.59 (1H, 
d, J = 9.0 Hz, H-7), 8.16 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6) 44.3 (t), 50.5 (q), 55.7 (t), 
79.6 (s), 95.5 (d), 106.2 (d), 109.2 (d), 111.0 (s), 123.5 (s), 125.1 (s), 130.4 (d), 150.6 (s); Anal. 
Calculated for C12H12N2O2 (MW: 216.24) : C, 66.65; H, 5.59; N, 12.96%. Found: C, 66.29; H, 5.73; 
N, 13.18%. 
General procedure for the synthesis of 1-(2-hydroxy-ethyl)-1H-indole-3-carbothioamides 
(62a-d)  
A solution of phosphorus pentasulfide (P4S10) (1.4 g, 4.22 mmol) in anhydrous ethanol (3 mL) was 
stirred at room temperature for 1 hour. The appropriate indole carbonitrile 72a-d (0.7 g, 2.11 mmol) 
were added and the reaction mixture was stirred at room temperature for 2 hours. The precipitate 
obtained was filtered off, dried, and crystallized with ethanol to afford the desired products 62b-d. 
In case of derivative 62a the reaction mixture was concentrated under vacuum. The resulting crude 
was purified by column chromatography using dichloromethane:methanol (98:2) as eluent. 
1-(2-Hydroxy-ethyl)-1H-indole-3-carbothioamide (62a) 
N
CH2CH2OH
S
NH2
 
Yield: 80%, orange solid; mp: 130-131 °C; IR: 3384 (OH), 1653 (CS) cm-1; 1H NMR (200 MHz, 
DMSO-d6) 3.74 (2H, t, J = 5.0 Hz, CH2), 4.26 (2H, t, J = 5.3 Hz, CH2), 5.02 (1H, s, OH), 7.13-
7.26 (2H, m, H-5 and H-6), 7.51-7.60 (1H, m, H-7), 8.14 (1H, s, H-2), 8.56-8.64 (1H, m, H-4), 8.81 
(1H, s, SH), 8.98 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6) 48.7 (t), 59.6 (t), 110.6 (d), 115.2 
(s), 120.9 (d), 121.8 (d), 121.9 (d), 126.1 (s), 132.3 (d), 136.8 (s), 193.0 (s); Anal. Calculated for 
C11H12N2OS (MW: 220.29) : C, 59.97; H, 5.49; N, 12.72%. Found: C, 59.66; H, 5.67; N, 12.85%. 
5-Bromo-1-(2-hydroxy-ethyl)-1H-indole-3-carbothioamide (62b) 
N
Br
CH2CH2OH
S
NH2
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Yield: 70%, white solid; mp: 195-196 °C; IR: 3414 (OH), 1646 (CS) cm-1; 1H NMR (200 MHz, 
DMSO-d6) 3.73 (2H, t, J = 5.2 Hz, CH2), 4.25 (2H, t, J = 5.2 Hz, CH2), 7.35 (1H, dd, J = 8.7, 2.0 
Hz, H-6), 7.56 (1H, d, J = 8.7 Hz, H-7), 8.18 (1H, s, H-2), 8.89 (1H, d, J = 2.0 Hz, H-4), 8.92 (1H, 
s, SH), 9.04 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6) 49.0 (t), 59.6 (t), 112.8 (d), 113.9 (s), 
114.4 (s), 124.1 (d), 124.4 (d), 128.1 (s), 132.6 (d), 135.7 (s), 192.5 (s); Anal. Calculated for 
C11H11BrN2OS (MW: 299.19) : C, 44.16; H, 3.71; N, 9.36%. Found: C, 43.93; H, 3.61; N, 9.69%. 
5-Fluoro-1-(2-hydroxy-ethyl)-1H-indole-3-carbothioamide (62c) 
N
F
CH2CH2OH
S
NH2
 
Yield: 70%, light yellow solid; mp: 176-177 °C; IR: 3410 (OH), 1683 (CS) cm-1; 1H NMR (200 
MHz, DMSO-d6) 3.46 (2H, t, J = 5.1 Hz, CH2), 4.26 (2H, t, J = 5.0 Hz, CH2), 4.61 (1H, s, OH), 
7.07 (1H, td, J = 11.1, 9.0, 2.6 Hz, H-6), 7.56-7.62 (1H, m, H-7), 8.21 (1H, s, H-2), 8.44 (1H, dd, J 
= 11.1, 2.5 Hz, H-4), 8.87 (1H, s, SH), 9.00 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6) 49.1 (t), 
59.7 (t), 106.8 (d, JC4-F = 25.7 Hz), 110.1 (d, JC6-F = 26.3 Hz), 112.0 (d, JC7-F = 9.9 Hz), 114.9 (d, 
JC7a-F = 4.6 Hz), 127.0 (d, JC3a-F = 11.0 Hz), 133.3 (d), 133.6 (s), 158.1 (d, JC5-F = 232.9 Hz), 192.6 
(s); Anal. Calculated for C11H11FN2OS (MW: 238.28) : C, 55.45; H, 4.65; N, 11.76%. Found: C, 
55.18; H, 4.52; N, 12.16%. 
1-(2-Hydroxy-ethyl)-5-methoxy-1H-indole-3-carbothioamide (62d) 
N
H3CO
CH2CH2OH
S
NH2
 
Yield: 75%, light orange solid; mp: 171-172 °C; IR: 3378 (OH), 1684 (CS) cm-1; 1H NMR (200 
MHz, DMSO-d6) 3.71 (2H, t, J = 5.1 Hz, CH2), 3.78 (3H, s, CH3), 4.21 (2H, t, J = 5.1 Hz, CH2), 
4.99 (1H, s, OH), 6.85 (1H, dd, J = 8.9, 2.4 Hz, H-6), 7.45 (1H, d, J = 8.9 Hz, H-7), 8.10 (1H, s, H-
2), 8.19 (1H, d, J = 2.4 Hz, H-4), 8.75 (1H, s, SH), 8.91 (1H, s, NH); 13C NMR (50 MHz, DMSO-
d6) 48.9 (t), 55.2 (q), 59.7 (t), 103.8 (d), 111.4 (d), 111.6 (d), 114.7 (s), 126.8 (s), 131.8 (s), 132.6 
(d), 154.8 (s), 192.8 (s); Anal. Calculated for C12H14N2O2S (MW: 250.32) : C, 57.58; H, 5.64; N, 
11.19%. Found: C, 57.76; H, 5.85; N, 10.80%. 
79 
 
General procedure for the synthesis of 2-{3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-
indol-1-yl}-ethanols (55a-h) 
Compounds 55a-h were prepared from 62a-d using the same synthetic procedure described for 
compounds 69a,b. 
2-{3-[4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethanol (55a)  
N
CH2CH2OH
N
S
N
H
N
 
Conditions: 2 hours at reflux. Yield: 98%, yellow solid; mp: 243-244 °C; IR: 3365 (OH), 3136 
(NH) cm-1; 1H NMR (200 MHz, DMSO-d6) 3.80 (2H, t, J = 5.1 Hz, CH2), 4.36 (2H, t, J = 5.2 Hz, 
CH2), 7.26-7.34 (2H, m, H-5’ and H-6’), 7.51-7.57 (1H, m, H-5’’), 7.63-7.67 (1H, m, H-7’), 7.89 
(1H, s, H-2’), 8.26-8.31 (3H, m, H-2’’, H-4’ and H-5), 8.51 (1H, d, J = 4.4 Hz, H-6’’), 9.06 (1H, d, 
J = 7.3 Hz, H-4’’), 12.74 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6) 48.6 (t), 59.9 (t), 108.3 
(d), 109.3 (s), 111.0 (d), 111.2 (s), 116.2 (d), 120.2 (d), 121.0 (d), 122.3 (d), 124.3 (s), 124.6 (s), 
126.4 (d), 130.4 (d), 132.2 (d), 136.6 (s), 138.4 (d), 142.5 (s), 147.8 (s), 162.2 (s); Anal. Calculated 
for C20H16N4OS (MW: 360.43) : C, 66.65; H, 4.47; N, 15.54%. Found: C, 66.31; H, 4.66; N, 
15.69%. 
2-{3-[4-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethanol (55b)  
N
CH2CH2OH
N
S
N
N
CH3  
Conditions: 1 hour at reflux. Yield: 98%, yellow solid; mp: 257-258 °C; IR: 3222 (OH) cm-1; 1H 
NMR (200 MHz, DMSO-d6) 3.80 (2H, t, J = 5.0 Hz, CH2), 3.98 (3H, s, CH3), 4.35 (2H, t, J = 4.9 
Hz, CH2), 7.25-7.34 (2H, m, H-5’ and H-6’), 7.43-7.50 (1H, m, H-5’’), 7.62-7.68 (1H, m,H-7’), 
7.82 (1H, s, H-2’), 8.25-8.32 (3H, m, H-2’’, H-4’ and H-5), 8.51 (1H, d, J = 4.4 Hz, H-6’’), 8.90 
(1H, d, J = 7.1 Hz, H-4’’); 13C NMR (50 MHz, DMSO-d6) 32.0 (q), 48.6 (t), 59.9 (t), 107.9 (d), 
109.0 (s), 109.5 (s), 110.9 (d), 116.1 (d), 119.4 (s), 120.3 (d), 121.0 (d), 122.3 (d), 124.5 (s), 130.0 
(d), 130.5 (d), 132.3 (d), 136.6 (s), 139.3 (d), 143.9 (s), 147.7 (s), 162.2 (s); Anal. Calculated for 
C21H18N4OS (MW: 374.46) : C, 67.36; H, 4.85; N, 14.96%. Found: C, 67.69; H, 4.71; N, 14.77%. 
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2-{5-Bromo-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethanol (55c)  
N
CH2CH2OH
Br N
S
N
H
N
 
Conditions: 30 minutes at reflux. Yield: 90%, yellow solid; mp: 259-260 °C; IR: 3364 (OH), 3136 
(NH) cm-1; 1H NMR (200 MHz, DMSO-d6) 3.77-3.81 (2H, m, CH2), 4.33-4.37 (2H, m, CH2), 
7.40-7.44 (2H, m, H-5’’and H-6’), 7.65 (1H, d, J = 8.7 Hz, H-7’), 7.83 (1H, s, H-2’), 8.20 (1H, s, H-
2’’), 8.27 (1H, s, H-5), 8.43-8.51 (2H, m, H-4’ and H-6’’), 8.88 (1H, d, J = 6.6 Hz, H-4’’), 12.41 
(1H, bs, NH); 13C NMR (50 MHz, DMSO-d6) 48.8 (t), 59.9 (t), 108.6 (d), 108.9 (s), 111.1 (s), 
113.2 (d), 113.6 (s), 116.0 (d), 120.4 (s), 122.6 (d), 124.7 (d), 126.2 (s), 126.4 (d), 131.6 (d), 133.8 
(d), 135.5 (s), 138.0 (d), 142.8 (s), 148.3 (s), 161.6 (s); Anal. Calculated for C20H15BrN4OS (MW: 
439.33) : C, 54.68; H, 3.44; N, 12.75%. Found: C, 54.91; H, 3.55; N, 12.41%. 
2-{5-Bromo-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethanol 
(55d) 
N
CH2CH2OH
Br N
S
N
N
CH3  
Conditions: 30 minutes at reflux. Yield: 90%, yellow solid; mp: 286-287 °C; IR: 3364 (OH) cm-1; 
1H NMR (200 MHz, DMSO-d6) 3.78 (2H, t, J = 5.0 Hz, CH2), 3.96 (3H, s, CH3), 4.34 (2H, t, J = 
4.8 Hz, CH2), 7.32-7.45 (2H, m, H-5’’ and H-6’), 7.64 (1H, d, J = 8.8 Hz, H-7’), 7.77 (1H, s, H-2’), 
8.22 (1H, s, H-2’’), 8.26 (1H, s, H-5), 8.43-8.50 (2H, m, H-4’ and H-6’’), 8.77 (1H, d, J = 7.9 Hz, 
H-4’’); 13C NMR (50 MHz, DMSO-d6) 31.5 (q), 48.8 (t), 60.0 (t), 107.1 (d), 107.6 (s), 109.0 (s), 
109.2 (s), 113.2 (d), 113.5 (s), 116.0 (d), 118.4 (s), 122.6 (d), 124.8 (d), 126.2 (s), 129.1 (d), 130.3 
(d), 131.5 (d), 135.5 (s), 141.2 (d), 148.9 (s), 161.4 (s); Anal. Calculated for C21H17BrN4OS (MW: 
453.35) : C, 55.64; H, 3.78; N, 12.36%. Found: C, 55.47; H, 3.62; N, 12.69%. 
2-{5-Fluoro-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethanol (55e)  
N
CH2CH2OH
F N
S
N
H
N
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Conditions: 30 minutes at reflux. Yield: 98%, yellow solid; mp: 261-262 °C; IR: 3249 (OH), 3069 
(NH) cm-1; 1H NMR (200 MHz, DMSO-d6) 3.77-3.81 (2H, m, CH2), 4.33-4.37 (2H, m, CH2), 
7.12-7.21 (1H, m, H-6’), 7.43-7.50 (1H, m, H-5’’), 7.65-7.71 (1H, m, H-7’), 7.85 (1H, s, H-2’), 
8.02 (1H, d, J = 9.3 Hz, H-4’), 8.28 (2H, d, J = 5.2 Hz, H-2’’ and H-5), 8.47 (1H, d, J = 3.6 Hz, H-
6’’), 8.94 (1H, d, J = 7.6 Hz, H-4’’), 12.59 (1H, bs, NH); Anal. Calculated for C20H15FN4OS (MW: 
378.42) : C, 63.48; H, 4.00; N, 14.81%. Found: C, 63.83; H, 3.79; N, 14.67%. 
2-{5-Fluoro-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethanol 
(55f) 
N
CH2CH2OH
F N
S
N
N
CH3  
Conditions: 30 minutes at reflux. Yield: 98%, yellow solid; mp: 268-269 °C; IR: 3370 (OH) cm-1; 
1H NMR (200 MHz, DMSO-d6) 3.79 (2H, t, J = 4.6 Hz, CH2), 3.97 (3H, s, CH3), 4.35 (2H, t, J = 
4.8 Hz, CH2), 7.34-7.40 (2H, m, H-5’’ and H-6’), 7.64-7.70 (1H, m, H-7’), 7.76 (1H, s, H-2’), 8.05 
(1H, d, J = 9.5 Hz, H-4’), 8.27 (2H, s, H-2’’ and H-5), 8.45 (1H, d, J = 4.5 Hz, H-6’’), 8.75 (1H, d, J 
= 7.8 Hz, H-4’’); 13C NMR (50 MHz, DMSO-d6) 31.5 (q), 48.9 (t), 60.0 (t), 105.3 (d, JC4’-F = 
24.8 Hz), 107.4 (d), 109.3 (s), 109.5 (d, JC7a-F = 4.6 Hz), 110.5 (d, JC6’-F = 25.9 Hz), 112.3 (d, JC7’-F 
= 10.2 Hz), 116.1 (d), 118.3 (s), 124.9 (d, JC3a-F = 10.6 Hz), 129.6 (d), 130.6 (d), 131.9 (d), 133.4 
(s), 140.9 (d), 145.8 (s), 148.7 (s), 158.1 (d, JC5’-F = 236.5 Hz), 161.7 (s); Anal. Calculated for 
C21H17FN4OS (MW: 392.45) : C, 64.27; H, 4.37; N, 14.28%. Found: C, 64.54; H, 4.48; N, 13.90%. 
2-{5-Methoxy-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethanol (55g)  
N
CH2CH2OH
H3CO N
S
N
H
N
 
Conditions: 2 hours at reflux. Yield: 98%, yellow solid; mp: 253-254 °C; IR: 3371 (OH), 3176 
(NH) cm-1; 1H NMR (200 MHz, DMSO-d6) 3.78 (2H, t, J = 5.1 Hz, CH2), 3.90 (3H, s, CH3), 4.31 
(2H, t, J = 5.0 Hz, CH2), 6.93 (1H, dd, J = 8.9, 2.3 Hz, H-6’), 7.46-7.57 (2H, m, H-5’’and H-7’), 
7.84 (2H, s, H-2’ and H-2’’), 8.18 (1H, s, H-5), 8.29 (1H, s, H-4’), 8.49 (1H, d, J = 4.6 Hz, H-6’’), 
9.10 (1H, d, J = 7.5 Hz, H-4’’), 12.69 (1H, bs, NH); Anal. Calculated for C21H18N4O2S (MW: 
390.46) : C, 64.60; H, 4.65; N, 14.35%. Found: C, 64.38; H, 4.55; N, 14.67%. 
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2-{5-Methoxy-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-thiazol-2-yl]-indol-1-yl}-ethanol 
(55h)  
N
CH2CH2OH
H3CO N
S
N
N
CH3  
Conditions: 30 minutes at reflux. Yield: 98%, yellow solid; mp: 258-259°C; IR: 3363 (OH) cm-1; 
1H NMR (200 MHz, DMSO-d6) 3.77 (2H, t, J = 5.0 Hz, CH2), 3.90 (3H, s, CH3), 3.97 (3H, s, 
CH3), 4.30 (2H, t, J = 4.8 Hz, CH2), 6.93 (1H, dd, J = 8.9, 2.2 Hz, H-6’), 7.40 (1H, dd, J = 7.9, 5.1 
Hz, H-5’’), 7.54 (1H, d, J = 8.9 Hz, H-7’), 7.75 (1H, s, H-2’), 7.81 (1H, d, J = 2.2 Hz, H-4’), 8.17 
(1H, s, H-2’’), 8.26 (1H, s, H-5), 8.48 (1H, d, J = 4.3 Hz, H-6’’), 8.92 (1H, d, J = 7.3 Hz, H-4’’); 13C 
NMR (50 MHz, DMSO-d6) 31.9 (q), 48.8 (t), 55.2 (q), 60.0 (t), 101.9 (d), 107.4 (d), 108.7 (s), 
109.4 (s), 111.8 (d), 112.2 (d), 115.9 (d), 119.4 (s), 125.1 (s), 129.6 (d), 130.7 (d), 131.7 (s), 132.0 
(d), 139.7 (d), 144.2 (s), 147.8 (s), 154.8 (s), 162.5 (s); Anal. Calculated for C22H20N4O2S (MW: 
404.48) : C, 65.33; H, 4.98; N, 13.85%. Found: C, 65.14; H, 4.86; N, 14.16%. 
Synthesis of the 4-(2-chloroethyl)morpholine  (77)  
To a solution of 4-(2-chloroethyl)morpholine hydrochloride 76 (0.8 g, 4.30 mmol) in water (5 mL) 
was added 5% aqueous solution of sodium hydroxide (NaOH) up to pH = 11-12 and stirred at room 
temperature for 10 minutes. The resulting mixture was extracted with dichloromethane (2 × 10 mL), 
dried (Na2SO4), filtered and the solvent evaporated under reduced pressure. Yield: 98%, yellow oil. 
Analytical and spectroscopic data were in accordance with those previously reported [126]. 
General procedure for the synthesis of 1-(2-morpholin-4-yl-ethyl)-1H-indole-3-carbonitriles 
(78a-d) 
To a solution of the appropriate indole carbonitrile 70a-d (0.3 g, 1.35 mmol) in dry DMF (2 mL), 
was slowly added at 0-5 °C, sodium hydride 60% dispersion in mineral oil (NaH) (0.05 g, 2.03 
mmol) and the reaction mixture was stirred at room temperature for 30 minutes. After that, it was 
added dropwise a solution of 4-(2-chloroethyl)morpholine 77 (0.8 g, 5.40 mmol) in dry DMF (2 
mL), and the reaction mixture was stirred at 50 °C for 1-2 hours. After cooling, the mixture was 
poured into water and ice and the obtained precipitate was filtered off, dried, to give the desired 
products 78a-d. 
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1-(2-Morpholin-4-yl-ethyl)-1H-indole-3-carbonitrile (78a)  
N
CN
CH2
CH2
N
O  
Conditions: heated for 2 hours at 50 °C. Yield: 94%, brown solid; mp: 89-90 °C; IR: 2220 (CN) cm-
1; 1H NMR (200 MHz, DMSO-d6) 2.42 (4H, t, J = 4.6 Hz, 2 × CH2), 2.69 (2H, t, J = 6.2 Hz, 
CH2), 3.53 (4H, t, J = 4.6 Hz, 2 × CH2), 4.38 (2H, t, J = 6.2 Hz, CH2), 7.23-7.38 (2H, m, H-5 and H-
6), 7.63-7.73 (2H, m, H-4 and H-7), 8.31 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6) 43.3 (t), 
53.1 (2 × t), 57.1 (t), 66.1 (2 × t), 83.2 (s), 111.5 (d), 116.1 (s), 118.6 (d), 121.8 (d), 123.2 (d), 127.0 
(s), 135.2 (s), 137.3 (d); Anal. Calculated for C15H17N3O (MW: 255.31) : C, 70.56; H, 6.71; N, 
16.46%. Found: C, 70.66; H, 6.91; N, 16.16%. 
5-Bromo-1-(2-morpholin-4-yl-ethyl)-1H-indole-3-carbonitrile (78b)  
N
CN
CH2
Br
CH2
N
O  
Conditions: heated for 1 hour at 50 °C. Yield: 95%, brown solid; mp: 128-129 °C; IR: 2220 (CN) 
cm-1; 1H NMR (200 MHz, DMSO-d6) 2.41 (4H, t, J = 4.5 Hz, 2 × CH2), 2.67 (2H, t, J = 6.1 Hz, 
CH2), 3.51 (4H, t, J = 4.5 Hz, 2 × CH2), 4.38 (2H, t, J = 6.1 Hz, CH2), 7.48 (1H, dd, J = 8.8, 1.8 Hz, 
H-6), 7.73 (1H, d, J = 8.8 Hz, H-7), 7.81 (1H, d, J = 1.8 Hz, H-4), 8.37 (1H, s, H-2); 13C NMR (50 
MHz, DMSO-d6) 43.6 (t), 53.0 (2 × t), 57.1 (t), 66.1 (2 × t), 82.9 (s), 113.8 (d), 114.6 (s), 115.4 
(s), 120.9 (d), 125.9 (d), 128.5 (s), 134.1 (s), 138.6 (d); Anal. Calculated for C15H16BrN3O (MW: 
334.21) : C, 53.91; H, 4.83; N, 12.57%. Found: C, 54.28; H, 4.69; N, 12.34%. 
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5-Fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indole-3-carbonitrile (78c)  
N
CN
CH2
F
CH2
N
O  
Conditions: heated for 1 hour at 50 °C. Yield: 95%, brown solid; mp: 86-87 °C; IR: 2220 (CN) cm-
1; 1H NMR (200 MHz, DMSO-d6) 2.41 (4H, t, J = 4.5 Hz, 2 × CH2), 2.68 (2H, t, J = 6.1 Hz, 
CH2), 3.52 (4H, t, J = 4.5 Hz, 2 × CH2), 4.38 (2H, t, J = 6.2 Hz, CH2), 7.21 (1H, td, J = 11.7, 9.3, 
2.5 Hz, H-6), 7.43 (1H, dd, J = 9.1, 2.4 Hz, H-7), 7.73-7.79 (1H, m, H-4), 8.37 (1H, s, H-2); 13C 
NMR (50 MHz, DMSO-d6) 43.6 (t), 53.1 (2 × t), 57.1 (t), 66.1 (2 × t), 83.4 (d, JC7a-F = 4.4 Hz), 
103.9 (d, JC4-F = 24.9 Hz), 111.7 (d, JC6-F = 26.3 Hz), 113.2 (d, JC7-F = 9.6 Hz), 115.7 (s), 127.5 (d, 
JC3a-F = 10.8 Hz), 132.0 (s), 138.9 (d), 158.4 (d, JC5-F = 239.5 Hz); Anal. Calculated for C15H16FN3O 
(MW: 273.13) : C, 65.92; H, 5.90; N, 15.37%. Found: C, 66.20; H, 6.01; N, 14.98%. 
5-Methoxy-1-(2-morpholin-4-yl-ethyl)-1H-indole-3-carbonitrile (78d)  
N
CN
CH2
H3CO
CH2
N
O  
Conditions: heated for 1 hour at 50 °C. Yield: 88%, brown solid; mp: 78-79 °C; IR: 2217 (CN) cm-
1; 1H NMR (200 MHz, DMSO-d6) 2.41 (4H, t, J = 4.5 Hz, 2 × CH2), 2.66 (2H, t, J = 6.2 Hz, 
CH2), 3.52 (4H, t, J = 4.5 Hz, 2 × CH2), 3.82 (3H, s, CH3), 4.33 (2H, t, J = 6.2 Hz, CH2), 6.93 (1H, 
dd, J = 9.0, 2.4 Hz, H-6), 7.09 (1H, d, J = 2.4 Hz, H-4), 7.61 (1H, d, J = 9.0 Hz, H-7), 8.22 (1H, s, 
H-2); 13C NMR (50 MHz, DMSO-d6) 43.5 (t), 53.1 (2 × t), 55.4 (q), 57.2 (t), 66.1 (2 × t), 82.8 
(s), 100.0 (d), 112.5 (d), 113.5 (d), 116.3 (s), 127.8 (s), 130.1 (s), 137.1 (d), 155.4 (s); Anal. 
Calculated for C16H19N3O2 (MW: 285.15) : C, 67.35; H, 6.71; N, 14.73%. Found: C, 67.22; H, 6.97; 
N, 14.60%. 
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General procedure for the synthesis of 1-(2-morpholin-4-yl-ethyl)-1H-indole-3-
carbothioamides (75a-d) 
A solution of phosphorus pentasulfide (P4S10) (1.4 g, 3.17 mmol) in anhydrous ethanol (3 mL) was 
stirred at room temperature for 1 hour. The appropriate indole carbonitrile 78a-d, (0.7 g, 2.11 
mmol) were added and the reaction mixture was heated under reflux for 1 hour. The solvent was 
removed under reduced pressure and the residue was treated with 20% aqueous solution of sodium 
hydrogencarbonate (NaHCO3) (22 mL) up to pH = 8-9 and stirred at room temperature for 24 hours. 
The resulting mixture was extracted with ethyl acetate (3 × 20 mL), dried (Na2SO4), filtered and 
concentrated under vacuum. The product was purified by column chromatography using 
dichloromethane:methanol (98:2) as eluent. 
1-(2-Morpholin-4-yl-ethyl)-1H-indole-3-carbothioamide (75a)  
N
CH2
CH2
N
O
S
NH2
 
Yield: 73%, yellow solid; mp: 157-158 °C; IR: 1653 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6) 
2.44 (4H, t, J = 4.5 Hz, 2 × CH2), 2.69 (2H, t, J = 6.3 Hz, CH2), 3.55 (4H, t, J = 4.5 Hz, 2 × CH2), 
4.33 (2H, t, J = 6.3 Hz, CH2), 7.13-7.27 (2H, m, H-5 and H-6), 7.56 (1H, dd, J = 6.1, 1.7 Hz, H-7), 
8.16 (1H, s, H-2), 8.58 (1H, dd, J = 6.9, 1.0 Hz, H-4), 8.80 (1H, s, SH), 9.00 (1H, s, NH); 13C NMR 
(50 MHz, DMSO-d6) 43.0 (t), 53.2 (2 × t), 57.3 (t), 66.1 (2 × t), 110.4 (d), 115.4 (s), 121.0 (d), 
121.8 (d), 122.0 (d), 125.9 (s), 132.0 (d), 136.6 (s), 193.0 (s); Anal. Calculated for C15H19N3OS 
(MW: 289.40) : C, 62.25; H, 6.62; N, 14.52%. Found: C, 62.01; H, 6.49; N, 14.89%. 
5-Bromo-1-(2-morpholin-4-yl-ethyl)-1H-indole-3-carbothioamide (75b)  
N
CH2
Br
CH2
N
O
S
NH2
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Yield: 81%, yellow solid; mp: 212-213 °C; IR: 1653 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6) 
2.42 (4H, t, J = 4.4 Hz, 2 × CH2), 2.67 (2H, t, J = 6.1 Hz, CH2), 3.53 (4H, t, J = 4.4 Hz, 2 × CH2), 
4.33 (2H, t, J = 6.2 Hz, CH2), 7.36 (1H, dd, J = 8.7, 2.0 Hz, H-6), 7.59 (1H, d, J = 8.7 Hz, H-7), 8.20 
(1H, s, H-2), 8.88 (1H, d, J = 2.0 Hz, H-4), 8.92 (1H, s, SH), 9.07 (1H, s, NH); 13C NMR (50 MHz, 
DMSO-d6) 43.6 (t), 53.1 (2 × t), 57.2 (t), 66.1 (2 × t), 112.7 (d), 114.0 (s), 114.6 (s), 124.1 (d), 
124.5 (d), 127.9 (s), 132.4 (d), 135.5 (s), 192.4 (s); Anal. Calculated for C15H18BrN3OS (MW: 
368.29) : C, 48.92; H, 4.93; N, 11.41%. Found: C, 48.63; H, 5.33; N, 11.30%. 
5-Fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indole-3-carbothioamide (75c)  
N
CH2
F
CH2
N
O
S
NH2
 
Yield: 76%, yellow solid; mp: 175-176 °C; IR: 1684 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6) 
2.43 (4H, t, J = 4.6 Hz, 2 × CH2), 2.68 (2H, t, J = 6.2 Hz, CH2), 3.54 (4H, t, J = 4.4 Hz, 2 × CH2), 
4.33 (2H, t, J = 6.3 Hz, CH2), 7.09 (1H, td, J = 11.0, 9.1, 2.6 Hz, H-6), 7.58-7.65 (1H, m, H-7), 8.23 
(1H, s, H-2), 8.43 (1H, dd, J = 11.0, 2.6 Hz, H-4), 8.86 (1H, s, SH), 9.02 (1H, s, NH); 13C NMR (50 
MHz, DMSO-d6) 43.3 (t), 53.1 (2 × t), 57.3 (t), 66.1 (2 × t), 106.8 (d, JC4-F = 26.1 Hz), 110.1 (d, 
JC6-F = 26.1 Hz), 111.9 (d, JC7-F = 9.9 Hz), 115.0 (d, JC7a-F = 4.6 Hz), 126.8 (d, JC3a-F = 10.9 Hz), 
133.0 (d), 133.4 (s), 158.1 (d, JC5-F = 230.5 Hz), 192.6 (s); Anal. Calculated for C15H18FN3OS (MW: 
307.39) : C, 58.61; H, 5.90; N, 13.67%. Found: C, 58.31; H, 6.08; N, 13.79%. 
5-Methoxy-1-(2-morpholin-4-yl-ethyl)-1H-indole-3-carbothioamide (75d)  
N
CH2
H3CO
CH2
N
O
S
NH2
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Yield: 77%, yellow solid; mp: 56-57 °C; IR: 1653 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6) 
2.43 (4H, t, J = 4.5 Hz, 2 × CH2), 2.67 (2H, t, J = 6.3 Hz, CH2), 3.55 (4H, t, J = 4.4 Hz, 2 × CH2), 
3.78 (3H, s, CH3), 4.29 (2H, t, J = 6.2 Hz, CH2), 6.86 (1H, dd, J = 8.9, 2.5 Hz, H-6), 7.48 (1H, d, J = 
8.9 Hz, H-7), 8.13 (1H, s, H-2), 8.18 (1H, d, J = 2.5 Hz, H-4), 8.74 (1H, s, SH), 8.92 (1H, s, NH); 
13C NMR (50 MHz, DMSO-d6) 43.2 (t), 53.2 (2 × t), 55.2 (q), 57.3 (t), 66.1 (2 × t), 103.8 (d), 
111.2 (d), 111.7 (d), 114.9 (s), 126.7 (s), 131.7 (s), 132.3 (d), 154.8 (s), 192.8 (s); Anal. Calculated 
for C16H21N3O2S (MW: 319.42) : C, 60.16; H, 6.63; N, 13.16%. Found: C, 60.03; H, 6.95; N, 
12.97%. 
General procedure for the synthesis of 3-{2-[1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl]-
thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine hydrobromides (56a-h) 
Compounds 56a-h were prepared from 75a-d using the same synthetic procedure described for 
compounds 69a,b.  
3-{2-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromide (56a)  
N
CH2
N
S
N
H
N
CH2
N
HBr
O  
Conditions: 30 minutes at reflux. Yield: 70%, light brown solid; mp: 246-247 °C; IR: 3119 (NH), 
2976 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6) 3.21-3.79 (8H, m, 4 × CH2), 4.01 (2H, s, 
CH2), 4.76 (2H, t, J = 6.7 Hz, CH2), 7.25 (1H, dd, J = 7.9, 4.7 Hz, H-5’’), 7.32-7.42 (2H, m, H-
5’and H-6’), 7.73-7.77 (2H, m, H-2’ and H-7’), 8.12 (1H, d, J = 2.5 Hz, H-2’’), 8.31-8.41 (3H, m, 
H-4’, H-5 and H-6’’), 8.65 (1H, dd, J = 8.0, 1.3 Hz, H-4’’), 10.19 (1H, bs, NH+), 12.00 (1H, bs, 
NH); 13C NMR (50 MHz, DMSO-d6) 40.1 (t), 51.5 (2 × t), 54.3 (t), 63.2 (2 × t), 107.2 (d), 109.9 
(s), 110.7 (s), 110.8 (d), 116.1 (d), 117.5 (s), 120.7 (d), 121.5 (d), 122.9 (d), 124.8 (d + s), 128.6 (d), 
129.4 (d), 136.3 (s), 142.9 (d), 148.6 (s), 149.9 (s), 161.3 (s); Anal. Calculated for C24H24BrN5OS 
(MW: 510.45) : C, 56.47; H, 4.74; N, 13.72%. Found: C, 56.25; H, 4.61; N, 14.07%. 
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1-Methyl-3-{2-[1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (56b)  
N
CH2
N
S
N
N
CH2
N
HBr
O
CH3
 
Conditions: 30 minutes at reflux. Yield: 80%, light yellow solid; mp: 240-241 °C; IR: 2951 (NH+) 
cm-1; 1H NMR (200 MHz, DMSO-d6) 3.20-3.80 (8H, m, 4 × CH2), 3.94-4.08 (5H, m, CH2 and 
CH3), 4.76 (2H, s, CH2), 7.24-7.43 (3H, m, H-5’, H-5’’ and H-6’), 7.74-7.78 (2H, m, H-2’ and H-
4’), 8.20 (1H, s, H-2’’), 8.33 (1H, s, H-5), 8.36-8.44 (2H, m, H-6’’ and H-7’), 8.63 (1H, dd, J = 7.9, 
1.4 Hz, H-4’’), 10.16 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6) 31.0 (q), 40.7 (t), 51.5 (2 × 
t), 54.3 (t), 63.2 (2 × t), 107.1 (d), 108.9 (s), 110.7 (d), 110.8 (s), 116.2 (d), 117.3 (s), 120.9 (d), 
121.5 (d), 122.9 (d), 124.8 (s), 128.7 (d), 128.8 (d), 129.4 (d), 136.3 (s), 142.9 (d), 147.6 (s), 149.5 
(s), 161.4 (s); Anal. Calculated for C25H26BrN5OS (MW: 524.48) : C, 57.25; H, 5.00; N, 13.35%. 
Found: C, 57.61; H, 4.79; N, 13.20%. 
3-{2-[5-Bromo-1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (56c)  
N
CH2
N
S
N
H
N
CH2
N
HBr
Br
O  
Conditions: 30 minutes at reflux. Yield: 81%, light brown solid; mp: 249-250 °C; IR: 3186 (NH), 
2978 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6) 3.20-3.77 (8H, m, 4 × CH2), 3.98-4.10 (2H, m, 
CH2), 4.75 (2H, t, J = 6.7 Hz, CH2), 7.24 (1H, dd, J = 7.9, 4.7 Hz, H-5’’), 7.53 (1H, dd, J = 8.7, 1.8 
Hz, H-6’), 7.77 (1H, d, J = 9.1 Hz, H-7’), 7.79 (1H, s, H-2’), 8.10 (1H, d, J = 2.5 Hz, H-2’’), 8.34 
(1H, dd, J = 4.7, 1.1 Hz, H-6’’), 8.39 (1H, s, H-5), 8.60 (1H, d, J = 1.8 Hz, H-4’), 8.65 (1H, dd, J = 
7.9, 1.1 Hz, H-4’’), 10.18 (1H, bs, NH+), 12.02 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6) 
40.2 (t), 51.4 (2 × t), 54.2 (t), 63.1 (2 × t), 107.4 (d), 109.8 (s), 110.2 (s), 112.9 (d), 114.1 (s), 
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116.0 (d), 117.2 (s), 123.1 (d), 124.7 (d), 125.3 (d), 126.5 (s), 128.6 (d), 130.7 (d), 135.0 (s), 142.9 
(d), 148.4 (s), 149.9 (s), 160.7 (s); Anal. Calculated for C24H23Br2N5OS (MW: 589.35) : C, 48.91; 
H, 3.93; N, 11.88%. Found: C, 48.72; H, 4.27; N, 11.73%. 
3-{2-[5-Bromo-1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (56d)  
N
CH2
N
S
N
N
CH2
N
HBr
Br
O
CH3
 
Conditions: 30 minutes at reflux. Yield: 98%, white solid; mp: 271-272 °C; IR: 2972 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6) 3.20-3.84 (8H, m, 4 × CH2), 3.94-4.07 (5H, m, CH2 and CH3), 
4.72-4.78 (2H, m, CH2), 7.27 (1H, dd, J = 7.9, 4.7 Hz, H-5’’), 7.54 (1H, dd, J = 8.7, 1.8 Hz, H-6’), 
7.74-7.78 (2H, m, H-2’ and H-7’), 8.16 (1H, s, H-2’’), 8.37-8.40 (2H, m, H-5 and H-6’’), 8.57 (1H, 
d, J = 1.8 Hz, H-4’), 8.64 (1H, dd, J = 7.9, 1.4 Hz, H-4’’), 10.0 (1H, bs, NH+); 13C NMR (50 MHz, 
DMSO-d6) 31.0 (q), 40.2 (t), 51.4 (2 × t), 54.1 (t), 63.1 (2 × t), 107.4 (d), 108.6 (s), 110.2 (s), 
113.0 (d), 114.1 (s), 116.1 (d), 117.3 (s), 123.0 (d), 125.4 (d), 126.4 (s), 128.5 (d), 128.6 (d), 130.8 
(d), 135.1 (s), 142.9 (d), 147.5 (s), 149.6 (s), 160.8 (s); Anal. Calculated for C25H25Br2N5OS (MW: 
603.37) : C, 49.76; H, 4.18; N, 11.61%. Found: C, 49.55; H, 4.55; N, 11.45%. 
3-{2-[5-Fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (56e)  
N
CH2
N
S
N
H
N
CH2
N
HBr
F
O  
Conditions: 30 minutes at reflux. Yield: 95%, light yellow solid; mp: 264-265 °C; IR: 3119 (NH), 
2960 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6) 3.24-3.78 (8H, m, 4 × CH2), 3.99-4.08 (2H, m, 
CH2), 4.75 (2H, t, J = 5.5 Hz, CH2), 7.21-7.32 (2H, m, H5’’ and H-6’), 7.77-7.83 (2H, m, H-2’ and 
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H-7’), 8.11 (1H, dd, J = 10.8, 2.5 Hz, H-4’), 8.14 (1H, d, J = 2.5 Hz, H-2’’), 8.33 (1H, dd, J = 4.7, 
1.4 Hz, H-6’’), 8.40 (1H, s, H-5), 8.62 (1H, dd, J = 7.8, 1.4 Hz, H-4’’), 10.17 (1H, bs, NH+), 12.02 
(1H, bs, NH); 13C NMR (50 MHz, DMSO-d6) 40.3 (t), 51.4 (2 × t), 54.2 (t), 63.2 (2 × t), 105.7 (d, 
JC4’-F = 25.7 Hz), 107.2 (d), 109.9 (s), 110.8 (d, JC7a-F = 4.6 Hz), 111.1 (d, JC6’-F = 25.4 Hz), 112.2 
(d, JC7’-F = 8.9 Hz), 116.1 (d), 117.1 (s), 124.9 (d), 125.2 (d, JC3a-F = 10.7 Hz), 128.5 (d), 131.2 (d), 
133.0 (s), 142.9 (d), 148.5 (s), 149.9 (s), 158.3 (d, JC5’-F = 234.6 Hz), 161.0 (s); Anal. Calculated for 
C24H23BrFN5OS (MW: 528.44) : C, 54.55; H, 4.39; N, 13.25%. Found: C, 54.43; H, 4.23; N, 
13.53%. 
3-{2-[5-Fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (56f)  
N
CH2
N
S
N
N
CH2
N
HBr
F
O
CH3
 
Conditions: 30 minutes at reflux. Yield: 98%, light yellow solid; mp: 281-282 °C; IR: 2975 (NH+) 
cm-1; 1H NMR (200 MHz, DMSO-d6) 3.20-3.86 (8H, m, 4 × CH2), 3.94-4.07 (5H, m, CH2 and 
CH3), 4.72-4.78 (2H, m, CH2), 7.24-7.32 (2H, m, H5’’ and H-6’), 7.76-7.82 (2H, m, H-2’ and H-
7’), 8.13 (1H, dd, J = 9.8, 2.5 Hz, H-4’), 8.22 (1H, s, H-2’’), 8.36-8.39 (2H, m, H-5 and H-6’’), 8.59 
(1H, dd, J = 8.0, 1.4 Hz, H-4’’), 9.99 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6) 30.9 (q), 
40.3 (t), 51.4 (2 × t), 54.2 (t), 63.1 (2 × t), 105.8 (d, JC4’-F = 24.4 Hz), 107.2 (d), 108.8 (s), 110.8 (d, 
JC7a-F = 4.6 Hz), 111.1 (d, JC6’-F = 26.2 Hz), 112.2 (d, JC7’-F = 10.2 Hz), 116.2 (d), 117.3 (s), 125.2 
(d, JC3a-F = 10.7 Hz), 128.5 (d), 128.9 (d), 131.3 (d), 133.0 (s), 142.9 (d), 147.6 (s), 149.6 (s), 158.4 
(d, JC5’-F = 234.1 Hz), 161.1 (s); Anal. Calculated for C25H25BrFN5OS (MW: 542.47) : C, 55.35; H, 
4.65; N, 12.91%. Found: C, 55.45; H, 4.95; N, 12.51%. 
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3-{2-[5-Methoxy-1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (56g)  
N
CH2
N
S
N
H
N
CH2
N
HBr
O
H3CO
 
Conditions: 30 minutes at reflux. Yield: 92%, light brown solid; mp: 272-273 °C; IR: 3134 (NH), 
2974 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6) 3.23-3.80 (8H, m, 4 × CH2), 3.92-4.05 (5H, m, 
CH2 and CH3), 4.68-4.74 (2H, m, CH2), 7.02 (1H, dd, J = 9.0, 2.4 Hz, H-6’), 7.21 (1H, dd, J = 7.9, 
4.7 Hz, H-5’’), 7.66 (1H, d, J = 9.0 Hz, H-7’), 7.73 (1H, s, H-2’), 7.97 (1H, d, J = 2.4 Hz, H-4’), 
8.11 (1H, d, J = 2.4 Hz, H-2’’), 8.26 (1H, s, H-5), 8.32 (1H, dd, J = 4.7, 1.3 Hz, H-6’’), 8.73 (1H, d, 
J = 7.9 Hz, H-4’’), 10.20 (1H, bs, NH+), 11.98 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  
40.3 (t), 51.5 (2 × t), 54.3 (t), 55.2 (q), 63.2 (2 × t), 102.3 (d), 106.7 (d), 109.9 (s), 110.5 (s), 111.6 
(d), 112.9 (d), 116.0 (d), 117.3 (s), 124.5 (d), 125.4 (s), 128.7 (d), 129.7 (d), 131.3 (s), 142.9 (d), 
148.5 (s), 149.9 (s), 155.2 (s), 161.6 (s); Anal. Calculated for C25H26BrN5O2S (MW: 540.48) : C, 
55.56; H, 4.85; N, 12.96%. Found: C, 55.78; H, 4.52; N, 13.07%. 
3-{2-[5-Methoxy-1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (56h)  
N
CH2
N
S
N
N
CH2
N
HBr
O
H3CO
CH3
 
Conditions: 30 minutes at reflux. Yield: 93%, white solid; mp: 200-201 °C; IR: 2954 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6) 3.17-3.77 (8H, m, 4 × CH2), 3.92-4.06 (8H, m, CH2 and 2 × 
CH3), 4.67-4.73 (2H, m, CH2), 7.02 (1H, dd, J = 9.0, 2.4 Hz, H-6’), 7.24 (1H, dd, J = 7.9, 4.7 Hz, H-
5’’), 7.65 (1H, d, J = 9.0 Hz, H-7’), 7.71 (1H, s, H-2’), 7.95 (1H, d, J = 2.4 Hz, H-4’), 8.15 (1H, s, 
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H-2’’), 8.25 (1H, s, H-5), 8.37 (1H, dd, J = 4.7, 1.5 Hz, H-6’’), 8.72 (1H, dd, J = 7.9, 1.5 Hz, H-4’’), 
10.07 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6) 31.0 (q), 40.3 (t), 51.5 (2 × t), 54.3 (t), 55.3 
(q), 63.2 (2 × t), 102.4 (d), 106.7 (d), 108.8 (s), 110.5 (s), 111.6 (d), 112.8 (d), 116.1 (d), 117.5 (s), 
125.4 (s), 128.4 (d), 128.8 (d), 129.8 (d), 131.3 (s), 142.9 (d), 147.6 (s), 149.6 (s), 155.2 (s), 161.7 
(s); Anal. Calculated for C26H28BrN5O2S (MW: 554.50) : C, 56.32; H, 5.09; N, 12.63%. Found: C, 
56.19; H, 4.86; N, 12.99%. 
General procedure for the synthesis of 1-(3-bromo-propyl)-1H-indole-3-carbonitriles (81a-d)  
To a solution of the appropriate indole carbonitrile 70a-d (0.4 g, 1.80 mmol) in dry DMF (2 mL), 
was slowly added at 0-5 °C, sodium hydride 60% dispersion in mineral oil (NaH) (0.06 g, 2.70 
mmol) and the reaction mixture was stirred at room temperature for 30 minutes. After that, it was 
added dropwise 1,3-dibromopropane 80 (0.91 mL, 9.00 mmol) and the reaction mixture was stirred 
at room temperature for 2-24 hours. Then, the mixture was poured into water and ice and extracted 
with ethyl acetate (3 × 20 mL), dried (Na2SO4), filtered and the solvent evaporated under reduced 
pressure. The residue was purified by column chromatography using petroleum ether:ethyl acetate 
(7:3) as eluent. 
1-(3-Bromo-propyl)-1H-indole-3-carbonitrile (81a)  
N
CN
CH2CH2CH2Br 
Conditions: rt for 2 hours. Yield: 70%, white solid; mp: 52-53 °C; IR: 2220 (CN) cm-1; 1H NMR 
(200 MHz, DMSO-d6) 2.27-2.40 (2H, m, CH2), 3.47 (2H, t, J = 6.5 Hz, CH2), 4.39 (2H, t, J = 6.8 
Hz, CH2), 7.24-7.40 (2H, m, H-5 and H-6), 7.64-7.73 (2H, m, H-4 and H-7), 8.32 (1H, s, H-2); 
13C 
NMR (50 MHz, DMSO-d6) 31.1 (t), 32.3 (t), 44.7 (t), 83.7 (s), 111.4 (d), 115.9 (s), 118.8 (d), 
122.0 (d), 123.5 (d), 127.1 (s), 135.0 (s), 136.8 (d); Anal. Calculated for C12H11BrN2 (MW: 263.13) 
: C, 54.77; H, 4.21; N, 10.65%. Found: C, 54.53; H, 4.58; N, 10.52%. 
5-Bromo-1-(3-bromo-propyl)-1H-indole-3-carbonitrile (81b)  
N
Br CN
CH2CH2CH2Br 
Conditions: rt for 24 hours. Yield: 80%, white solid; mp: 113-114°C; IR: 2220 (CN) cm-1; 1H NMR 
(200 MHz, DMSO-d6) 2.25-2.39 (2H, m, CH2), 3.47 (2H, t, J = 6.6 Hz, CH2), 4.39 (2H, t, J = 6.8 
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Hz, CH2), 7.50 (1H, dd, J = 8.8, 1.9 Hz, H-6), 7.73 (1H, d, J = 8.8 Hz, H-7), 7.83 (1H, d, J = 1.9 Hz, 
H-4), 8.39 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6) 31.0 (t), 32.2 (t), 45.0 (t), 83.5 (s), 113.6 
(d), 114.8 (s), 115.2 (s), 121.0 (d), 126.2 (d), 128.7 (s), 134.0 (s), 138.2 (d); Anal. Calculated for 
C12H10Br2N2 (MW: 342.03) : C, 42.14; H, 2.95; N, 8.19%. Found: C, 41.94; H, 3.29; N, 8.05%. 
1-(3-Bromo-propyl)-5-fluoro-1H-indole-3-carbonitrile (81c)  
N
F CN
CH2CH2CH2Br 
Conditions: rt for 2 hours. Yield: 80%, white solid; mp: 108-109 °C; IR: 2220 (CN) cm-1; 1H NMR 
(200 MHz, DMSO-d6) 2.29-2.36 (2H, m, CH2),3.47 (2H, t, J = 5.8 Hz, CH2), 4.39 (2H, t, J = 6.1 
Hz, CH2), 7.18-7.27 (1H, m, H-6), 7.44 (1H, d, J = 8.5 Hz, H-7), 7.72-7.78 (1H, m, H-4), 8.38 (1H, 
s, H-2); 13C NMR (50 MHz, DMSO-d6) 31.0 (t), 32.2 (t), 45.1 (t), 84.0 (d, JC7a-F = 4.6 Hz), 104.1 
(d, JC4-F = 24.9 Hz), 112.0 (d, JC6-F = 26.2 Hz), 113.0 (d, JC7-F = 9.9 Hz), 115.5 (s), 127.6 (d, JC3a-F = 
10.8 Hz), 131.8 (s), 138.4 (d), 158.5 (d, JC5-F = 236.9 Hz); Anal. Calculated for C12H10BrFN2 (MW: 
281.12) : C, 51.27; H, 3.59; N, 9.96%. Found: C, 51.49; H, 3.27; N, 10.06%. 
1-(3-Bromo-propyl)-5-methoxy-1H-indole-3-carbonitrile (81d)  
N
H3CO
CN
CH2CH2CH2Br 
Conditions: rt for 2 hours. Yield: 70%, white solid; mp: 177-178 °C; IR: 2221 (CN) cm-1; 1H NMR 
(200 MHz, DMSO-d6) 2.28-2.34 (2H, m, CH2), 3.42-3.49 (2H, m, CH2), 3.82 (3H, s, CH3), 4.32-
4.38 (2H, m, CH2), 6.97 (1H, d, J = 8.4 Hz, H-6), 7.10 (1H, s, H-4), 7.61 (1H, d, J = 8.4 Hz, H-7), 
8.23 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6) 31.1 (t), 32.3 (t), 44.9 (t), 55.4 (q), 83.3 (s), 
100.1 (d), 112.4 (d), 113.8 (d), 116.1 (s), 127.9 (s), 130.0 (s), 136.6 (d), 155.5 (s); Anal. Calculated 
for C13H13BrN2O (MW: 293.16) : C, 53.26; H, 4.47; N, 9.56%. Found: C, 53.11; H, 4.35; N, 9.83% 
General procedure for the synthesis of the derivatives 1-(3-morpholin-4-yl-propyl)-1H-indole-
3-carbonitriles (83a-d)  
A mixture of appropriate indole carbonitrile 81a-d (0.5 g, 1.46 mmol), morpholine 82 (1.27 mL, 
14.69 mmol), and potassium carbonate (K2CO3) (0.35 g, 2.54 mmol), in dry DMF (5.5 mL) was 
stirred at 50 °C for 1-2 hours. After cooling, the mixture was poured into water and ice and the 
obtained precipitate was filtered off, dried, to give the desired products.  
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1-(3-Morpholin-4-yl-propyl)-1H-indole-3-carbonitrile (83a)  
N
CN
CH2
CH2
CH2
N
O  
Conditions: heated for 1 hour at 50 °C. Yield: 90%, white solid; mp: 104-105 °C; IR: 2220 (CN) 
cm-1; 1H NMR (200 MHz, DMSO-d6) 1.87-2.01 (2H, m, CH2), 2.19 (2H, t, J = 6.4 Hz, CH2), 
2.27 (4H, t, J = 4.5 Hz, 2 × CH2), 3.54 (4H, t, J = 4.6 Hz, 2 × CH2), 4.31 (2H, t, J = 6.8 Hz, CH2), 
7.23-7.39 (2H, m, H-5 and H-6), 7.63-7.74 (2H, m, H-4 and H-7), 8.31 (1H, s, H-2); 13C NMR (50 
MHz, DMSO-d6) 26.0 (t), 44.3 (t), 53.1 (2 × t), 54.6 (t), 66.0 (2 × t), 83.3 (s), 111.5 (d), 116.0 (s), 
118.6 (d), 121.8 (d), 123.2 (d), 127.0 (s), 135.2 (s), 137.0 (d); Anal. Calculated for C16H19N3O 
(MW: 269.34) : C, 71.35; H, 7.11; N, 15.60%. Found: C, 70.95; H, 7.27; N, 15.84%. 
5-Bromo-1-(3-morpholin-4-yl-propyl)-1H-indole-3-carbonitrile (83b)  
N
CN
CH2
Br
CH2
CH2
N
O  
Conditions: heated for 2 hours at 50 °C. Yield: 98%, white solid; mp: 121-122 °C; IR: 2220 (CN) 
cm-1; 1H NMR (200 MHz, DMSO-d6) 1.90-1.96 (2H, m, CH2), 2.14-2.19 (2H, m, CH2), 2.22-
2.26 (4H, m, 2 × CH2), 3.50-3.55 (4H, m, 2 × CH2), 4.27-4.33 (2H, m, CH2), 7.47 (1H, d, J = 8.8 
Hz, H-6), 7.72 (1H, d, J = 8.8 Hz, H-7), 7.81 (1H, s, H-4), 8.38 (1H, s, H-2); 13C NMR (50 MHz, 
DMSO-d6) 25.9 (t), 44.5 (t), 53.0 (2 × t), 54.5 (t), 66.0 (2 × t), 83.1 (s), 113.7 (d), 114.6 (s), 115.3 
(s), 120.9 (d), 126.0 (d), 128.6 (s), 134.1 (s), 138.3 (d); Anal. Calculated for C16H18BrN3O (MW: 
348.24) : C, 55.18; H, 5.21; N, 12.07%. Found: C, 55.01; H, 5.05; N, 12.40%. 
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5-Fluoro-1-(3-morpholin-4-yl-propyl)-1H-indole-3-carbonitrile (83c)  
N
CN
CH2
F
CH2
CH2
N
O  
Conditions: heated for 1 hour at 50 °C. Yield: 98%, white solid; mp: 76-77 °C; IR: 2220 (CN) cm-1; 
1H NMR (200 MHz, DMSO-d6) 1.87-2.00 (2H, m, CH2), 2.19 (2H, t, J = 6.4 Hz, CH2), 2.25 (4H, 
t, J = 4.2 Hz, 2 × CH2), 3.53 (4H, t, J = 4.4 Hz, 2 × CH2), 4.30 (2H, t, J = 6.7 Hz, CH2), 7.21 (1H, 
td, J = 11.7, 9.3, 2.5 Hz, H-6), 7.43 (1H, dd, J = 9.2, 2.5 Hz, H-7), 7.73-7.80 (1H, m, H-4),8.39 
(1H, s, H-2); 13C NMR (50 MHz, DMSO-d6) 26.0 (t), 44.6 (t), 53.0 (2 × t), 54.6 (t), 66.0 (2 × t), 
83.5 (d, JC7a-F = 4.5 Hz), 103.9 (d, JC4-F = 24.6 Hz), 111.7 (d, JC6-F = 26.3 Hz), 113.2 (d, JC7-F = 9.9 
Hz), 115.6 (s), 127.5 (d, JC3a-F = 11.0 Hz), 132.0 (s), 138.5 (d),158.5 (d, JC5-F = 246.0 Hz); Anal. 
Calculated for C16H18FN3O (MW: 287.33) : C, 66.88; H, 6.31; N, 14.62%. Found: C, 67.02; H, 
6.48; N, 14.31%. 
5-Methoxy-1-(3-morpholin-4-yl-propyl)-1H-indole-3-carbonitrile (83d)  
N
CN
CH2
H3CO
CH2
CH2
N
O  
Conditions: heated for 1 hour at 50 °C; work-up: the oil residue was extracted with ethyl acetate (3 
× 20 mL) and purified by column chromatography using dichloromethane:methanol (98:2) as 
eluent. Yield: 90%, yellow oil; IR: 2215 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.85-1.98 
(2H, m, CH2), 2.17 (2H, t, J = 6.4 Hz, CH2), 2.25-2.29 (4H, m, 2 × CH2), 3.55 (4H, t, J = 4.5 Hz, 2 
× CH2), 3.82 (3H, s, CH3), 4.25 (2H, t, J = 6.7 Hz, CH2), 6.94 (1H, dd, J = 9.0, 2.4 Hz, H-6), 7.08 
(1H, d, J = 2.4 Hz, H-4), 7.60 (1H, d, J = 9.0 Hz, H-7), 8.22 (1H, s, H-2); 13C NMR (50 MHz, 
DMSO-d6) 26.1 (t), 44.3 (t), 53.1 (2 × t), 54.6 (t), 55.4 (q), 66.0 (2 × t), 82.9 (s), 99.9 (d), 112.5 
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(d), 113.6 (d), 116.2 (s), 127.9 (s), 130.1 (s), 136.7 (d), 155.4 (s); Anal. Calculated for C17H21N3O2 
(MW: 299.37) : C, 68.20; H, 7.07; N, 14.04%. Found: C, 68.46; H, 6.68; N, 14.17%. 
General procedure for the synthesis of 1-(3-morpholin-4-yl-propyl)-1H-indole-3-
carbothioamides (79a-d) 
Compounds 79a-d were prepared from 83a-d using the same synthetic procedure described for 
compounds 75a-d.  
1-(3-Morpholin-4-yl-propyl)-1H-indole-3-carbothioamide (79a)  
N
CH2
CH2
CH2
N
O
S
NH2
 
Conditions: 2 hours at reflux. Yield: 70%, yellow solid; mp: 168-169 °C; IR: 1653 (CS) cm-1; 1H 
NMR (200 MHz, DMSO-d6) 1.87-2.00 (2H, m, CH2), 2.21 (2H, t, J = 6.5 Hz, CH2), 2.30 (4H, t, J 
= 4.3 Hz, 2 × CH2), 3.58 (4H, t, J = 4.5 Hz, 2 × CH2), 4.26 (2H, t, J = 6.7 Hz, CH2), 7.13-7.27 (2H, 
m, H-5 and H-6), 7.57 (1H, dd, J = 6.3, 1.7 Hz, H-7), 8.15 (1H, s, H-2), 8.56-8.61 (1H, m, H-4), 
8.79 (1H, s, SH), 9.00 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6) 26.1 (t), 43.7 (t), 53.1 (2 × t), 
54.7 (t), 66.1 (2 × t), 110.5 (d), 115.4 (s), 121.0 (d), 121.8 (d), 122.0 (d), 126.0 (s), 131.7 (d), 136.6 
(s), 193.0 (s); Anal. Calculated for C16H21N3OS (MW: 303.42) : C, 63.33; H, 6.98; N, 13.85%. 
Found: C, 63.55; H, 7.09 ; N, 13.52%. 
5-Bromo-1-(3-morpholin-4-yl-propyl)-1H-indole-3-carbothioamide (79b)  
N
CH2
Br
CH2
CH2
N
O
S
NH2
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Conditions: 1 hour at reflux. Yield: 61%, yellow solid; mp: 99-100 °C; IR: 1653 (CS) cm-1; 1H 
NMR (200 MHz, DMSO-d6) 1.85-1.99 (2H, m, CH2), 2.19 (2H, t, J = 6.3 Hz, CH2), 2.28 (4H, t, J 
= 4.2 Hz, 2 × CH2), 3.56 (4H, t, J = 4.4 Hz, 2 × CH2), 4.25 (2H, t, J = 6.6 Hz, CH2), 7.35 (1H, dd, J 
= 8.7, 2.0 Hz, H-6), 7.58 (1H, d, J = 8.7 Hz, H-7), 8.19 (1H, s, H-2), 8.87 (1H, d, J = 2.0 Hz, H-4), 
8.92 (1H, s, SH),9.07 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6) 26.0 (t), 44.0 (t), 53.1 (2 × t), 
54.6 (t), 66.0 (2 × t), 112.7 (d), 114.0 (s), 114.6 (s), 124.1 (d), 124.5 (d), 128.0 (s), 132.1 (d), 135.5 
(s), 192.4 (s); Anal. Calculated for C16H20BrN3OS (MW: 382.32) : C, 50.26; H, 5.27; N, 10.99%. 
Found: C, 50.44; H, 5.40; N, 10.68%. 
5-Fluoro-1-(3-morpholin-4-yl-propyl)-1H-indole-3-carbothioamide (79c)  
N
CH2
F
CH2
CH2
N
O
S
NH2
 
Conditions: 2 hours at reflux. Yield: 60%, yellow solid; mp: 149-150 °C; IR: 1629 (CS) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.87-2.00 (2H, m, CH2), 2.20 (2H, t, J = 6.4 Hz, CH2), 2.28 ( 4H, t, 
J = 4.0 Hz, 2 × CH2), 3.67 (4H, t, J = 4.5 Hz, 2 × CH2), 4.26 (2H, t, J = 6.6 Hz, CH2), 7.08 (1H, td, 
J = 11.1, 9.0, 2.6 Hz, H-6), 7.58-7.64 (1H, m, H-7), 8.22 (1H, s, H-2), 8.43 (1H, dd, J = 11.1, 2.6 
Hz, H-4), 8.85 (1H, s, SH), 9.02 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6) 26.0 (t), 44.1 (t), 
53.1 (2 × t), 54.6 (t), 66.0 (2 × t), 106.9 (d, JC4-F = 25.6 Hz), 110.2 (d, JC6-F = 26.0 Hz), 111.9 (d, JC7-
F = 10.0 Hz), 115.1 (d, JC7a-F = 4.9 Hz), 126.9 (d, JC3a-F = 10.9 Hz), 132.7 (d), 133.4 (s), 158.1 (d, 
JC5-F = 233.2 Hz), 192.6 (s); Anal. Calculated for C16H20FN3OS (MW: 321.41) : C, 59.79; H, 6.27; 
N, 13.07%. Found: C, 59.54; H, 6.14; N, 13.45%. 
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5-Methoxy-1-(3-morpholin-4-yl-propyl)-1H-indole-3-carbothioamide (79d)  
N
CH2
H3CO
CH2
CH2
N
O
S
NH2
 
Conditions: 2 hours at reflux. Yield: 72%, yellow solid; mp: 157-158 °C; IR: 1653 (CS) cm-1; 1H 
NMR (200 MHz, DMSO-d6) 1.85-1.98 (2H, m, CH2), 2.19 (2H, t, J = 7.0 Hz, CH2), 2.29 (4H, t, J 
= 4.4 Hz, 2 × CH2), 3.58 (4H, t, J = 4.5 Hz, 2 × CH2), 3.78 (3H, s, CH3), 4.21 (2H, t, J = 6.6 Hz, 
CH2), 6.86 (1H, dd, J = 8.9, 2.5 Hz, H-6), 7.47 (1H, d, J = 8.9 Hz, H-7), 8.11 (1H, s, H-2), 8.18 (1H, 
d, J = 2.5 Hz, H-4), 8.73 (1H, s, SH),8.92 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6) 26.1 (t), 
43.9 (t), 53.1 (2 × t), 54.6 (t), 55.2 (q), 66.1 (2 × t), 103.8 (d), 111.2 (d), 111.8 (d), 114.9 (s), 126.7 
(s), 131.7 (s), 132.0 (d), 154.8 (s), 192.8 (s); Anal. Calculated for C17H23N3O2S (MW: 333.45) : C, 
61.23; H, 6.95; N, 12.60%. Found: C, 61.35; H, 7.10; N, 12.33%. 
General procedure for the synthesis of 3-{2-[1-(3-morpholin-4-yl-propyl)-1H-indol-3-yl]-
thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine hydrobromides (57a-h) 
Compounds 57a-h were prepared from 79a-d using the same synthetic procedure described for 
compounds 69a,b.  
3-{2-[1-(3-Morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromide (57a)  
N
CH2
N
S
N
H
N
CH2
CH2
N
O
HBr
 
Conditions: 30 minutes at reflux. Yield: 80%, white solid; mp: 240-241 °C; IR: 3448 (NH), 2973 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  2.28-2.35 (2H, m, CH2), 3.07-3.23 (4H, m, 2 × 
CH2), 3.49-3.79 (4H, m, 2 × CH2), 3.94-3.99 (2H, m, CH2), 4.43 (2H, t, J = 6.3 Hz, CH2), 7.21-7.35 
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(3H, m, H-5’, H-5’’ and H-6’), 7.68-7.74 (2H, m, H-2’ and H-7’), 8.12 (1H, d, J = 1.70 Hz, H-2’’), 
8.31-8.39 (3H, m, H-4’, H-5 and H-6’’), 8.64 (1H, d, J = 7.6 Hz, H-4’’), 10.04 (1H, bs, NH+), 11.99 
(1H, bs, NH); 13C NMR (50 MHz, DMSO-d6) 23.9 (t), 43.2 (t), 51.1 (2 × t), 53.5 (t), 63.3 (2 × t), 
106.9 (d), 110.0 (s), 110.3 (s), 110.7 (d), 116.1 (d), 117.1 (s), 120.7 (d), 121.2 (d), 122.6 (d), 124.8 
(d + s), 128.5 (d), 129.3 (d), 136.3 (s), 143.0 (d), 148.7 (s), 149.8 (s), 161.5 (s); Anal. Calculated for 
C25H26BrN5OS (MW: 524.48) : C, 57.25; H, 5.00; N, 13.35%. Found: C, 57.15; H, 4.82; N, 
13.63%. 
1-Methyl-3-{2-[1-(3-morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (57b)  
N
CH2
N
S
N
N
CH3
CH2
CH2
N
O
HBr
 
 
Conditions: 1 hour at reflux. Yield: 80%, brown solid; mp: 225-226 °C; IR: 2972 (NH+) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  2.24-2.34 (2H, m, CH2), 3.07-3.20 (4H, m, 2 × CH2), 3.50-3.78 
(4H, m, 2 × CH2), 3.94-3.99 (5H, m, CH2 and CH3), 4.43 (2H, t, J = 6.3 Hz, CH2), 7.24-7.35 (3H, 
m, H-5’, H-5’’ and H-6’), 7.70 (1H, d, J = 8.7 Hz, H-4’), 7.73 (1H, s, H-2’), 8.20 (1H, s, H-2’’), 
8.30 (1H, s, H-5), 8.36-8.42 (2H, m, H-6’’ and H-7’), 8.63 (1H, d, J = 7.5 Hz, H-4’’), 9.99 (1H, bs, 
NH+); 13C NMR (50 MHz, DMSO-d6) 23.9 (t), 30.9 (q), 43.1 (t), 51.1 (2 × t), 53.5 (t), 63.2 (2 × 
t), 106.8 (d), 108.9 (s), 110.2 (s), 110.6 (d), 113.6 (s), 116.2 (d), 117.2 (s), 120.8 (d), 121.2 (d), 
122.6 (d), 124.7 (d), 128.6 (d), 129.4 (d), 136.3 (s), 142.9 (d), 147.6 (s), 149.4 (s), 161.6 (s); Anal. 
Calculated for C26H28BrN5OS (MW: 538.50) : C, 57.99; H, 5.24; N, 13.01%. Found: C, 58.09; H, 
5.34; N, 12.81%. 
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3-{2-[5-Bromo-1-(3-morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridinehydrobromide (57c)  
N
CH2
Br N
S
N
H
N
CH2
CH2
N
O
HBr
 
Conditions: 30 minutes at reflux. Yield: 87%, brown solid; mp: 252-253 °C; IR: 3450 (NH), 2975 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6) 2.20-2.39 (2H, m, CH2), 3.06-3.16 (4H, m, 2 × 
CH2), 3.50-3.77 (4H, m, 2 × CH2), 3.94-4.00 (2H, m, CH2), 4.42 (2H, t, J = 6.6 Hz, CH2), 7.24 (1H, 
dd, J = 7.9, 4.7 Hz, H-5’’), 7.48 (1H, dd, J = 8.7, 1.8 Hz, H-6’), 7.71 (1H, d, J = 8.7 Hz, H-7’), 7.77 
(1H, s, H-2’), 8.10 (1H, d, J = 2.2 Hz, H-2’’), 8.33 (1H, dd, J = 4.7, 1.2 Hz, H-6’’), 8.37 (1H, s, H-
5), 8.56 (1H, d, J = 1.8 Hz, H-4’), 8.65 (1H, d, J = 7.9 Hz, H-4’’), 9.97 (1H, bs, NH+), 12.01 (1H, 
bs, NH); 13C NMR (50 MHz, DMSO-d6) 23.9 (t), 43.3 (t), 51.1 (2 × t), 53.4 (t), 63.2 (2 × t), 
107.1 (d), 109.7 (s), 109.8 (s), 112.9 (d), 113.8 (s), 116.0 (d), 117.2 (s), 123.0 (d), 124.7 (d), 125.1 
(d), 126.4 (s), 128.5 (d), 130.7 (d), 135.1 (s), 142.9 (d), 148.5 (s), 149.8 (s),161.0 (s); Anal. 
Calculated for C25H25Br2N5OS (MW: 603.37) : C, 49.76; H, 4.18; N, 11.61%. Found: C, 49.49; H, 
4.06; N, 12.00%. 
3-{2-[5-Bromo-1-(3-morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (57d)  
N
CH2
Br N
S
N
N
CH3
CH2
CH2
N
O
HBr
 
Conditions: 30 minutes at reflux. Yield: 90%, white solid; mp: 209-210 °C; IR: 2972 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6) 2.18-2.37 (2H, m, CH2), 3.05-3.16 (4H, m, 2 × CH2), 3.49-3.73 
(4H, m, 2 × CH2), 3.94-4.00 (5H, m, CH2 and CH3), 4.42 (2H, t, J = 6.5 Hz, CH2), 7.26 (1H, dd, J = 
7.8, 4.7 Hz, H-5’’), 7.49 (1H, d, J = 8.6 Hz, H-6’), 7.72 (1H, d, J = 8.6 Hz, H-7’), 7.74 (1H, s, H-
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2’), 8.15 (1H, s, H-2’’), 8.35 (1H, s, H-5), 8.37 (1H, d, J = 4.7 Hz, H-6’’), 8.55 (1H, s, H-4’), 8.64 
(1H, d, J = 7.8 Hz, H-4’’), 9.78 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6) 23.9 (t), 31.0 (q), 
43.3 (t), 51.1 (2 × t), 53.4 (t), 63.3 (2 × t), 107.2 (d), 108.7 (s), 109.8 (s), 112.9 (d), 113.9 (s), 116.1 
(d), 117.3 (s), 123.0 (d), 125.1 (d), 126.4 (s), 128.5 (d), 128.6 (d), 130.7 (d), 135.1 (s), 142.9 (d), 
147.6 (s), 149.6 (s), 161.1 (s); Anal. Calculated for C26H27Br2N5OS (MW: 617.40) : C, 50.58; H, 
4.41; N, 11.34%. Found: C, 50.74; H, 4.12; N, 11.47%. 
3-{2-[5-Fluoro-1-(3-morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (57e)  
N
CH2
F N
S
N
H
N
CH2
CH2
N
O
HBr
 
Conditions: 30 minutes at reflux. Yield: 85%, white solid; mp: 270-271 °C; IR: 3447 (NH), 2971 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6) 2.23-2.37 (2H, m, CH2), 3.06-3.17 (4H, m, 2 × 
CH2), 3.50-3.78 (4H, m, 2 × CH2), 3.94-4.00 (2H, m, CH2), 4.43 (2H, t, J = 6.2 Hz, CH2), 7.16-7.28 
(2H, m, H5’’ and H-6’), 7.71-7.78 (2H, m, H-2’ and H-7’), 8.05-8.14 (2H, m, H-2’’ and H-4’), 
8.32-8.38 (2H, m, H-5 and H-6’’), 8.62 (1H, d, J = 6.9 Hz, H-4’’), 10.06 (1H, bs, NH+), 12.02 (1H, 
bs, NH); 13C NMR (50 MHz, DMSO-d6) 23.9 (t), 43.4 (t), 51.1 (2 × t), 53.4 (t), 63.2 (2 × t), 
105.6 (d, JC4’-F = 24.9 Hz), 107.0 (d), 109.9 (s), 110.3 (d, JC7a-F = 4.4 Hz), 110.8 (d, JC6’-F = 26.4 
Hz), 112.1 (d, JC7’-F = 9.9 Hz), 116.1 (d), 117.2 (s), 124.9 (d), 125.1 (d, JC3a-F = 10.5 Hz), 128.5 (d), 
131.1 (d), 133.0 (s), 142.9 (d), 148.5 (s), 149.8 (s), 158.2 (d, JC5’-F = 234.7 Hz), 161.2 (s); Anal. 
Calculated for C25H25BrFN5OS (MW: 542.47) : C, 55.35; H, 4.65; N, 12.91%. Found: C, 55.17; H, 
4.50; N, 13.24%. 
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3-{2-[5-Fluoro-1-(3-morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (57f)  
N
CH2
F N
S
N
N
CH3
CH2
CH2
N
O
HBr
 
Conditions: 30 minutes at reflux. Yield: 98%, white solid; mp: 233-234 °C; IR: 2972 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6) 2.22-2.36 (2H, m, CH2), 3.07-3.18 (4H, m, 2 × CH2), 3.50-3.77 
(4H, m, 2 × CH2), 3.94-4.00 (5H, m, CH2 and CH3), 4.42 (2H, t, J = 6.7 Hz, CH2), 7.17-7.29 (2H, 
m, H5’’ and H-6’), 7.71-7.78 (2H, m, H-2’ and H-7’), 8.11 (1H, dd, J = 9.9, 2.4 Hz, H-4’), 8.22 
(1H, s, H-2’’), 8.28-8.37 (2H, m, H-5 and H-6’’), 8.60 (1H, d, J = 6.8 Hz, H-4’’), 9.96 (1H, bs, 
NH+); 13C NMR (50 MHz, DMSO-d6) 23.9 (t), 30.9 (q), 43.4 (t), 51.1 (2 × t), 53.4 (t), 63.2 (2 × 
t), 105.7 (d, JC4’-F = 24.9 Hz), 106.9 (d), 108.8 (s), 110.3 (d, JC7a-F = 4.4 Hz), 110.9 (d, JC6’-F = 26.1 
Hz), 112.1 (d, JC7’-F = 10.1 Hz), 116.2 (d), 117.2 (s), 125.1 (d, JC3a-F = 10.6 Hz), 128.5 (d), 128.8 
(d), 131.2 (d), 133.1(s), 142.9 (d), 147.6 (s), 149.5 (s), 158.2 (d, JC5’-F = 234.0 Hz), 161.3 (s); Anal. 
Calculated for C26H27BrFN5OS (MW: 556.49) : C, 56.12; H, 4.89; N, 12.58%. Found: C, 56.48; H, 
4.72; N, 12.39%. 
3-{2-[5-Methoxy-1-(3-morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (57g)  
N
CH2
N
S
N
H
N
CH2
CH2
N
O
HBr
H3CO
 
Conditions: 30 minutes at reflux. Yield: 98%, white solid; mp: 256-257 °C; IR: 3450 (NH), 2974 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6) 2.24-2.35 (2H, m, CH2), 3.06-3.16 (4H, m, 2 × 
CH2), 3.39-3.55 (4H, m, 2 × CH2), 3.73-3.79 (2H, m, CH2), 3.91 (3H, s, CH3), 4.37 (2H, t, J = 6.2 
Hz, CH2), 6.97 (1H, dd, J = 9.0, 2.3 Hz, H-6’), 7.20 (1H, dd, J = 7.9, 4.7 Hz, H-5’’), 7.60 (1H, d, J = 
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9.0 Hz, H-7’), 7.71 (1H, s, H-2’), 7.95 (1H, d, J = 2.3Hz, H-4’), 8.11 (1H, d, J = 2.1 Hz, H-2’’), 
8.23 (1H, s, H-5), 8.32 (1H, d, J = 4.7 Hz, H-6’’), 8.73 (1H, d, J = 7.9Hz, H-4’’), 10.05 (1H, bs, 
NH+), 11.96 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6) 24.0 (t), 43.3 (t), 51.2 (2 × t), 53.5 (t), 
55.2 (q), 63.3 (2 × t), 102.2 (d), 106.3 (d), 109.4 (s), 109.9 (s), 111.5 (d), 112.6 (d), 115.9 (d), 117.2 
(s), 124.4 (d), 125.3 (s), 128.6 (d), 129.6 (d), 131.3 (s), 143.0 (d), 148.6 (s), 149.8 (s), 154.9 (s), 
161.8 (s); Anal. Calculated for C26H28BrN5O2S (MW: 554.50) : C, 56.32; H, 5.09; N, 12.63%. 
Found: C, 56.18; H, 4.88; N, 12.98%. 
3-{2-[5-Methoxy-1-(3-morpholin-4-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (57h)  
N
CH2
N
S
N
N
CH3
CH2
CH2
N
O
HBr
H3CO
 
Conditions: 30 minutes at reflux. Yield: 98%, white solid; mp: 218-219 °C; IR: 2962 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6) 2.20-2.32 (2H, m, CH2), 3.05-3.16 (4H, m, 2 × CH2), 3.43-3.71 
(4H, m, 2 × CH2), 3.92 (3H, s, CH3), 3.93 (3H, s, CH3), 3.98-4.07 (2H, m, CH2), 4.37 (2H, t, J = 6.2 
Hz, CH2), 6.99 (1H, dd, J = 8.9, 2.4 Hz, H-6’), 7.24 (1H, dd, J = 7.9, 4.7 Hz, H-5’’), 7.59 (1H, d, J = 
8.9 Hz, H-7’), 7.69 (1H, s, H-2’), 7.93 (1H, d, J = 2.4 Hz, H-4’), 8.15 (1H, s, H-2’’), 8.22 (1H, s, H-
5), 8.36 (1H, dd, J = 4.6, 1.4 Hz, H-6’’), 8.71 (1H, dd, J = 7.9, 1.4 Hz, H-4’’), 9.74 (1H, bs, NH+); 
13C NMR (50 MHz, DMSO-d6) 24.0 (t), 31.0 (q), 43.3 (t), 51.1 (2 × t), 53.5 (t), 55.2 (q), 63.2 (2 
× t), 102.3 (d), 106.4 (d), 108.9 (s), 109.9 (s), 111.5 (d), 112.6 (d), 116.0 (d), 117.4 (s), 125.3 (s), 
128.3 (d), 128.8 (d), 129.6 (d), 131.3 (s), 142.9 (d), 147.5 (s), 149.5 (s), 154.9 (s), 161.9 (s); Anal. 
Calculated for C27H30BrN5O2S (MW: 568.53) : C, 57.04; H, 5.32; N, 12.32%. Found: C, 57.37; H, 
5.18; N, 12.13%. 
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General procedure for the synthesis of 1-(4-bromo-butyl)-1H-indole-3-carbonitriles (86a-d)  
To a solution of the appropriate indole carbonitrile 70a-d (0.5 g, 2.25 mmol) in dry DMF (2.6 mL), 
was slowly added at 0-5 °C, sodium hydride 60% dispersion in mineral oil (NaH) (0.08 g, 3.38 
mmol) and the reaction mixture was stirred at room temperature for 30 minutes. After that, it was 
added dropwise 1,4-dibromobutane 85 (1.34 mL, 11.25 mmol) and the reaction mixture was stirred 
at room temperature for 1-2 hours. Then, the mixture was poured into water and ice and extracted 
with ethyl acetate (3 × 20 mL), dried (Na2SO4), filtered and the solvent evaporated under reduced 
pressure. The residue was purified by column chromatography using petroleum ether:ethyl acetate 
(8:2) as eluent. 
1-(4-Bromo-butyl)-1H-indole-3-carbonitrile (86a)  
N
CN
CH2
CH2
CH2
CH2
Br  
Conditions: 1 hour at rt. Yield: 86%, yellow oil; IR: 2219 (CN) cm-1; 1H NMR (200 MHz, DMSO-
d6)  1.72-1.99 (4H, m, 2 × CH2), 3.55 (2H, t, J = 6.5 Hz, CH2), 4.32 (2H, t, J = 6.6 Hz, CH2), 7.24-
7.40 (2H, m, H-5 and H-6), 7.64-8.32 (2H, m, H-4 and H-7), 8.34 (1H, s, H-2); 13C NMR (50 MHz, 
DMSO-d6) 28.0 (t), 29.3 (t), 34.3 (t), 45.4 (t), 83.4 (s), 111.5 (d), 116.0 (s), 118.7 (d), 121.9 (d), 
123.4 (d), 127.1 (s), 135.1 (s),136.8 (d); Anal. Calculated for C13H13BrN2 (MW: 277.16) :C, 56.34; 
H, 4.73; N, 10.11%. Found: C, 56.08; H, 4.62; N, 10.48%. 
5-Bromo-1-(4-bromo-butyl)-1H-indole-3-carbonitrile (86b)  
N
CN
CH2
Br
CH2
CH2
CH2
Br  
Conditions: 2 hours at rt. Yield: 80%, white solid; mp: 112-113 °C; IR: 2222 (CN) cm-1; 1H NMR 
(200 MHz, DMSO-d6)  1.70-1.94 (4H, m, 2 × CH2), 3.55 (2H, t, J = 6.5 Hz, CH2), 4.32 (2H, t, J = 
6.6 Hz, CH2), 7.49 (1H, dd, J = 8.8, 1.9 Hz, H-6), 7.74 (1H, d, J = 8.8 Hz, H-7), 7.82 (1H, d, J = 1.9 
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Hz, H-4),8.40 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6) 28.0 (t), 29.2 (t), 34.3 (t), 45.6 (t), 
83.2 (s), 113.7 (d), 114.8 (s), 115.2 (s), 121.0 (d), 126.1 (d), 128.6 (s), 134.0 (s),138.1 (d); Anal. 
Calculated for C13H12Br2N2 (MW: 356.06) : C, 43.85; H, 3.40; N, 7.87%. Found: C, 43.63; H, 3.26; 
N, 8.23%. 
1-(4-Bromo-butyl)-5-fluoro-1H-indole-3-carbonitrile (86c)  
N
CN
CH2
F
CH2
CH2
CH2
Br  
Conditions: 2 hours at rt. Yield: 80%, yellow solid; mp: 66-67 °C; IR: 2221 (CN) cm-1; 1H NMR 
(200 MHz, DMSO-d6)  1.67-1.99 (4H, m, 2 × CH2), 3.55 (2H, t, J = 6.5 Hz, CH2), 4.32 (2H, t, J = 
6.6 Hz, CH2), 7.22 (1H, td, J = 11.7, 9.3, 2.5 Hz, H-6), 7.45 (1H, dd, J = 9.1, 2.4 Hz, H-7), 7.75-
7.81 (1H, m, H-4), 8.41 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6) 28.0 (t), 29.2 (t), 34.3 (t), 
45.7 (t), 83.7 (d, JC7a-F = 4.5 Hz), 104.0 (d, JC4-F = 24.8 Hz), 111.9 (d, JC6-F = 26.2 Hz), 113.2 (d, JC7-
F = 9.7 Hz), 115.5 (s), 127.6 (d, JC3a-F = 10.9 Hz), 131.9 (s), 138.4 (d), 158.5 (d, JC5-F = 236.4 Hz); 
Anal. Calculated for C13H12BrFN2 (MW: 295.15) : C, 52.90; H, 4.10; N, 9.49%. Found: C, 52.67; H, 
4.47; N, 9.35%. 
1-(4-Bromo-butyl)-5-methoxy-1H-indole-3-carbonitrile (86d)  
N
CN
CH2
CH2
CH2
CH2
Br
H3CO
 
Conditions: 1 hour at rt. Yield: 80%, white solid; mp: 69-70 °C; IR: 2217 (CN) cm-1; 1H NMR (200 
MHz, DMSO-d6)  1.67-1.96 (4H, m, 2 × CH2), 3.54 (2H, t, J = 6.5 Hz, CH2), 3.82 (3H, s, CH3), 
4.27 (2H, t, J = 6.5 Hz, CH2), 6.96 (1H, dd, J = 9.0, 2.4 Hz, H-6), 7.10 (1H, d, J = 2.4 Hz, H-4), 7.62 
(1H, d, J = 9.0 Hz, H-7), 8.25 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  28.1 (t), 29.3 (t), 34.3 
(t), 45.5 (t), 55.4 (q), 83.0 (s), 100.0 (d), 112.5 (d), 113.7 (d), 116.2 (s), 127.9 (s), 130.0 (s), 136.5 
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(d), 155.4 (s); Anal. Calculated for C14H15BrN2O (MW: 307.19) : C, 54.74; H, 4.92; N, 9.12%. 
Found: C, 54.37; H, 5.07; N, 9.34%. 
General procedure for the synthesis of 1-(4-morpholin-4-yl-butyl)-1H-indole-3-carbonitriles 
(87a-d) 
Compounds 87a-d were prepared from 86a-d using the same synthetic procedure described for 
compounds 83a-d.  
1-(4-Morpholin-4-yl-butyl)-1H-indole-3-carbonitrile (87a)  
N
CN
CH2
CH2
CH2
CH2
N
O  
Conditions: heated for 1 hour at 50 °C. Yield: 90%, white solid; mp: 79-80 °C; IR: 2257 (CN), cm-
1; 1H NMR (200 MHz, DMSO-d6)  1.30-1.45 (2H, m, CH2), 1.73-1.87 (2H, m, CH2), 2.20-2.28 
(6H, m, 3 × CH2), 3.52 (4H, t, J = 4.6 Hz, 2 × CH2), 4.28 (2H, t, J = 7.0 Hz, CH2), 7.23-7.39 (2H, 
m, H-5 and H-6), 7.63-7.73 (2H, m, H-4 and H-7), 8.33 (1H, s, H-2); 13C NMR (50 MHz, DMSO-
d6)  22.8 (t), 27.0 (t), 46.2 (t), 53.1 (2 × t), 57.2 (t), 66.1 (2 × t), 83.2 (s), 111.6 (d), 116.0 (s), 
118.7 (d), 121.8 (d), 123.3 (d), 127.1 (s), 135.1 (s), 136.8 (d); Anal. Calculated for C17H21N3O 
(MW: 283.37) : C, 72.06; H, 7.47; N, 14.83%. Found: C, 72.16; H, 7.64; N, 14.56%. 
5-Bromo-1-(4-morpholin-4-yl-butyl)-1H-indole-3-carbonitrile (87b)  
N
CN
CH2
Br
CH2
CH2
CH2
N
O  
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Conditions: heated for 1 hour at 50 °C. Yield: 92%, white solid; mp: 110-111 °C; IR: 2220 (CN) 
cm-1; 1H NMR (200 MHz, DMSO-d6)  1.30-1.43 (2H, m, CH2), 1.71-1.85 (2H, m, CH2), 2.20-
2.26 (6H, m, 3 × CH2), 3.52 (4H, s, 2 × CH2),4.27 (2H, t, J = 6.6 Hz, CH2), 7.48 (1H, d, J = 8.9 Hz, 
H-6), 7.72 (1H, d, J = 8.9 Hz, H-7), 7.81 (1H, s, H-4), 8.39 (1H, s, H-2); 13C NMR (50 MHz, 
DMSO-d6)  22.8 (t), 27.0 (t), 46.4 (t), 53.1 (2 × t), 57.2 (t), 66.1 (2 × t), 83.0 (s), 113.7 (d), 114.7 
(s), 115.3 (s), 121.0 (d), 126.0 (d), 128.7 (s), 134.0 (s), 138.1 (d); Anal. Calculated for C17H20BrN3O 
(MW: 362.26) : C, 56.36; H, 5.56; N, 11.60%. Found: C, 56.20; H, 5.42; N, 11.90%. 
5-Fluoro-1-(4-morpholin-4-yl-butyl)-1H-indole-3-carbonitrile (87c)  
N
CN
CH2
F
CH2
CH2
CH2
N
O  
Conditions: heated for 2 hours at 50 °C. Yield: 90%, white solid; mp: 89-90 °C; IR: 2221 (CN) cm-
1; 1H NMR (200 MHz, DMSO-d6)  1.30-1.45 (2H, m, CH2), 1.72-1.87 (2H, m, CH2), 2.20-2.29 
(6H, m, 3 × CH2), 3.52 (4H, t, J = 4.6 Hz, 2 × CH2), 4.27 (2H, t, J = 7.0 Hz, CH2), 7.21 (1H, td, J = 
11.7, 9.3, 2.5 Hz, H-6), 7.44 (1H, dd, J = 9.2, 2.5 Hz, H-7), 7.73-7.79 (1H, m, H-4), 8.40 (1H, s, H-
2); 13C NMR (50 MHz, DMSO-d6)  22.8 (t), 27.0 (t), 46.5 (t), 53.1 (2 × t), 57.2 (t), 66.1 (2 × t), 
83.5 (d, JC7a-F = 4.6 Hz), 104.0 (d, JC4-F = 24.7 Hz), 111.8 (d, JC6-F = 26.2 Hz), 113.2 (d, JC7-F = 9.9 
Hz), 115.6 (s), 127.6 (d, JC3a-F = 10.9 Hz), 131.9 (s), 138.4 (d), 158.5 (d, JC5-F = 233.0 Hz); Anal. 
Calculated for C17H20FN3O (MW: 301.36) : C, 67.75; H, 6.69; N, 13.94%. Found: C, 67.38; H, 
6.91; N, 14.09%. 
5-Methoxy-1-(4-morpholin-4-yl-butyl)-1H-indole-3-carbonitrile (87d)  
N
CN
CH2
CH2
CH2
CH2
N
O
H3CO
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Conditions: heated for 1 hour at 50 °C. Yield: 90%, white solid; mp: 86-87 °C; IR: 2217 (CN), cm-
1; 1H NMR (200 MHz, DMSO-d6)  1.28-1.43 (2H, m, CH2), 1.70-1.85 (2H, m, CH2), 2.19-2.26 
(6H, m, 3 × CH2), 3.52 (4H, t, J = 4.5 Hz, 2 × CH2), 3.82 (3H, s, CH3), 4.23 (2H, t, J = 6.9 Hz, 
CH2), 6.95 (1H, dd, J = 9.0, 2.3 Hz, H-6), 7.09 (1H, d, J = 2.3 Hz, H-4), 7.61 (1H, d, J = 9.0 Hz, H-
7), 8.23 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  22.8 (t), 27.1 (t), 46.3 (t), 53.1 (2 × t), 55.4 
(q), 57.2 (t), 66.1 (2 × t), 82 8 (s), 100.0 (d), 112.5 (d), 113.6 (d), 116.2 (s), 127.9 (s), 130.0 (s), 
136.6 (d), 155.4 (s); Anal. Calculated for C18H23N3O2 (MW: 313.39) : C, 68.98; H, 7.40; N, 13.41%. 
Found: C, 68.69; H, 7.30; N, 13.80%. 
General procedure for the synthesis of 1-(4-morpholin-4-yl-butyl)-1H-indole-3-
carbothioamides (84a-d) 
Compounds 84a-d were prepared from 87a-d using the same synthetic procedure described for 
compounds 75a-d.  
1-(4-Morpholin-4-yl-butyl)-1H-indole-3-carbothioamide (84a)  
N
CH2
CH2
CH2
CH2
N
O
S
NH2
 
Conditions: 3 hours at reflux. Yield: 90%, yellow solid; mp: 85-86 °C; IR: 1653 (CS) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.38-1.49 (2H, m, CH2), 1.74-1.88 (2H, m, CH2), 2.23-2.30 (6H, m, 
3 × CH2), 3.54 (4H, t, J = 4.5 Hz, 2 × CH2),4.23 (2H, t, J = 6.9 Hz, CH2), 7.14-7.27 (2H, m, H-5 
and H-6), 7.58 (1H, dd, J = 6.3, 1.7 Hz, H-7), 8.14 (1H, s, H-2), 8.59 (1H, dd, J = 6.1, 1.8 Hz, H-4), 
8.81 (1H, s, SH), 9.00 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  22.9 (t), 27.1 (t), 45.7 (t), 
53.1 (2 × t), 57.3 (t), 66.1 (2 × t), 110.5 (d), 115.4 (s), 121.0 (d), 121.9 (d), 122.0 (d), 126.0 (s), 
131.3 (d), 136.5 (s), 193.0 (s); Anal. Calculated for C17H23N3OS (MW: 317.45) : C, 64.32; H, 7.30; 
N, 13.24%. Found: C, 64.15; H, 7.16; N, 13.55%. 
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5-Bromo-1-(4-morpholin-4-yl-butyl)-1H-indole-3-carbothioamide (84b)  
N
CH2
Br
CH2
CH2
CH2
N
O
S
NH2
 
Conditions: 2 hours at reflux. Yield: 84%, yellow solid; mp: 175-176 °C; IR: 1653 (CS) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.36-1.43 (2H, m, CH2), 1.72-1.83 (2H, m CH2), 2.22-2.29 (6H, m, 
3 × CH2), 3.53 (4H, t, J = 4.5 Hz, 2 × CH2), 4.23 (2H, t, J = 6.8 Hz, CH2), 7.37 (1H, dd, J = 8.7, 2.0 
Hz, H-6), 7.59 (1H, d, J = 8.7 Hz, H-7), 8.19 (1H, s, H-2), 8.89 (1H, d, J = 2.0Hz, H-4), 8.93 (1H, s, 
SH), 9.08 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  22.9 (t), 27 1 (t), 45.9 (t), 53.1 (2 × t), 
57.3 (t), 66.1 (2 × t), 112.7 (d), 114.0 (s), 114.5 (s), 124.2 (d), 124.6 (d), 128.1 (s), 131.7 (d), 135.4 
(s), 192.4 (s); Anal. Calculated for C17H22BrN3OS (MW: 396.35) : C, 51.52; H, 5.59; N, 10.60%. 
Found: C, 51.16; H, 5.77; N, 10.78%. 
5-Fluoro-1-(4-morpholin-4-yl-butyl)-1H-indole-3-carbothioamide (84c)  
N
CH2
F
CH2
CH2
CH2
N
O
S
NH2
 
Conditions: 1 hour at reflux. Yield: 89%, yellow solid; mp: 122-123 °C; IR: 1683 (CS) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.39-1.54 (2H, m, CH2), 1.78-1.93 (2H, m CH2), 2.29-2.34 (6H, m, 
3 × CH2), 3.59 (4H, t, J = 4.4, 2 × CH2), 4.28 (2H, t, J = 7.0 Hz, CH2), 7.15 (1H, td, J = 11.1, 9.1, 
2.6 Hz, H-6), 7.63-7.70 (1H, m, H-7), 8.27 (1H, s, H-2), 8.48 (1H, dd, J = 11.1, 2.6 Hz, H-4), 8.91 
(1H, s, SH), 9.07 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  22.8 (t), 27.1 (t), 46.0 (t), 53.1 (2 
× t), 57.3 (t), 66.0 (2 × t), 106.9 (d, JC4-F = 25.8 Hz), 110.2 (d, JC6-F = 26.1 Hz), 111.9 (d, JC7-F = 9.1 
Hz), 115.0 (d, JC7a-F = 4.7 Hz), 127.0 (d, JC3a-F = 10.9 Hz), 132.4 (d), 133.3 (s), 158.1 (d, JC5-F = 
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233.3 Hz), 192.6 (s); Anal. Calculated for C17H22FN3OS (MW: 335.44) : C, 60.87; H, 6.61; N, 
12.53%. Found: C, 60.53; H, 6.84; N, 12.64%. 
5-Methoxy-1-(4-morpholin-4-yl-butyl)-1H-indole-3-carbothioamide (84d)  
N
CH2
CH2
CH2
CH2
N
O
S
NH2H3CO
 
Conditions: 1 hour at reflux. Yield: 91%, yellow solid; mp: 120-121 °C; IR: 1623 (CS) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.32-1.47 (2H, m, CH2), 1.72-1.86 (2H, m, CH2), 2.22-2.29 (6H, m, 
3 × CH2), 3.53 (4H, t, J = 4.5 Hz, 3 × CH2), 3.78 (3H, s, CH3), 4.18 (2H, t, J = 7.0 Hz, CH2), 6.86 
(1H, dd, J = 8.9, 2.5 Hz, H-6), 7.48 (1H, d, J = 8.9 Hz, H-7), 8.11 (1H, s, H-2), 8.19 (1H, d, J = 2.4 
Hz, H-4), 8.75 (1H, s, SH), 8.92 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  22.8 (t), 27.1 (t), 
45.9 (t), 53.1 (2 × t), 55.2 (q), 57.3 (t), 66.0 (2 × t), 103.9 (d), 111.3 (d), 111.8 (d), 114 8 (s), 116.1 
(s), 126.8 (s), 131.6 (d), 154.8 (s), 192.8 (s); Anal. Calculated for C18H25N3O2S (MW: 347.48) : C, 
62.22; H, 7.25; N, 12.09%. Found: C, 61.91; H, 7.37; N, 12.28%. 
General procedure for the synthesis of 3-{2-[1-(4-morpholin-4-yl-butyl)-1H-indol-3-yl]-
thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine hydrobromides (58a-h) 
Compounds 58a-h were prepared from 84a-d using the same synthetic procedure described for 
compounds 69a,b. 
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3-{2-[1-(4-Morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromide (58a)  
N
CH2
N
S
N
H
N
CH2
CH2
CH2 HBr
N
O  
Conditions: rt for 24 hours. Yield: 82%, white solid; mp: 243-244 °C; IR: 3450 (NH), 2971 (NH+) 
cm-1; 1H NMR (200 MHz, DMSO-d6)  1.66-1.68 (2H, m, CH2), 1.86-1.90 (2H, m, CH2), 3.06-
3.26 (4H, m, 2 × CH2), 3.43-3.69 (4H, m, 2 × CH2), 3.93-3.98 (2H, m, CH2), 4.37 (2H, t, J = 6.1 
Hz, CH2), 7.20-7.34 (3H, m, H-5’, H-5’’ and H-6’), 7.66-7.73 (2H, m, H-2’ and H-7’), 8.11 (1H, d, 
J = 2.5 Hz, H-2’’), 8.28-8.38 (3H, m, H-4’, H-5 and H-6’’), 8.63 (1H, d, J = 6.9 Hz, H-4’’), 9.59 
(1H, bs, NH+), 11.98 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  20.2 (t), 26.6 (t), 45.2 (t), 
51.0 (2 × t), 55.4 (t), 63.2 (2 × t), 106.9 (d), 109.9 (s), 110.0 (s), 110.7 (d), 116.1 (d), 117.3 (s), 
120.6 (d), 121.0 (d), 122.4 (d), 124.7 (d), 124.8 (s), 128.8 (d), 129.5 (d), 136.3 (s), 142.6 (d), 148.3 
(s), 149.7 (s), 161.6 (s); Anal. Calculated for C26H28BrN5OS (MW: 538.50) : C, 57.99; H, 5.24; N, 
13.01%. Found: C, 58.09; H, 5.34; N, 12.81%. 
1-Methyl-3-{2-[1-(4-morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (58b)  
N
CH2
N
S
N
N
CH3
CH2
CH2
CH2 HBr
N
O  
Conditions: rt for 24 hours. Yield: 72%, white solid; mp: 195-196 °C; IR: 2970 (NH+) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.66-1.68 (2H, m, CH2), 1.86-1.90 (2H, m, CH2), 3.01-3.16 (4H, m, 
2 × CH2), 3.43-3.68 (4H, m, 2 × CH2), 3.94-3.99 (5H, m, CH2 and CH3), 4.37 (2H, t, J = 6.2 Hz, 
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CH2), 7.24-7.37 (3H, m, H-5’, H-5’’ and H-6’), 7.66-7.72 (2H, m, H-2’ and H-4’), 8.20 (1H, s, H-
2’’), 8.28 (1H, s, H-5), 8.36-8.41 (2H, m, H-6’’ and H-7’), 8.62 (1H, d, J = 7.9 Hz, H-4’’), 9.52 
(1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6)  20.3 (t), 26.6 (t), 30.9 (q), 45.2 (t), 51.0 (2 × t), 
55.4 (t), 63.2 (2 × t), 106.7 (d), 108.9 (s), 109.9 (s), 110.7 (d), 116.2 (d), 117.2 (s), 120.7 (d), 121.0 
(d), 122.5 (d), 124.7 (s), 128.6 (d), 128.7 (d), 129.6 (d), 136.3 (s), 142.9 (d), 147.6 (s), 149.4 (s), 
161.6 (s); Anal. Calculated for C27H30BrN5OS (MW: 552.53) : C, 58.69; H, 5.47; N, 12.68%. 
Found: C, 58.29; H, 5.72; N, 12.83%. 
3-{2-[5-Bromo-1-(4-morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (58c)  
N
CH2
N
S
N
H
N
CH2
CH2
CH2 HBr
N
O
Br
 
Conditions: rt for 24 hours. Yield: 70%, brown solid; mp: 169-170 °C; IR: 3450 (NH), 2971 (NH+) 
cm-1; 1H NMR (200 MHz, DMSO-d6)  1.57-1.66 (2H, m, CH2), 1.84-1.92 (2H, m, CH2), 2.84-
3.12 (4H, m, 2 × CH2), 3.42-3.71 (4H, m, 2 × CH2), 3.93-3.98 (2H, m, CH2), 4.36 (2H, s, CH2), 
7.23 (1H, dd, J = 7.4, 4.8 Hz, H-5’’), 7.46 (1H, d, J = 8.5 Hz, H-6’), 7.70 (1H, d, J = 8.6 Hz, H-7’), 
7.75 (1H, s, H-2’), 8.09 (1H, s, H-2’’), 8.32-8.35 (2H, m, H-4’ and H-5), 8.57-8.66 (2H, m, H-4’’ 
and H-6’’), 9.87 (1H, bs, NH+), 12.00 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  20.2 (t), 
26.7 (t), 45.4 (t), 51.0 (2 × t), 55.4 (t), 63.2 (2 × t), 107.0 (d), 109.5 (s), 109.8 (s), 112.9 (d), 113.7 
(s), 116.0 (d), 117.0 (s), 123.0 (d), 124.6 (d), 125.0 (d), 126.3 (s), 128.4 (d), 130.8 (d), 135.1 (s), 
143.1 (d), 148.7 (s), 149.9 (s), 161.0 (s); Anal. Calculated for C26H27Br2N5OS (MW: 617.40) : C, 
50.58; H, 4.41; N, 11.34%. Found: C, 50.32; H, 4.79; N, 11.22%. 
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3-{2-[5-Bromo-1-(4-morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (58d)  
N
CH2
N
S
N
N
CH2
CH2
CH2 HBr
N
O
Br
CH3
 
Conditions: rt for 24 hours. Yield: 74%, white solid; mp: 187-188 °C; IR: 2971 (NH+) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.57-1.69 (2H, m, CH2), 1.84-1.92 (2H, m, CH2), 3.01-3.26 (4H, m, 
2 × CH2), 3.45-3.67 (4H, m, 2 × CH2), 3.94-3.99 (5H, m, CH2 and CH3), 4.36 (2H, t, J = 6.2 Hz, 
CH2), 7.26 (1H, dd, J = 8.0, 4.6 Hz, H-5’’), 7.47 (1H, dd, J = 8.8, 1.9 Hz, H-6’), 7.70 (1H, d, J = 8.8 
Hz, H-7’), 7.74 (1H, s, H-2’), 8.15 (1H, s, H-2’’), 8.34 (1H, s, H-5), 8.38 (1H, dd, J = 4.6, 1.4 Hz, 
H-6’’), 8.55 (1H, d, J = 1.9 Hz, H-4’), 8.64 (1H, dd, J = 8.0, 1.4 Hz, H-4’’), 9.50 (1H, bs, NH+); 13C 
NMR (50 MHz, DMSO-d6)  20.3 (t), 26.7 (t), 30.9 (q), 45.4 (t), 51.2 (2 × t), 55.5 (t), 63.4 (2 × t), 
107.1 (d), 108.7 (s), 109.5 (s), 112.9 (d), 113.7 (s), 116.1 (d), 117.3 (s), 122.9 (d), 125.0 (d), 126.3 
(s), 128.4 (d), 128.6 (d), 130.9 (d), 135.1 (s), 143.0 (d), 147.6 (s), 149.6 (s), 161.1 (s); Anal. 
Calculated for C27H29Br2N5OS (MW: 631.43) : C, 51.36; H, 4.63; N, 11.09%. Found: C, 50.99; H, 
4.85; N, 11.24%. 
3-{2-[5-Fluoro-1-(4-morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (58e)  
N
CH2
F N
S
N
H
N
CH2
CH2
CH2 HBr
N
O  
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Conditions: rt for 24 hours. Yield: 92%, yellow solid; mp: 226-227 °C; IR: 3449 (NH), 2972 (NH+) 
cm-1; 1H NMR (200 MHz, DMSO-d6)  1.64-1.66 (2H, m, CH2), 1.78-1.95 (2H, m, CH2), 2.92-
3.24 (4H, m, 2 × CH2), 3.53-3.79 (4H, m, 2 × CH2), 3.85-4.07 (2H, m, CH2), 4.36 (2H, s, CH2), 
7.08-7.24 (2H, m, H5’’ and H-6’), 7.60-7.75 (2H, m, H-2’ and H-7’), 7.88-8.11 (2H, m, H-2’’ and 
H-4’), 8.31-8.35 (2H, m, H-5 and H-6’’), 8.60 (1H, d, J = 7.7 Hz, H-4’’), 9.62 (1H, bs, NH+), 11.98 
(1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  20.3 (t), 26.7 (t), 45.5 (t), 51.1 (2 × t), 55.5 (t), 
63.3 (2 × t), 105.5 (d, JC4’-F = 23.5 Hz), 106.8 (d), 109.9 (s), 110.0 (d, JC7a-F = 4.7 Hz), 110.7 (d, JC6’-
F = 26.6 Hz), 112.2 (d, JC7’-F = 9.9 Hz), 116.1 (d), 117.1 (s), 124.8 (d), 125.0 (d, JC3a-F = 10.7 Hz), 
128.3 (d), 131.2 (d), 133.1 (s), 143.1 (d), 148.8 (s), 149.9 (s), 158.1 (d, JC5’-F = 234.2 Hz), 161.3 (s); 
Anal. Calculated for C26H27BrFN5OS (MW: 556.49) : C, 56.12; H, 4.89; N, 12.58%. Found: C, 
56.22; H, 5.09; N, 12.28%. 
3-{2-[5-Fluoro-1-(4-morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (58f)  
N
CH2
F N
S
N
N
CH3
CH2
CH2
CH2 HBr
N
O  
Conditions: rt for 24 hours. Yield: 95%, white solid; mp: 245-246 °C; IR: 2969 (NH+) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.64-1.67 (2H, m, CH2), 1.85-1.92 (2H, m, CH2), 3.01-3.16 (4H, m, 
2 × CH2), 3.43-3.69 (4H, m, 2 × CH2), 3.94-3.99 (5H, m, CH2 and CH3), 4.37 (2H, t, J = 6.3 Hz, 
CH2), 7.15-7.30 (2H, m, H5’’ and H-6’), 7.69-7.76 (2H, m, H-2’ and H-7’), 8.10 (1H, dd, J = 9.9, 
2.5 Hz, H-4’), 8.21 (1H, s, H-2’’), 8.35 (1H, s, H-5), 8.37 (1H, dd, J = 4.6, 1.4 Hz, H-6’’), 8.56 (1H, 
dd, J = 8.0, 1.4 Hz, H-4’’), 9.52 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6)  20.3 (t), 26.6 (t), 
30.9 (q), 45.4 (t), 51.0 (2 × t), 55.4 (t), 63.2 (2 × t), 105.6 (d, JC4’-F = 24.6 Hz), 106.8 (d), 108.8 (s), 
110.0 (d, JC7a-F = 4.5 Hz), 110.8 (d, JC6’-F = 26.6 Hz), 112.2 (d, JC7’-F = 9.6 Hz), 116.2 (d), 117.2 (s), 
125.0 (d, JC3a-F = 10.8 Hz), 128.5 (d), 128.8 (d), 131.3 (d), 133.1 (s), 142.9 (d), 147.7 (s), 149.5 (s), 
158.2 (d, JC5’-F = 233.9 Hz), 161.4 (s); Anal. Calculated for C27H29BrFN5OS (MW: 570.52) : C, 
56.84; H, 5.12; N, 12.28%. Found : C, 56.68; H, 5.02; N, 12.54%. 
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3-{2-[5-Methoxy-1-(4-morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (58g)  
N
CH2
N
S
N
H
N
CH2
CH2
CH2 HBr
N
O
H3CO
 
Conditions: rt for 24 hours. Yield: 76%, brown solid; mp: 233-234 °C; IR: 3451 (NH), 2972 (NH+) 
cm-1; 1H NMR (200 MHz, DMSO-d6)  1.64-1.67 (2H, m, CH2), 1.84-1.87 (2H, m, CH2), 3.00-
3.13 (4H, m, 2 × CH2), 3.47-3.69 (4H, m, 2 × CH2), 3.91-3.99 (5H, m, CH2 and CH3), 4.32 (2H, s, 
CH2), 6.96 (1H, d, J = 8.9 Hz, H-6’), 7.21 (1H, dd, J = 7.7, 4.9 Hz, H-5’’), 7.59 (1H, d, J = 8.9 Hz, 
H-7’), 7.70 (1H, s, H-2’), 7.94 (1H, s, H-4’), 8.11 (1H, d, J = 2.0 Hz, H-2’’), 8.21 (1H, s, H-5), 8.32 
(1H, d, J = 4.9 Hz, H-6’’), 8.74 (1H, d, J = 7.7 Hz, H-4’’), 9.62 (1H, bs, NH+), 11.99 (1H, bs, NH); 
13C NMR (50 MHz, DMSO-d6)  20.2 (t), 26.7 (t), 45.3 (t), 51.0 (2 × t), 55.1 (q), 55.4 (t), 63.2 (2 × 
t), 102.1 (d), 106.4 (d), 109.6 (s), 110.0 (s), 111.6 (d), 112.6 (d), 115.9 (d), 117.4 (s), 124.5 (d), 
125.3 (s), 128.9 (d), 129.8 (d), 131.3 (s), 142.7 (d), 148.2 (s), 149.7 (s), 154.8 (s), 161.9 (s); Anal. 
Calculated for C27H30BrN5O2S (MW: 567.13) : C, 57.04; H, 5.32; N, 12.32%. Found: C, 56.71; H, 
5.52; N, 12.45%. 
3-{2-[5-Methoxy-1-(4-morpholin-4-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (58h)  
N
CH2
N
S
N
N
CH2
CH2
CH2 HBr
N
O
H3CO
CH3
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Conditions: rt for 24 hours. Yield: 88%, white solid; mp: 216-217 °C; IR: 2951 (NH+) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.64-1.67 (2H, m, CH2), 1.84-1.92 (2H, m, CH2), 3.01-3.26 (4H, m, 
2 × CH2), 3.43-3.68 (4H, m, 2 × CH2), 3.92 (3H, s, CH3), 3.93 (3H, s, CH3), 3.93-3.99 (2H, m, 
CH2), 4.32 (2H, t, J = 6.3 Hz, CH2), 6.97 (1H, dd, J = 8.9, 2.5 Hz, H-6’), 7.24 (1H, dd, J = 7.9, 4.7 
Hz, H-5’’), 7.59 (1H, d, J = 8.9 Hz, H-7’), 7.68 (1H, s, H-2’), 7.92 (1H, d, J = 2.5 Hz, H-4’), 8.15 
(1H, s, H-2’’), 8.21 (1H, s, H-5), 8.37 (1H, dd, J = 4.7, 1.4 Hz, H-6’’), 8.71 (1H, dd, J = 7.9, 1.4 Hz, 
H-4’’), 9.52 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6)  20.3 (t), 26.7 (t), 31.0 (q), 45.3 (t), 
51.0 (2 × t), 55.2 (q), 55.4 (t), 63.2 (2 × t), 102.2 (d), 106.3 (d), 108.9 (s), 109.6 (s), 111.6 (d), 112.5 
(d), 116.0 (d), 117.4 (s), 125.3 (s), 128.2 (d), 128.8 (d), 129.8 (d), 131.3 (s), 142.9 (d), 147.5 (s), 
149.5 (s), 154.9 (s), 161.9 (s); Anal. Calculated for C28H32BrN5O2S (MW: 582.55) : C, 57.73; H, 
5.54; N, 12.02%. Found: C, 57.43; H, 5.66; N, 12.20%. 
Synthesis of the 1-(2-chloroethyl)piperidine hydrochloride (90) 
To a solution of 1-(2-chloroethyl)piperidine hydrochloride 89 (0.5 g, 2.72 mmol) in water (3 mL), 
was added 5% aqueous solution of sodium hydroxide (NaOH) up to pH = 11-12 and stirred at room 
temperature for 10 minutes. The resulting mixture was extracted with dichloromethane (2 × 10 mL), 
dried (Na2SO4), filtered and the solvent evaporated under reduced pressure. Yield: 87%, yellow oil. 
Analytical and spectroscopic data were in accordance with those previously reported [127]. 
General procedure for the synthesis of 1-(2-piperidin-1-yl-ethyl)-1H-indole-3-carbonitriles 
(91a-d)  
To a solution of the appropriate indole carbonitrile 70a-d (0.5 g, 2.90 mmol) in dry DMF (6.5 mL), 
was slowly added at 0-5 °C, sodium hydride 60% dispersion in mineral oil (NaH) (0.10 g, 4.35 
mmol) and the reaction mixture was stirred at room temperature for 30 minutes. After that, it was 
added dropwise a solution of 1-(2-chloroethyl)piperidine hydrochloride 90 (1.7 g, 11.60 mmol) in 
dry DMF (2 mL), and the reaction mixture was stirred at room temperature for 12 hours. Then, the 
mixture was poured into water and ice and extracted with ethyl acetate (3 × 20 mL), dried 
(Na2SO4), filtered and the solvent evaporated under reduced pressure. The residue was purified by 
column chromatography using petroleum ether:ethyl acetate (6:4) as eluent. 
 
 
 
117 
 
1-(2-Piperidin-1-yl-ethyl)-1H-indole-3-carbonitrile (91a)  
N
CN
CH2
CH2
N
 
Yield: 98%, yellow solid; mp: 92-93 °C; IR: 2220 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.39-1.44 (6H, m, 3 × CH2), 2.35-2.38 (4H, m, 2 × CH2), 2.63 (2H, t, J = 6.3 Hz, CH2),4.36 (2H, t, 
J = 6.4 Hz, CH2),7.23-7.38 (2H, m, H-5 and H-6), 7.62-7.72 (2H, m, H-4 and H-7), 8.28 (1H, s, H-
2); 13C NMR (50 MHz, DMSO-d6)  23.8 (t), 25.5 (2 × t), 43.8 (t), 53.9 (2 × t), 57.5 (t), 83.1 (s), 
111.5 (d), 116.1 (s), 118.6 (d), 121.8 (d), 123.2 (d), 127.0 (s), 135.2 (s), 137.3 (d); Anal. Calculated 
for C16H19N3 (MW: 253.34) : C, 75.85; H, 7.56; N, 16.59%. Found: C, 75.56; H, 7.68; N, 16.76%. 
5-Bromo-1-(2-piperidin-1-yl-ethyl)-1H-indole-3-carbonitrile (91b)  
N
CN
CH2
Br
CH2
N
 
Yield: 90%, white solid; mp: 100-101 °C; IR: 2220 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6) 
1.38-1.41 (6H, m, 3 × CH2), 2.35 (4H, s, 2 × CH2), 2.61 (2H, t, J = 6.2 Hz, CH2), 4.35 (2H, t, J = 
6.2 Hz, CH2), 7.47 (1H, dd, J = 8.8, 1.8 Hz, H-6), 7.70 (1H, d, J = 8.8 Hz, H-7), 7.79 (1H, d, J = 1.8 
Hz, H-4), 8.34 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  23.8 (t), 25.5 (2 × t), 44.1 (t), 53.9 (2 
× t), 57.5 (t), 82.8 (s), 113.8 (d), 114.6 (s), 115.4 (s), 120.8 (d), 125.9 (d), 128.5 (s), 134.2 (s), 138.6 
(d); Anal. Calculated for C16H18BrN3 (MW: 332.24) : C, 57.84; H, 5.46; N, 12.65%. Found: C, 
57.95; H, 5.57; N, 12.43%. 
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5-Fluoro-1-(2-piperidin-1-yl-ethyl)-1H-indole-3-carbonitrile (91c)  
N
CN
CH2
F
CH2
N
 
Yield: 98%, white solid; mp: 56-57 °C; IR: 2220 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.39-1.46 (6H, m, 3 × CH2), 2.34-2.37 (4H, m, 2 × CH2), 2.62 (2H, t, J = 6.2 Hz, CH2),4.36 (2H, t, 
J = 6.3 Hz, CH2), 7.20 (1H, td, J = 11.8, 9.3, 2.5 Hz, H-6),7.43 (1H, dd, J = 9.1, 2.4 Hz, H-7), 7.72-
7.78 (1H, m, H-4), 8.34 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  23.8 (t), 25.5 (2 × t), 44.1 
(t), 53.9 (2 × t), 57.5 (t), 83.4 (d, JC7a-F = 4.5 Hz), 103.9 (d, JC4-F = 24.8 Hz), 111.7 (d, JC6-F = 26.2 
Hz), 113.2 (d, JC7-F = 9.8 Hz), 115.7 (s), 127.5 (d, JC3a-F = 10.9 Hz), 132.0 (s), 138.8 (d), 158.4 (d, 
JC5-F = 236.6 Hz); Anal. Calculated for C16H18FN3 (MW: 271.33) : C, 70.82; H, 6.69; N, 15.49%. 
Found: C, 71.04; H, 6.79; N, 15.17%. 
5-Methoxy-1-(2-piperidin-1-yl-ethyl)-1H-indole-3-carbonitrile (91d)  
N
CN
CH2
H3CO
CH2
N
 
Yield: 94%, yellow oil; IR: 2217 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.39-1.46 (6H, m, 3 
× CH2), 2.34-2.36 (4H, m, 2 × CH2), 2.61 (2H, t, J = 6.3 Hz, CH2),s, CH3), 4.30 (2H, t, J 
= 6.4 Hz, CH2), 6.94 (1H, dd, J = 9.0, 2.4 Hz, H-6), 7.08 (1H, d, J = 2.4 Hz, H-4), 7.59 (1H, d, J = 
9.0 Hz, H-7), 8.19 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  23.8 (t), 25.5 (2 × t), 44.0 (t), 
53.9 (2 × t), 55.3 (q), 57.6 (t), 82.7 (s), 99.9 (d), 112.5 (d), 113.5 (d), 116.3 (s), 127.8 (s), 130.1 (s), 
137.0 (d), 155.3 (s); Anal. Calculated for C17H21N3O (MW: 283.37) : C, 72.06; H, 7.47; N, 14.83%. 
Found: C, 71.90; H, 7.34; N, 15.12%. 
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General procedure for the synthesis of 1-(2-piperidin-1-yl-ethyl)-1H-indole-3-carbothioamides 
(88a-d) 
Compounds 88a-d were prepared from 91a-d using the same synthetic procedure described for 
compounds 75a-d.  
1-(2-Piperidin-1-yl-ethyl)-1H-indole-3-carbothioamide (88a)  
N
CH2
CH2
N
S
NH2
 
Yield: 72%, yellow solid; mp: 126-127 °C; IR: 1654 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.39-1.47 (6H, m, 3 × CH2), 2.38-2.40 (4H, m, 2 × CH2), 2.64 (2H, t, J = 6.4 Hz, CH2), 4.31 (2H, t, 
J = 6.5 Hz, CH2), 7.13-7.26 (2H, m, H-5 and H-6), 7.56 (1H, dd, J = 6.2, 1.6 Hz, H-7), 8.15 (1H, s, 
H-2), 8.57 (1H, dd, J = 6.9, 2.8 Hz, H-4), 8.90 (1H, s, SH), 8.98 (1H, s, NH); 13C NMR (50 MHz, 
DMSO-d6)  23.9 (t), 25.5 (2 × t), 43.5 (t), 54.0 (2 × t), 57.7 (t), 110.4 (d), 115.4 (s), 120.9 (d), 
121.8 (d), 122.0 (d), 125.9 (s), 132.0 (d), 136.6 (s), 193.0 (s); Anal. Calculated for C16H21N3S (MW: 
287.42) : C, 66.86; H, 7.36; N, 14.62%. Found: C, 67.03; H, 7.51; N, 14.30%. 
5-Bromo-1-(2-piperidin-1-yl-ethyl)-1H-indole-3-carbothioamide (88b)  
N
CH2
Br
CH2
N
S
NH2
 
Yield: 71%, yellow solid; mp: 177-178 °C; IR: 1607 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.35-1.45 (6H, m, 3 × CH2), 2.37-2.38 (4H, m, 2 × CH2), 2.62 (2H, t, J = 5.9 Hz, CH2), 4.30 (2H, t, 
J = 5.3 Hz, CH2), 7.35 (1H, d, J = 8.7 Hz, H-6), 7.57 (1H, d, J = 8.7 Hz, H-7), 8.18 (1H, s, H-2), 
8.86 (1H, s, H-4), 8.91 (1H, s, SH), 9.06 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  23.8 (t), 
25.5 (2 × t), 43.8 (t), 54.0 (2 × t), 57.7 (t), 112.7 (d), 113.9 (s), 114.5 (s), 124.0 (d), 124.5 (d), 127.9 
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(s), 132.4 (d), 135.5 (s), 192.4 (s); Anal. Calculated for C16H20BrN3S (MW: 366.32) : C, 52.46; H, 
5.50; N, 11.47%. Found: C, 52.80; H, 5.40; N, 11.23%. 
5-Fluoro-1-(2-piperidin-1-yl-ethyl)-1H-indole-3-carbothioamide (88c)  
N
CH2
F
CH2
N
S
NH2
 
Yield: 67%, yellow solid; mp: 144-145 °C; IR: 1623 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.36-1.46 (6H, m, 3 × CH2), 2.36-2.39 (4H, m, 2 × CH2), 2.63 (2H, t, J = 6.3 Hz, CH2), 4.31 (2H, t, 
J = 6.3 Hz, CH2), 7.08 (1H, td, J = 11.0, 9.0, 2.6 Hz, H-6), 7.57-7.64 (1H, m, H-7), 8.22 (1H, s, H-
2), 8.42 (1H, dd, J = 11.0, 2.6 Hz, H-4), 8.86 (1H, s, SH), 9.03 (1H, s, NH); 13C NMR (50 MHz, 
DMSO-d6)  23.8 (t), 25.5 (2 × t), 43.8 (t), 54.0 (2 × t), 57.7 (t), 106.8 (d, JC4-F = 25.9 Hz), 110.1 
(d, JC6-F = 26.5 Hz), 111.9 (d, JC7-F = 9.9 Hz), 115.0 (d, JC7a-F = 4.7 Hz), 126.8 (d, JC3a-F = 10.9 Hz), 
133.1 (d), 133.5 (s), 158.1 (d, JC5-F = 232.9 Hz), 192.6 (s); Anal. Calculated for C16H20FN3S (MW: 
305.41) : C, 62.92; H, 6.60; N, 13.76%. Found: C, 62.70; H, 6.93; N, 13.65%. 
5-Methoxy-1-(2-piperidin-1-yl-ethyl)-1H-indole-3-carbothioamide (88d)  
N
CH2
H3CO
CH2
N
S
NH2
 
Yield: 70%, yellow solid; mp: 152-153 °C; IR: 1654 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.42-1.46 (6H, m, 3 × CH2), 2.36-2.39 (4H, m, 2 × CH2), 2.62 (2H, t, J = 6.3 Hz, CH2), 3.78 (3H, s, 
CH3), 4.26 (2H, t, J = 6.4 Hz, CH2), 6.85 (1H, dd, J = 9.0, 2.4 Hz, H-6), 7.46 (1H, d, J = 9.0 Hz, H-
7), 8.11 (1H, s, H-2), 8.17 (1H, d, J = 2.4 Hz, H-4), 8.73 (1H, s, SH), 8.90 (1H, s, NH); 13C NMR 
(50 MHz, DMSO-d6)  23.8 (t), 25.5 (2 × t), 43.7 (t), 54.0 (2 × t), 55.2 (q), 57.8 (t), 103.8 (d), 
111.2 (d), 111.7 (d), 114.8 (s), 126.6 (s), 131.7 (s), 132.3 (d), 154.8 (s), 192.8 (s); Anal. Calculated 
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for C17H23N3OS (MW: 317.45) : C, 64.32; H, 7.30; N, 13.24%. Found: C, 64.20; H, 7.65; N, 
13.01%. 
General procedure for the synthesis of 3-{2-[1-(2-piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-
4-yl}-1H-pyrrolo[2,3-b]pyridine hydrobromides (59a-h) 
Compounds 59a-h were prepared from 88a-d using the same synthetic procedure described for 
compounds 69a,b. 
3-{2-[1-(2-Piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromide (59a)  
N
CH2
N
S
N
H
N
CH2
N
HBr
 
Conditions: 30 minutes at reflux. Yield: 86%, light brown solid; mp: 258-259 °C; IR: 3106 (NH), 
2979 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.37-1.83 (6H, m, 3 × CH2), 2.85-3.05 (2H, m, 
CH2), 3.57-3.61 (4H, m, 2 × CH2), 4.76 (2H, t, J = 6.6 Hz, CH2), 7.24 (1H, dd, J = 7.9, 4.7 Hz, H-
5’’), 7.32-7.42 (2H, m, H-5’and H-6’), 7.74-7.78 (2H, m, H-2’ and H-7’), 8.12 (1H, d, J = 2.6 Hz, 
H-2’’), 8.31-8.41 (3H, m, H-4’, H-5 and H-6’’), 8.64 (1H, dd, J = 7.9, 1.1 Hz, H-4’’), 9.62 (1H, bs, 
NH+), 11.99 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  21.1 (t), 22.3 (2 × t), 40.3 (t), 52.5 (2 
× t), 54.0 (t), 107.1(d), 109.9 (s), 110.7 (d), 110.8 (s), 116.1 (d), 117.1 (s), 120.7 (d), 121.5 (d), 
122.9 (d), 124.8 (d + s), 128.5 (d), 129.4 (d), 136.3 (s), 143.1 (d), 148.7 (s), 149.9 (s), 161.2 (s); 
Anal. Calculated for C25H26BrN5S (MW: 508.48) : C, 59.05; H, 5.15; N, 13.77%. Found: C, 58.90; 
H, 4.97; N, 14.10%. 
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1-Methyl-3-{2-[1-(2-piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (59b) 
N
CH2
N
S
N
N
CH2
N
HBr
CH3
 
Conditions: 30 minutes at reflux. Yield: 70%, light pink solid; mp: 209-210 °C; IR: 2954 (NH+) cm-
1; 1H NMR (200 MHz, DMSO-d6)  1.42-1.83 (6H, m, 3 × CH2), 2.89-3.04 (2H, m, CH2), 3.57-
3.61 (4H, m, 2 × CH2), 3.94 (3H, s, CH3), 4.75 (2H, s, CH2), 7.24-7.42 (3H, m, H-5’, H-5’’ and H-
6’), 7.74-7.78 (2H, m, H-2’ and H-4’), 8.07 (1H, s, H-2’’), 8.21 (1H, s, H-5), 8.32-8.43 (2H, m, H-
6’’ and H-7’), 8.63 (1H, d, J = 6.7 Hz, H-4’’), 9.57 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6) 
 21.1 (t), 22.3 (2 × t), 30.9 (q), 40.3 (t), 52.5 (2 × t), 54.1 (t), 107.0 (d), 108.7 (s), 110.6 (s), 110.7 
(d), 116.0 (d), 117.1 (s), 120.8 (d), 121.3 (d), 122.8 (d), 124.8 (s), 128.4 (d), 128.6 (d), 129.2 (d), 
136.3 (s), 142.9 (d), 147.5 (s), 149.6 (s), 161.4 (s); Anal. Calculated for C26H28BrN5S (MW: 522.50) 
: C, 59.77; H, 5.40; N, 13.40%. Found: C, 59.60; H, 5.76; N, 13.21%. 
3-{2-[5-Bromo-1-(2-piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (59c)  
N
CH2
N
S
N
H
N
CH2
N
HBr
Br
 
Conditions: 30 minutes at reflux. Yield: 71%, yellow solid; mp: 277-278 °C; IR: 3124 (NH), 2972 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.37-1.83 (6H, m, 3 × CH2), 2.87-3.03 (2H, m, 
CH2), 3.54-3.59 (4H, m, 2 × CH2), 4.75 (2H, t, J = 6.6 Hz, CH2), 7.23 (1H, dd, J = 7.8, 4.7 Hz, H-
5’’), 7.53 (1H, d, J = 8.4 Hz, H-6’), 7.77 (1H, d, J = 6.8 Hz, H-7’), 7.78 (1H, s, H-2’), 8.10 (1H, d, J 
= 1.9 Hz, H-2’’), 8.33 (1H, s, H-4’), 8.38 (1H, s, H-5), 8.61 (1H, d, J = 4.7 Hz, H-6’’), 8.64 (1H, d, 
J = 7.8 Hz, H-4’’), 9.59 (1H, bs, NH+), 12.01 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  21.1 
(t), 22.3 (2 × t), 40.5 (t), 52.5 (2 × t), 54.0 (t), 107.3 (d), 109.8 (s), 110.3 (s), 112.9 (d), 114.1 (s), 
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116.0 (d), 117.1 (s), 123.1 (d), 124.7 (d), 125.3 (d), 126.4 (s), 128.4 (d), 130.7 (d), 135.1 (s), 143.0 
(d), 148.6 (s), 149.9 (s), 160.7 (s); Anal. Calculated for C25H25Br2N5S (MW: 587.37) : C, 51.12; H, 
4.29; N, 11.92%. Found: C, 51.50; H, 4.16; N, 11.67%. 
3-{2-[5-Bromo-1-(2-piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (59d)  
N
CH2
N
S
N
N
CH2
N
HBr
Br
CH3
 
Conditions: 30 minutes at reflux. Yield: 78%, white solid; mp: 251-252 °C; IR: 2971 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6)  1.37-1.90 (6H, m, 3 × CH2), 2.98-3.09 (2H, m, CH2), 3.54-3.60 
(4H, m, 2 × CH2), 3.94 (3H, s, CH3), 4.50 (2H, t, J = 6.3 Hz, CH2), 7.26 (1H, dd, J = 7.9, 4.7 Hz, H-
5’’), 7.53 (1H, dd, J = 8.8, 1.8 Hz, H-6’), 7.74-7.79 (2H, m, H-2’ and H-7’), 8.16 (1H, s, H-2’’), 
8.38-8.39 (2H, m, H-5 and H-6’’), 8.57 (1H, d, J = 1.8 Hz, H-4’), 8.63 (1H, dd, J = 7.9, 1,4 Hz, H-
4’’), 9.52 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6)  21.1 (t), 22.3 (2 × t), 31.0 (q), 40.5 (t), 
52.5 (2 × t), 53.9 (t), 107.4 (d), 108.6 (s), 110.2 (s), 112.9 (d), 114.1 (s), 116.1 (d), 117.3 (s), 123.0 
(d), 125.4 (d), 126.4 (s), 128.5 (d), 128.6 (d), 130.8 (d), 135.1 (s), 143.0 (d), 147.6 (s), 149.7 (s), 
160.8 (s); Anal. Calculated for C26H27Br2N5S (MW: 601.40) : C, 51.93; H, 4.53; N, 11.65%. Found: 
C, 51.79; H, 4.90; N, 11.42%. 
3-{2-[5-Fluoro-1-(2-piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (59e)  
N
CH2
N
S
N
H
N
CH2
N
HBr
F
 
Conditions: 30 minutes at reflux. Yield: 86%, light yellow solid; mp: 263-264 °C; IR: 3110 (NH), 
2979 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.37-1.90 (6H, m, 3 × CH2), 2.98-3.08 (2H, m, 
CH2), 3.55-3.61 (4H, m, 2 × CH2), 4.75 (2H, t, J = 7.3 Hz, CH2), 7.20-7.32 (2H, m, H5’’ and H-6’), 
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7.77-7.83 (2H, m, H-2’ and H-7’), 8.08 (1H, dd, J = 10.4, 2.5 Hz, H-4’), 8.13 (1H, d, J = 2.5 Hz, H-
2’’), 8.32 (1H, dd, J = 4.7, 1.4 Hz, H-6’’), 8.40 (1H, s, H-5), 8.61 (1H, dd, J = 8.2, 1.4 Hz, H-4’’), 
9.60 (1H, bs, NH+), 11.99 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  21.1 (t), 22.3 (2 × t), 
40.6 (t), 52.5 (2 × t), 54.0 (t), 105.7 (d, JC4’-F = 23.6 Hz), 107.2 (d), 109.8 (s), 110.8 (d, JC7a-F = 4.6 
Hz), 111.1 (d, JC6’-F = 26.2 Hz), 112.2 (d, JC7’-F = 9.9 Hz), 116.1 (d), 117.0 (s), 124.9 (d), 125.1 (d, 
JC3a-F = 10.6 Hz), 128.3 (d), 131.1 (d), 133.0 (s), 143.1 (d), 148.7 (s), 149.9 (s), 158.3 (d, JC5’-F = 
235.5 Hz), 161.0 (s); Anal. Calculated for C25H25BrFN5S (MW: 526.47) : C, 57.03; H, 4.79; N, 
13.30%. Found: C, 57.40; H, 4.65; N, 13.07%. 
3-{2-[5-Fluoro-1-(2-piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobrimide (59f)  
N
CH2
N
S
N
N
CH2
N
HBr
F
CH3
 
Conditions: 30 minutes at reflux. Yield: 91%, light pink solid; mp: 244-245 °C; IR: 2954 (NH+) cm-
1; 1H NMR (200 MHz, DMSO-d6)  1.32-1.90 (6H, m, 3 × CH2), 2.85-3.08 (2H, m, CH2), 3.55-
3.61 (4H, m, 2 × CH2), 3.94 (3H, s, CH3), 4.75 (2H, t, J = 7.0 Hz, CH2), 7.22-7.32 (2H, m, H5’’ and 
H-6’), 7.76-7.83 (2H, m, H-2’ and H-7’), 8.13 (1H, dd, J = 9.8, 2.5 Hz, H-4’), 8.22 (1H, s, H-2’’), 
8.36-8.40 (2H, m, H-5 and H-6’’), 8.59 (1H, dd, J = 8.0, 1.4 Hz, H-4’’), 9.54 (1H, bs, NH+); 13C 
NMR (50 MHz, DMSO-d6)  21.1 (t), 22.3 (2 × t), 30.9 (q), 40.6 (t), 52.5 (2 × t), 54.0 (t), 105.8 (d, 
JC4’-F = 24.0 Hz), 107.1 (d), 108.8 (s), 110.8 (d, JC7a-F = 4.6 Hz), 111.1 (d, JC6’-F = 25.4 Hz), 112.2 
(d, JC7’-F = 9.6 Hz), 116.2 (d), 117.2 (s), 125.1 (d, JC3a-F = 10.7 Hz), 128.5 (d), 128.8 (d), 131.2 (d), 
133.0 (s), 142.9 (d), 147.6 (s), 149.6 (s), 158.3 (d, JC5’-F = 235.1 Hz), 161.1 (s); Anal. Calculated for 
C26H27BrFN5S (MW: 540.49) : C, 57.78; H, 5.04; N, 12.96%. Found: C, 57.61; H, 5.38; N, 12.79%. 
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3-{2-[5-Methoxy-1-(2-piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (59g)  
N
CH2
N
S
N
H
N
CH2
N
HBr
H3CO
 
Conditions: 30 minutes at reflux. Yield: 80%, light yellow solid; mp: 290-291 °C; IR: 3072 (NH), 
2944 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.42-1.82 (6H, m, 3 × CH2), 2.86-3.02 (2H, m, 
CH2), 3.53-3.58 (4H, m, 2 × CH2), 3.92 (3H, s, CH3), 4.68-4.75 (2H, m, CH2), 7.02 (1H, d, J = 8.9 
Hz, H-6’), 7.21 (1H, dd, J = 7.5, 4.7 Hz, H-5’’), 7.67 (1H, d, J = 8.9 Hz, H-7’), 7.73 (1H, s, H-2’), 
7.96 (1H, s, H-4’), 8.11 (1H, s, H-2’’), 8.26 (1H, s, H-5), 8.31 (1H, d, J = 4.7 Hz, H-6’’), 8.72 (1H, 
d, J = 7.5 Hz, H-4’’), 9.66 (1H, bs, NH+), 11.98 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  
21.1 (t), 22.3 (2 × t), 40.4 (t), 52.5 (2 × t), 54.1 (t), 55.2 (q), 102.3 (d), 106.6 (d), 109.9 (s), 110.5 
(s), 111.5 (d), 112.9 (d), 115.9 (d), 117.2 (s), 124.5 (d), 125.4 (s), 128.6 (d), 129.6 (d), 131.2 (s), 
142.9 (d), 148.5 (s), 149.9 (s), 155.1 (s), 161.5 (s); Anal. Calculated for C26H28BrN5OS (MW: 
538.50) : C, 57.99; H, 5.24; N, 13.01%. Found: C, 58.09; H, 5.44; N, 12.71%. 
3-{2-[5-Methoxy-1-(2-piperidin-1-yl-ethyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (59h)  
N
CH2
N
S
N
N
CH2
N
HBr
H3CO
CH3
 
Conditions: 30 minutes at reflux. Yield: 91%, light orange solid; mp: 147-148 °C; IR: 2954 (NH+) 
cm-1; 1H NMR (200 MHz, DMSO-d6)  1.43-1.89 (6H, m, 3 × CH2), 2.84-3.07 (2H, m, CH2), 3.54-
3.59 (4H, m, 2 × CH2), 3.92 (3H, s, CH3), 3.93 (3H, s, CH3), 4.70 (2H, t, J = 6.8 Hz, CH2), 7.02 
(1H, dd, J = 9.0, 2.4 Hz, H-6’), 7.24 (1H, dd, J = 7.9, 4.6 Hz, H-5’’), 7.67 (1H, d, J = 9.0 Hz, H-7’), 
7.71 (1H, s, H-2’), 7.94 (1H, d, J = 2.4 Hz, H-4’), 8.16 (1H, s, H-2’’), 8.26 (1H, s, H-5), 8.37 (1H, 
dd, J = 4.6, 1.4 Hz, H-6’’), 8.72 (1H, dd, J = 7.9, 1.4 Hz, H-4’’), 9.56 (1H, bs, NH+); 13C NMR (50 
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MHz, DMSO-d6)  21.1 (t), 22.3 (2 × t), 31.0 (q), 40.5 (t), 52.5 (2 × t), 54.1 (t), 55.3 (q), 102.4 (d), 
106.7 (d), 108.8 (s), 110.4 (s), 111.6 (d), 112.8 (d), 116.0 (d), 117.4 (s), 125.3 (s), 128.3 (d), 128.7 
(d), 129.7 (d), 131.2 (s), 142.9 (d), 147.5 (s), 149.6 (s), 155.1 (s), 161.6 (s); Anal. Calculated for 
C27H30BrN5OS (MW: 552.53) : C, 58.69; H, 5.47; N, 12.68%. Found: C, 58.85; H, 5.12; N, 
12.87%. 
General procedure for the synthesis of 1-(3-piperidin-1-yl-propyl)-1H-indole-3-carbonitriles 
(94a-d) 
A mixture of appropriate indole carbonitrile 81a-d (0.4 g, 1.43 mmol), piperidine 93 (1.45 mL, 
14.68 mmol), and potassium carbonate (K2CO3) (0.34 g, 2.49 mmol), in dry DMF (5.4 mL) was 
stirred at 50 °C for 1 hour. After cooling, the mixture was poured into water and ice and extracted 
with dichloromethane (3 × 20 mL), dried (Na2SO4), filtered and the solvent evaporated under 
reduced pressure. The residue was purified by column chromatography using 
dichloromethane:methanol (98:2) as eluent. 
1-(3-Piperidin-1-yl-propyl)-1H-indole-3-carbonitrile (94a)  
N
CH2
CN
CH2
CH2
N
 
Yield: 93%, yellow oil; IR: 2220 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.35-1.47 (6H, m, 3 
× CH2), 1.86-1.99 (2H, m, CH2),2.15 (2H, t, J = 7.4 Hz, CH2), 2.21-2.26 (4H, m, 2 × CH2), 4.29 
(2H, t, J = 6.7 Hz, CH2), 7.23-7.38 (2H, m, H-5 and H-6), 7.63-7.72 (2H, m, H-4 and H-7), 8.29 
(1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  24.0 (t), 25.4 (2 × t), 26.5 (t), 44.3 (t), 53.8 (2 × t), 
54.9 (t), 83.2 (s), 111.5 (d), 116.0 (s), 118.6 (d), 121.8 (d), 123.2 (d), 127.0 (s), 135.2 (s), 136.9 (d); 
Anal. Calculated for C17H21N3 (MW: 267.37) : C, 76.37; H, 7.92; N, 15.72%. Found: C, 76.51; H, 
8.05; N, 15.45%. 
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5-Bromo-1-(3-piperidin-1-yl-propyl)-1H-indole-3-carbonitrile (94b)  
N
CH2
CN
CH2
CH2
Br
N
 
Yield: 81%, yellow oil; IR: 2220 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.37-1.45 (6H, m, 3 
× CH2), 1.85-1.98 (2H, m, CH2),2.12 (2H, t, J = 7.4 Hz, CH2), 2.18-2.24 (4H, m, 2 × CH2), 4.28 
(2H, t, J = 6.7 Hz, CH2), 7.47 (1H, dd, J = 8.8, 1.9 Hz, H-6), 7.71 (1H, d, J = 8.8 Hz, H-7), 7.81 
(1H, d, J = 1.8 Hz, H-4), 8.36 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  24.0 (t), 25.4 (2 × t), 
26.4 (t), 44.6 (t), 53.8 (2 × t), 54.8 (t), 83.0 (s), 113.7 (d), 114.6 (s), 115.3 (s), 120.9 (d), 125.9 (d), 
128.6 (s), 134.2 (s), 138.3 (d); Anal. Calculated for C17H20BrN3 (MW: 346.26) : C, 58.97; H, 5.82; 
N, 12.14%. Found: C, 59.23; H, 5.96; N, 11.74%. 
5-Fluoro-1-(3-piperidin-1-yl-propyl)-1H-indole-3-carbonitrile (94c)  
N
CH2
CN
CH2
CH2
F
N
 
Yield: 70%, yellow oil; IR: 2220 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.34-1.48 (6H, m, 3 
× CH2), 1.85-1.98 (2H, m, CH2), 2.13 (2H, t, J = 7.4 Hz, CH2), 2.19-2.24 (4H, m, 2 × CH2), 4.28 
(2H, t, J = 6.7 Hz, CH2), 7.20 (1H, td, J = 11.7, 9.3, 2.5 Hz, H-6),7.43 (1H, dd, J = 9.2, 2.4 Hz, H-
7), 7.71-7.78 (1H, m, H-4), 8.36 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  24.0 (t), 25.4 (2 × 
t), 26.4 (t), 44.6 (t), 53.8 (2 × t), 54.8 (t), 83.5 (d, JC7a-F = 4.5 Hz), 103.9 (d, JC4-F = 24.7 Hz), 111.7 
(d, JC6-F = 26.1 Hz), 113.2 (d, JC7-F = 9.8 Hz), 115.6 (s), 127.5 (d, JC3a-F = 10.9 Hz), 132.0 (s), 138.5 
(d), 158.4 (d, JC5-F = 236.7 Hz); Anal. Calculated for C17H20FN3 (MW: 285.36) : C, 71.55; H, 7.06; 
N, 14.73%. Found: C, 71.22; H, 7.18; N, 14.94%. 
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5-Methoxy-1-(3-piperidin-1-yl-propyl)-1H-indole-3-carbonitrile (94d)  
N
CH2
CN
CH2
CH2
H3CO
N
 
Yield: 82%, yellow oil; IR : 2216 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.35-1.50 (6H, m, 
3 × CH2), 1.84-1.97 (2H, m, CH2),2.13 (2H, t, J = 7.2 Hz, CH2), 2.21-2.25 (4H, m, 2 × CH2), 3.82 
(3H, s, CH3), 4.24 (2H, t, J = 6.7 Hz, CH2), 6.95 (1H, dd, J = 9.0, 2.4 Hz, H-6), 7.09 (1H, d, J = 2.4 
Hz, H-4), 7.60 (1H, d, J = 9.0 Hz, H-7), 8.21 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  24.0 
(t), 25.4 (2 × t), 26.5 (t), 44.4 (t), 53.8 (2 × t), 54.9 (t), 55.4 (q), 82.8 (s), 100.0 (d), 112.5 (d), 113.5 
(d), 116.2 (s), 127.8 (s), 130.1 (s), 136.7 (d), 155.4 (s); Anal. Calculated for C18H23N3O (MW: 
297.39) : C, 72.70; H, 7.80; N, 14.13%. Found: C, 72.33; H, 7.94; N, 14.36%. 
General procedure for the synthesis of 1-(3-piperidin-1-yl-propyl)-1H-indole-3-
carbothioamides (92a-d) 
Compounds 92a-d were prepared from 94a-d using the same synthetic procedure described for 
compounds 75a-d.  
1-(3-Piperidin-1-yl-propyl)-1H-indole-3-carbothioamide (92a)  
N
CH2
CH2
CH2
N
S
NH2
 
Yield: 80%, yellow solid; mp: 112-113 °C; IR: 1684 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.39-1.53 (6H, m, 3 × CH2), 1.92-1.99 (2H, m, CH2),2.26-2.35 (6H, m, 3 × CH2), 4.24 (2H, t, J = 
6.6 Hz, CH2), 7.14-7.26 (2H, m, H-5 and H-6), 7.56 (1H, d, J = 7.1 Hz, H-7), 8.15 (1H, s, H-2), 
8.59 (1H, d, J = 8.4 Hz, H-4), 8.80 (1H, s, SH), 8.99 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  
23.8 (t), 25.2 (2 × t), 26.3 (t), 43.7 (t), 53.7 (2 × t), 54.7 (t), 110.5 (d), 115.2 (s), 120.8 (d), 121.9 (d), 
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122.1 (d), 126.1 (s), 131.3 (d), 136.9 (s), 193.3 (s); Anal. Calculated for C17H23N3S (MW: 301.45) : 
C, 67.73; H, 7.69; N, 13.94%. Found: C, 67.48; H, 7.58; N, 14.30%. 
5-Bromo-1-(3-piperidin-1-yl-propyl)-1H-indole-3-carbothioamide (92b)  
N
CH2
CH2
CH2
Br
N
S
NH2
 
Yield: 82%, yellow solid; mp: 197-198 °C; IR: 1636 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.40-1.52 (6H, m, 3 × CH2), 1.91-1.98 (2H, m, CH2),2.27-2.37 (6H, m, 3 × CH2),4.24 (2H, t, J = 
6.5 Hz, CH2), 7.36 (1H, dd, J = 8.8, 1.8 Hz, H-6), 7.57 (1H, d, J = 8.8 Hz, H-7), 8.19 (1H, s, H-2), 
8.88 (1H, d, J = 1.8 Hz, H-4), 8.92 (1H, s, SH), 9.07 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  
23.5 (t), 25.0 (2 × t), 26.1 (t), 43.9 (t), 53.6 (2 × t), 54.6 (t), 112.6 (d), 114.0 (s), 114.6 (s), 124.1 (d), 
124.5 (d), 128.0 (s), 132.0 (d), 135.5 (s), 192.4 (s); Anal. Calculated for C17H22BrN3S (MW: 
380.35) : C, 53.68; H, 5.83; N, 11.05%. Found: C, 53.87; H, 5.95; N, 10.74%. 
5-Fluoro-1-(3-piperidin-1-yl-propyl)-1H-indole-3-carbothioamide (92c)  
N
CH2
CH2
CH2
F
N
S
NH2
 
Yield: 86%, yellow solid; mp: 77-78 °C; IR: 1623 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.42-1.56 (6H, m, 3 × CH2), 1.94-2.04 (2H, m, CH2),2.22 (2H, t, J = 7.2 Hz, CH2), 2.32 (4H, s, 2 × 
CH2), 4.29 (2H, t, J = 6.7 Hz, CH2), 7.14 (1H, td, J = 11.0, 9.1, 2.6 Hz, H-6), 7.62-7.69 (1H, m, H-
7), 8.27 (1H, s, H-2), 8.48 (1H, dd, J = 11.0, 2.6 Hz, H-4), 8.91 (1H, s, SH), 9.07 (1H, s, NH); 13C 
NMR (50 MHz, DMSO-d6)  24.0 (t), 25.5 (2 × t), 26.5 (t), 44.1 (t), 53.8 (2 × t), 54.9 (t), 106.9 (d, 
JC4-F = 26.0 Hz), 110.2 (d, JC6-F = 26.3 Hz), 111.8 (d, JC7-F = 9.7 Hz), 115.0 (d, JC7a-F = 4.6 Hz), 
126.9 (d, JC3a-F = 11.1 Hz), 132.6 (d), 133.5 (s), 158.1 (d, JC5-F = 233.0 Hz), 192.6 (s); Anal. 
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Calculated for C17H22FN3S (MW: 319.44) : C, 63.92; H, 6.94; N, 13.15%. Found: C, 63.74; H, 
6.74; N, 13.53%. 
5-Methoxy-1-(3-piperidin-1-yl-propyl)-1H-indole-3-carbothioamide (92d)  
N
CH2
CH2
CH2
H3CO
N
S
NH2
 
Yield: 88%, yellow solid; mp: 74-75 °C; IR: 1623 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.42-1.56 (6H, m, 3 × CH2), 1.95-2.01 (2H, m, CH2),2.28-2.47 (6H, m, 3 × CH2), 3.79 (3H, s, 
CH3), 4.21 (2H, t, J = 6.5 Hz, CH2), 6.86 (1H, dd, J = 8.9, 2.4 Hz, H-6), 7.47 (1H, d, J = 8.9 Hz, H-
7), 8.12 (1H, s, H-2), 8.17 (1H, d, J = 2.4 Hz, H-4), 8.74 (1H, s, SH), 8.92 (1H, s, NH); 13C NMR 
(50 MHz, DMSO-d6)  23.4 (t), 24.7 (2 × t), 26.0 (t), 43.8 (t), 53.4 (2 × t), 54.5 (t), 55.2 (q), 103.9 
(d), 111.2 (d), 111.8 (d), 115.0 (s), 126.7 (s), 131.7 (s), 131.8 (d), 154.8 (s), 192.9 (s); Anal. 
Calculated for C18H25N3OS (MW: 331.48) : C, 65.22; H, 7.60; N, 12.68%. Found: C, 65.46; H, 
7.75; N, 12.29%. 
General procedure for the synthesis of 3-{2-[1-(3-piperidin-1-yl-propyl)-1H-indol-3-yl]-
thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine hydrobromides (60a-h) 
Compounds 60a-h were prepared from 92a-d using the same synthetic procedure described for 
compounds 69a,b. 
3-{2-[1-(3-Piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromide (60a)  
N
CH2
N
S
N
H
N
CH2
CH2
HBrN
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Conditions: 30 minutes at reflux. Yield: 64%, light brown solid; mp: 228-229 °C; IR: 3113 (NH), 
2953 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.71-2.29 (6H, m, 3 × CH2), 2.62-2.78 (2H, 
m, CH2),3.21-3.61 (4H, m, 2 × CH2), 3.88-3.90 (2H, m, CH2), 4.83 (2H, t, J = 6.4 Hz, CH2),7.63-
7.78 (3H, m, H-5’, H-5’’ and H-6’), 8.09-8.17 (2H, m, H-2’ and H-7’), 8.54 (1H, d, J = 2.5 Hz, H-
2’’), 8.71-8.81 (3H, m, H-4’, H-5 and H-6’’), 9.06 (1H, d, J = 7.4 Hz, H-4’’), 9.56(1H, bs, NH+), 
12.42 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  21.2 (t), 22.5 (2 × t), 24.3 (t), 43.2 (t), 52.1 
(2 × t), 53.4 (t), 106.9 (d), 110.0 (s), 110.3 (s), 110.7 (d), 116.1 (d), 117.1 (s), 120.7 (d), 121.2 (d), 
122.6 (d), 124.8 (d + s), 128.5 (d), 129.3 (d), 136.3 (s), 143.0 (d), 148.7 (s), 149.8 (s), 161.5 (s); 
Anal. Calculated for C26H28BrN5S (MW: 522.50) : C, 59.77; H, 5.40; N, 13.40%. Found: C, 59.44; 
H, 5.56; N, 13.57%. 
1-Methyl-3-{2-[1-(3-piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (60b)  
N
CH2
N
S
N
N
CH2
CH2
HBrN
CH3
 
Conditions: 30 minutes at reflux. Yield: 56%, light brown solid; mp: 219-220 °C; IR: 2954 (NH+) 
cm-1; 1H NMR (200 MHz, DMSO-d6)  1.24-1.84 (6H, m, 3 × CH2), 2.15-2.35 (2H, m, CH2), 2.80-
3.17 (4H, m, 2 × CH2), 3.42-3.46 (2H, m, CH2), 3.94 (3H, s, CH3), 4.40 (2H, t, J = 6.0 Hz, 
CH2),7.24-7.39 (3H, m, H-5’, H-5’’ and H-6’), 7.67-7.73 (2H, m, H-2’ and H-4’), 8.20 (1H, s, H-
2’’), 8.28 (1H, s, H-5), 8.37-8.42 (2H, m, H-6’’ and H-7’), 8.62 (1H, dd, J = 7.9, 1.4 Hz, H-4’’), 
9.09 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6)  21.2 (t), 22.5 (2 × t), 24.3 (t), 31.0 (q), 43.2 
(t), 52.1 (2 × t), 53.4 (t), 106.9 (d), 108.9 (s), 110.3 (s), 110.7 (d), 116.2 (d), 117.3 (s), 120.8 (d), 
121.2 (d), 122.6 (d), 124.8 (s), 128.7 (2 × d), 129.4 (d), 136.3 (s), 142.9 (d), 147.6 (s), 149.4 (s), 
161.6 (s); Anal. Calculated for C27H30BrN5S (MW: 536.53) : C, 60.44; H, 5.64; N, 13.05%. Found: 
C, 60.16; H, 5.52; N, 13.45%. 
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3-{2-[5-Bromo-1-(3-piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (60c)  
N
CH2
N
S
N
H
N
CH2
CH2
HBr
Br
N
 
Conditions: 30 minutes at reflux. Yield: 66%, yellow solid; mp: 259-260 °C; IR: 3182 (NH), 2959 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.29-1.85 (6H, m, 3 × CH2), 2.22-2.32 (2H, m, 
CH2), 2.79-3.13 (4H, m, 2 × CH2), 3.39-3.50 (2H, m, CH2), 4.40 (2H, t, J = 6.6 Hz, CH2), 7.25 (1H, 
dd, J = 7.9, 4.6 Hz, H-5’’), 7.49 (1H, dd, J = 8.6, 1.4 Hz, H-6’), 7.71 (1H, d, J = 8.6 Hz, H-7’), 7.77 
(1H, s, H-2’), 8.11 (1H, d, J = 2.0 Hz, H-2’’), 8.34-8.35 (2H, m, H-5 and H-6’’), 8.58 (1H, d, J = 1.4 
Hz, H-4’), 8.67 (1H, dd, J = 7.8, 1.0 Hz, H-4’’), 9.20 (1H, bs, NH+), 12.05 (1H, bs, NH); 13C NMR 
(50 MHz, DMSO-d6)  21.2 (t), 22.5 (2 × t), 24.2 (t), 43.5 (t), 52.1 (2 × t), 53.3 (t), 107.4 (d), 109.8 
(s), 110.0 (s), 112.9 (d), 113.9 (s), 116.1 (d), 117.6 (s), 123.0 (d), 124.9 (d), 125.1 (d), 126.4 (s), 
129.3 (d), 130.7 (d), 135.1 (s), 142.3 (d), 147.8 (s), 149.7 (s), 161.1 (s); Anal. Calculated for 
C26H27Br2N5S (MW: 601.40) : C, 51.93; H, 4.53; N, 11.65%. Found: C, 52.03; H, 4.63; N, 11.45%. 
3-{2-[5-Bromo-1-(3-piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (60d)  
N
CH2
N
S
N
N
CH2
CH2
HBr
Br
N
CH3
 
Conditions: 30 minutes at reflux. Yield: 68%, light brown solid; mp: 285-286 °C; IR: 2952 (NH+) 
cm-1; 1H NMR (200 MHz, DMSO-d6)  1.27-1.84 (6H, m, 3 × CH2), 2.15-2.35 (2H, m, CH2), 2.75-
3.16 (4H, m, 2 × CH2), 3.40-3.47 (2H, m, CH2), 3.94 (3H, s, CH3), 4.37-4.43 (2H, m, CH2), 7.26 
(1H, dd, J = 7.8, 4.7 Hz, H-5’’), 7.49 (1H, dd, J = 8.9, 1.8 Hz, H-6’), 7.69-7.75 (2H, m, H-2’ and H-
7’), 8.16 (1H, s, H-2’’), 8.35-8.39 (2H, m, H-5 and H-6’’), 8.56 (1H, d, J = 1.8 Hz, H-4’), 8.63 (1H, 
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dd, J = 7.8, 1.0 Hz, H-4’’), 9.09 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6)  (t), 22.5 (2 × 
t), 24.2 (t), 31.1 (q), 43.4 (t), 52.1 (2 × t), 53.3 (t), 107.4 (d), 108.9 (s), 109.8 (s), 112.9 (d), 113.9 
(s), 116.1 (d), 117.7 (s), 123.0 (d), 125.2 (d), 126.4 (s), 128.7 (d), 129.2 (d), 130.8 (d), 135.1 (s), 
142.5 (d), 147.2 (s), 149.5 (s), 161.2 (s); Anal. Calculated for C27H29Br2N5S (MW: 615.43) : C, 
52.69; H, 4.75; N, 11.38%. Found: C, 52.30; H, 4.98; N, 11.54%. 
3-{2-[5-Fluoro-1-(3-piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (60e)  
N
CH2
N
S
N
H
N
CH2
CH2
HBr
F
N
 
Conditions: 30 minutes at reflux. Yield: 87%, yellow solid; mp: 247-248 °C; IR: 3177 (NH), 2952 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.24-1.80 (6H, m, 3 × CH2), 2.16-2.36 (2H, m, 
CH2),-(4H, m, 2 × CH2), 3.43-3.51 (2H, m, CH2), 4.36-4.43 (2H, m, CH2), 7.17-7.26 (2H, 
m, H-5’’ and H-6’), 7.70-7.74 (2H, m, H-2’ and H-7’), 8.05-8.11 (2H, m, H-2’’ and H-4’), 8.28-
8.42 (2H, m, H-5 and H-6’’), 8.61 (1H, d, J = 7.9 Hz, H-4’’), 9.12(1H, bs, NH+), 11.98 (1H, bs, 
NH); 13C NMR (50 MHz, DMSO-d6)  21.2 (t), 22.6 (2 × t), 24.3 (t), 43.5 (t), 52.1 (2 × t), 53.4 (t), 
105.6 (d, JC4’-F = 23.9 Hz), 106.9 (d), 109.9 (s), 110.3 (d, JC7a-F = 4.4 Hz), 110.8 (d, JC6’-F = 25.9 
Hz), 112.1 (d, JC7’-F = 9.9 Hz), 116.1 (d), 117.1 (s), 124.8 (d), 125.0 (d, JC3a-F = 10.3 Hz), 128.3 (d), 
131.1 (d), 133.1 (s), 143.1 (d), 148.7 (s), 149.9 (s), 158.2 (d, JC5’-F = 234.9 Hz), 161.2 (s); Anal. 
Calculated for C26H27BrFN5S (MW: 540.49) : C, 57.78; H, 5.04; N, 12.96%. Found: C, 57.90; H, 
5.29; N, 12.59%. 
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3-{2-[5-Fluoro-1-(3-piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (60f)  
N
CH2
N
S
N
N
CH2
CH2
HBr
F
CH3
N
 
Conditions: 30 minutes at reflux. Yield: 98%, yellow solid; mp: 217-218 °C; IR: 2965 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6)  1.25-1.75 (6H, m, 3 × CH2), 2.25-2.36 (2H, m, CH2), 2.80-3.17 
(4H, m, 2 × CH2), 3.40-3.47 (2H, m, CH2), 3.94 (3H, s, CH3), 4.41 (2H, t, J = 6.3 Hz, CH2), 7.17-
7.30 (2H, m, H-5’’ and H-6’), 7.71-7.78 (2H, m, H-2’ and H-7’), 8.11 (1H, dd, J = 9.9, 2.4 Hz, H-
4’), 8.22 (1H, s, H-2’’), 8.36-8.39 (2H, m, H-5 and H-6’’), 8.61 (1H, dd, J = 8.0, 1.3 Hz, H-4’’), 
9.38 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6)  21.1 (t), 22.5 (2 × t), 24.2 (t), 31.0 (q), 43.5 
(t), 52.0 (2 × t), 53.3 (t), 105.7 (d, JC4’-F = 23.8 Hz), 107.0 (d), 108.8 (s), 110.2 (d, JC7a-F = 4.5 Hz), 
110.9 (d, JC6’-F = 26.6 Hz), 112.1 (d, JC7’-F = 9.1 Hz), 116.2 (d), 117.3 (s), 125.0 (d, JC3a-F = 10.8 
Hz), 128.6 (d), 128.8 (d), 131.1 (d), 133.1 (s), 142.8 (d), 147.5 (s), 149.5 (s), 158.2 (d, JC5’-F = 233.9 
Hz), 161.3 (s); Anal. Calculated for C27H29BrFN5S (MW: 554.52 ) : C, 58.48; H, 5.27; N, 12.63%. 
Found: C, 58.34; H, 5.06; N, 12.98%. 
3-{2-[5-Methoxy-1-(3-piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (60g)  
N
CH2
N
S
N
H
N
CH2
CH2
HBr
H3CO
N
 
Conditions: 30 minutes at reflux. Yield: 82%, yellow solid; mp: 261-262 °C; IR: 3062 (NH), 2953 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.28-1.82 (6H, m, 3 × CH2), 2.16-2.34 (2H, m, 
CH2),2.76-3.12 (4H, m, 2 × CH2), 3.39-3.50 (2H, m, CH2), 3.91 (3H, s, CH3),4.36 (2H, t, J = 6.6 
Hz, CH2), 7.00 (1H, dd, J = 9.0, 2.5 Hz, H-6’), 7.23 (1H, dd, J = 7.9, 4.8 Hz, H-5’’), 7.60 (1H, d, J = 
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9.0 Hz, H-7’), 7.72 (1H, s, H-2’), 7.95 (1H, d, J = 2.5 Hz, H-4’), 8.12 (1H, d, J = 2.5 Hz, H-
2’’),8.22 (1H, s, H-5), 8.33 (1H, dd, J = 4.8, 1.4 Hz, H-6’’), 8.76 (1H, dd, J = 7.9, 1.4 Hz, H-4’’), 
9.31 (1H, bs, NH+), 12.03 (1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  21.2 (t), 22.5 (2 × t), 
24.3 (t), 43.4 (t), 52.1 (2 × t), 53.4 (t), 55.2 (q), 102.2 (d), 106.8 (d), 109.9 (s), 110.2 (s), 111.6 (d), 
112.7 (d), 116.0 (d), 117.9 (s), 124.8 (d), 125.3 (s), 129.6 (d), 129.7 (d), 131.4 (s), 142.0 (d), 147.5 
(s), 149.6 (s), 154.9 (s), 161.9 (s); Anal. Calculated for C27H30BrN5OS (MW: 552.53) : C, 58.69; H, 
5.47; N, 12.68%. Found: C, 58.50; H, 5.35; N, 12.99%. 
3-{2-[5-Methoxy-1-(3-piperidin-1-yl-propyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (60h)  
N
CH2
N
S
N
N
CH2
CH2
HBr
H3CO
N
CH3
 
Conditions: 30 minutes at reflux. Yield: 65%, yellow solid; mp: 262-263 °C; IR: 2934 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6)  1.23-1.83 (6H, m, 3 × CH2), 2.19-2.35 (2H, m, CH2),2.78-3.14 
(4H, m, 2 × CH2), 3.40-3.46 (2H, m, CH2), 3.91 (3H, s, CH3),3.94 (3H, s, CH3), 4.36 (2H, t, J = 6.5 
Hz, CH2), 6.98 (1H, dd, J = 8.9, 2.4 Hz, H-6’), 7.29 (1H, dd, J = 7.9, 4.8 Hz, H-5’’), 7.61 (1H, d, J = 
8.9 Hz, H-7’), 7.71 (1H, s, H-2’), 7.92 (1H, d, J = 2.4 Hz, H-4’), 8.18 (1H, s, H-2’’), 8.23 (1H, s, H-
5), 8.41 (1H, dd, J = 4.8, 1.3 Hz, H-6’’), 8.79 (1H, dd, J = 7.9, 1.3 Hz, H-4’’), 9.31 (1H, bs, NH+); 
Anal. Calculated for C28H32BrN5OS (MW: 566.56) : C, 59.36; H, 5.69; N, 12.36%. Found: C, 
59.57; H, 5.82; N, 12.02%. 
General procedure for the synthesis of 1-(4-piperidin-1-yl-butyl)-1H-indole-3-carbonitriles 
(96a-d) 
Compounds 96a-d were prepared from 86a-d using the same synthetic procedure described for 
compounds 94a-d. 
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1-(4-Piperidin-1-yl-butyl)-1H-indole-3-carbonitrile (96a)  
N
CH2
CN
CH2
CH2
CH2
N
 
Yield: 95%, orange solid; mp: 46-47 °C; IR: 2219 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.31-1.50 (8H, m, 4 × CH2), 1.72-1.87 (2H, m, CH2), 2.17-2.24 (6H, m, 3 × CH2), 4.28 (2H, t, J = 
7.0 Hz, CH2), 7.24-7.39 (2H, m, H-5 and H-6), 7.63-7.73 (2H, m, H-4 and H-7), 8.32 (1H, s, H-2); 
13C NMR (50 MHz, DMSO-d6)  23.2 (t), 24.0 (t), 25.6 (2 × t), 27.3 (t), 46.2 (t), 54.0 (2 × t), 57.7 
(t), 83.3 (s), 111.5 (d), 115.9 (s), 118.6 (d), 121.8 (d), 123.2 (d), 127.1 (s), 125.0 (s), 136.7 (d); 
Anal. Calculated for C18H23N3 (MW: 281.40) : C, 76.83; H, 8.24; N, 14.93%. Found: C, 76.52; H, 
8.38; N, 15.10%. 
5-Bromo-1-(4-piperidin-1-yl-butyl)-1H-indole-3-carbonitrile (96b)  
N
CH2
CN
CH2
CH2
CH2
N
Br
 
Yield: 96%, white solid; mp: 85-86 °C; IR: 2222 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.28-1.43 (8H, m, 4 × CH2), 1.69-1.83 (2H, m, CH2), 2.15-2.22 (6H, m, 3 × CH2), 4.27 (2H, t, J = 
7.0 Hz, CH2), 7.47 (1H, d, J = 8.8 Hz, H-6), 7.72 (1H, d, J = 8.8 Hz, H-7), 7.81 (1H, d, J = 1.8 Hz, 
H-4), 8.39 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  23.3 (t), 24.0 (t), 25.2 (2 × t), 27.2 (t), 
46.5 (t), 54.0 (2 × t), 57.7 (t), 82.8 (s), 113.9 (d), 114.8 (s), 115.2 (s), 120.8 (d), 125.9 (d), 128.6 (s), 
133.9 (s), 138.1 (d); Anal. Calculated for C18H22BrN3 (MW: 360.29) : C, 60.00; H, 6.15; N, 
11.66%. Found: C, 60.22; H, 5.83; N, 11.76%. 
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5-Fluoro-1-(4-piperidin-1-yl-butyl)-1H-indole-3-carbonitrile (96c)  
N
CH2
CN
CH2
CH2
CH2
N
F
 
Yield: 82%, yellow oil; IR: 2221 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.38-1.50 (8H, m, 4 
× CH2), 1.71-1.86 (2H, m, CH2), 2.21-2.40 (6H, m, 3 × CH2), 4.27 (2H, t, J = 7.0 Hz, CH2), 7.22 
(1H, td, J = 11.7, 9.3, 2.5 Hz, H-6),7.45 (1H, dd, J = 9.1, 2.5 Hz, H-7), 7.74-7.7.81 (1H, m, H-4), 
8.41 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  23.7 (t), 24.4 (t), 25.0 (2 × t), 27.0 (t), 46.4 (t), 
53.4 (2 × t), 57.6 (t), 83.5 (d, JC7a-F = 4.6 Hz), 104.0 (d, JC4-F = 24.9 Hz), 111.8 (d, JC6-F = 26.1 Hz), 
113.2 (d, JC7-F = 9.9 Hz), 115.6 (s), 127.6 (d, JC3a-F = 10.8 Hz), 131.8 (s), 138.4 (d), 158.5 (d, JC5-F = 
233.0 Hz); Anal. Calculated for C18H22FN3 (MW: 299.39) : C, 72.21; H, 7.41; N, 14.04%. Found: 
C, 72.08; H, 7.23; N, 14.35%. 
5-Methoxy-1-(4-piperidin-1-yl-butyl)-1H-indole-3-carbonitrile (96d)  
N
CH2
CN
CH2
CH2
CH2
N
H3CO
 
Yield: 96%, yellow oil; IR: 2216 (CN) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.28-1.47 (8H, m, 4 
× CH2), 1.69-1.83 (2H, m, CH2), 2.17-2.24 (6H, m, 3 × CH2), 3.82 (3H, s, CH3), 4.22 (2H, t, J = 7.0 
Hz, CH2), 6.95 (1H, dd, J = 9.0, 2.4 Hz, H-6), 7.09 (1H, d, J = 2.4 Hz, H-4), 7.61 (1H, d, J = 9.0 Hz, 
H-7), 8.24 (1H, s, H-2); 13C NMR (50 MHz, DMSO-d6)  23.2 (t), 24.0 (t), 25.4 (2 × t), 27.3 (t), 
46.4 (t), 54.0 (2 × t), 55.4 (q), 57.6 (t), 82.7 (s), 100.1 (d), 112.6 (d), 113.7 (d), 116.2 (s), 127.8 (s), 
129.9 (s), 136.6 (d), 155.4 (s); Anal. Calculated for C19H25N3O (MW: 311.42) : C, 73.28; H, 8.09; 
N, 13.49%. Found: C, 73.52; H, 8.21; N, 13.13%. 
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General procedure for the synthesis of 1-(4-piperidin-1-yl-butyl)-1H-indole-3- 
carbothioamides (95a-d) 
Compounds 95a-d were prepared from 96a-d using the same synthetic procedure described for 
compounds 75a-d.  
1-(4-Piperidin-1-yl-butyl)-1H-indole-3-carbothioamide (95a)  
N
CH2
CH2
CH2
CH2
N
S
NH2
 
Yield: 70%, yellow solid; mp: 100-101°C; IR: 1522 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  
1.38-1.45 (8H, m, 4 × CH2), 1.71-1.82 (2H, m, CH2), 2.24-2.30 (6H, m, 3 × CH2), 4.22 (2H, t, J = 
6.9 Hz, CH2), 7.14-7.26 (2H, m, H-5 and H-6), 7.57 (1H, dd, J = 6.9, 1.8 Hz, H-7), 8.15 (1H, s, H-
2), 8.61 (1H, dd, J = 6.9, 1.8 Hz, H-4), 8.82 (1H, s, SH), 9.00 (1H, s, NH); 13C NMR (50 MHz, 
DMSO-d6)  23.3 (t), 24.0 (t), 25.3 (2 × t), 27.3 (t), 45.8 (t), 53.8 (2 × t), 57.6 (t), 110.5 (d), 115.4 
(s), 121.0 (d), 121.9 (d), 122.1 (d), 126.1 (s), 131.4 (d), 136.6 (s), 193.0 (s); Anal. Calculated for 
C18H25N3S (MW: 315.48) : C, 68.53; H, 7.99; N, 13.32%. Found: C, 68.36; H, 7.84; N, 13.64%.
5-Bromo-1-(4-piperidin-1-yl-butyl)-1H-indole-3-carbothioamide (95b)  
N
CH2
CH2
CH2
CH2
N
S
NH2Br
 
Yield: 74%, yellow oil; IR: 1521 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.37-1.47 (8H, m, 4 
× CH2), 1.70-1.84 (2H, m, CH2), 2.29-2.31 (6H, m, 3 × CH2), 4.21 (2H, t, J = 6.8 Hz, CH2), 7.36 
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(1H, dd, J = 8.8, 1.9 Hz, H-6), 7.58 (1H, d, J = 8.8 Hz, H-7), 8.21 (1H, s, H-2), 8.90 (1H, d, J = 1.9 
Hz, H-4), 8.96 (1H, s, SH), 9.08 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  23.1 (t), 23.9 (t), 
25.3 (2 × t), 27.2 (t), 46.0 (t), 53.7 (2 × t), 57.5 (t), 112.7 (d),114.1 (s), 114.6 (s), 124.2 (d), 124.6 
(d), 128.2 (s), 131.8 (d), 135.4 (s), 192.4 (s); Anal. Calculated for C18H24BrN3S (MW: 394.37) : C, 
54.82; H, 6.13; N, 10.65%. Found: C, 54.68; H, 5.94; N, 10.98%. 
5-Fluoro-1-(4-piperidin-1-yl-butyl)-1H-indole-3-carbothioamide (95c)  
N
CH2
CH2
CH2
CH2
N
S
NH2F
 
Yield: 75%, yellow oil; IR: 1521 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.39-1.47 (8H, m, 4 
× CH2), 1.75-1.82 (2H, m, CH2), 2.25-2.34 (6H, m, 3 × CH2), 4.22 (2H, t, J = 6.8 Hz, CH2), 7.08 
(1H, td, J = 11.1, 9.0, 2.6 Hz, H-6), 7.57-7.64 (1H, m, H-7), 8.26 (1H, s, H-2), 8.46 (1H, dd, J = 
11.1, 2.6 Hz, H-4), 8.91 (1H, s, SH), 9.01 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  23.0 (t), 
23.7 (t), 25.1 (2 × t), 27.1 (t), 46.0 (t), 53.6 (2 × t), 57.3 (t), 106.9 (d, JC4-F = 25.6 Hz), 110.2 (d, JC6-F 
= 26.3 Hz), 111.8 (d, JC7-F = 9.9 Hz), 115.0 (d, JC7a-F = 4.7 Hz), 127.1 (d, JC3a-F = 11.1 Hz), 132.4 
(d), 133.3 (s), 158.1 (d, JC5-F = 233.3 Hz), 192.6 (s); Anal. Calculated for C18H24FN3S (MW: 
333.47) : C, 64.83; H, 7.25; N, 12.60%. Found: C, 64.57; H, 7.14; N, 12.97%. 
5-Methoxy-1-(4-piperidin-1-yl-butyl)-1H-indole-3-carbothioamide (95d)  
N
CH2
CH2
CH2
CH2
N
S
NH2H3CO
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Yield: 56%, yellow oil; IR: 1520 (CS) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.38-1.48 (8H, m, 4 
× CH2), 1.69-1.83 (2H, m, CH2), 2.29-2.32 (6H, m, 3 × CH2), 3.79 (3H, s, CH3),4.17 (2H, t, J = 6.8 
Hz, CH2), 6.86 (1H, dd, J = 8.9, 2.4 Hz, H-6), 7.47 (1H, d, J = 8.9 Hz, H-7),8.13 (1H, s, H-2), 8.21 
(1H, d, J = 2.4 Hz, H-4), 8.78 (1H, s, SH), 8.93 (1H, s, NH); 13C NMR (50 MHz, DMSO-d6)  23.1 
(t), 23.9 (t),25.2 (2 × t), 27.3 (t), 45.9 (t), 53.7 (2 × t), 55.3 (q), 57.5 (t), 103.9 (d), 111.3 (d), 111.8 
(d), 114.8 (s), 126.9 (s), 131.7 (d), 154.9 (s × 2), 192.8 (s); Anal. Calculated for C19H27N3OS (MW: 
345.50) : C, 66.05; H, 7.88; N, 12.16%. Found: C, 65.84; H, 8.28; N, 11.97%. 
General procedure for the synthesis 3-{2-[1-(4-piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-
yl}-1H-pyrrolo[2,3-b]pyridine hydrobromides (61a-h) 
Compounds 61a-h were prepared from 95a-d using the same synthetic procedure described for 
compounds 69a,b. 
3-{2-[1-(4-Piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-b]pyridine 
hydrobromide (61a)  
N
CH2
CH2
CH2
CH2
N
N
S
N
H
N
HBr
 
Conditions: 30 minutes at reflux. Yield: 74%, light yellow solid; mp: 275-276 °C; IR: 3132 (NH), 
2971 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.32-1.88 (10H, m, 5 × CH2), 2.76-3.12 (4H, 
m, 2 × CH2), 3.35-3.40 (2H, m, CH2), 4.36 (2H, t, J = 6.1 Hz, CH2), 7.21-7.34 (3H, m, H-5’, H-5’’ 
and H-6’), 7.65-7.74 (2H, m, H-2’ and H-7’), 8.12 (1H, d, J = 2.5 Hz, H-2’’), 8.30-8.38 (3H, m, H-
4’, H-5 and H-6’’), 8.65 (1H, d, J = 6.9 Hz, H-4’’), 9.25 (1H, bs, NH+), 12.00 (1H, bs, NH); 13C 
NMR (50 MHz, DMSO-d6)  20.6 (t), 21.2 (t), 22.4 (2 × t), 26.8 (t), 45.2 (t), 52.0 (2 × t), 55.2 (t), 
106.8 (d), 110.0 (2 × s), 110.8 (d), 116.1 (d), 117.1 (s), 120.6 (d), 121.1 (d), 122.5 (d), 124.7 (d + s), 
128.5 (d), 129.6 (d), 136.3 (s), 143.0 (d), 148.7 (s), 149.8 (s), 161.6 (s); Anal. Calculated for 
C27H30BrN5S (MW: 536.53) : C, 60.44; H, 5.64; N, 13.05%. Found: C, 60.10; H, 5.79; N, 13.24%. 
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1-Methyl-3-{2-[1-(4-piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (61b)  
N
CH2
CH2
CH2
CH2
N
N
S
N
N
HBr
CH3
 
Conditions: 30 minutes at reflux. Yield: 57%, yellow solid; mp: 179 °C; IR: 2951 (NH+) cm-1; 1H 
NMR (200 MHz, DMSO-d6)  1.32-1.88 (10H, m, 5 × CH2), 2.81-3.08 (4H, m, 2 × CH2), 3.63-
3.66 (2H, m, CH2), 3.94 (3H, s, CH3), 4.36 (2H, t, J = 5.9 Hz, CH2), 7.24-7.37 (3H, m, H-5’, H-5’’ 
and H-6’), 7.66-7.73 (2H, m, H-2’ and H-4’), 8.21 (1H, s, H-2’’), 8.30 (1H, s, H-5), 8.37-8.41 (2H, 
m, H-6’’ and H-7’), 8.64 (1H, d, J = 6.8 Hz, H-4’’), 9.22 (1H, bs, NH+); 13C NMR (50 MHz, 
DMSO-d6)  20.6 (t), 21.2 (t), 22.4 (2 × t), 26.8 (t), 31.0 (q), 45.2 (t), 52.0 (2 × t), 55.2 (t), 106. 8 
(d), 108.9 (s), 109.9 (s), 110.8 (d), 116.2 (d), 117.4 (s), 120.7 (d), 121.1 (d), 122.5 (d), 124.7 (s), 
128.8 (2 × d), 129.6 (d), 136.3 (s), 142.8 (d), 147.5 (s), 149.4 (s), 161.7 (s); Anal. Calculated for 
C28H32BrN5S (MW: 550.56) : C, 61.08; H, 5.86; N, 12.72%. Found: C, 61.35; H, 5.72; N, 12.59%. 
3-{2-[5-Bromo-1-(4-piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (61c)  
N
CH2
CH2
CH2
CH2
N
N
S
N
H
N
HBr
Br
 
Conditions: 30 minutes at reflux. Yield: 65%, light yellow solid; mp: 259-260 °C; IR: 3194 (NH), 
2971 (NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.38-1.86 (10H, m, 5 × CH2), 2.76-3.06 (4H, 
m, 2 × CH2), 3.35-3.41 (2H, m, CH2), 4.35 (2H, t, J = 6.0 Hz, CH2), 7.24 (1H, dd, J = 7.9, 4.7 Hz, 
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H-5’’), 7.45 (1H, dd, J = 8.8, 1.8 Hz, H-6’), 7.70 (1H, d, J = 8.8 Hz, H-7’), 7.76 (1H, s, H-2’), 8.11 
(1H, d, J = 2.4 Hz, H-2’’), 8.34 (1H, dd, J = 4.7, 1.8 Hz, H-6’’), 8.37 (1H, s, H-5), 8.57 (1H, d, J = 
1.8 Hz, H-4’), 8.66 (1H, d, J = 7.9 Hz, H-4’’), 9.28 (1H, bs, NH+), 12.03 (1H, bs, NH); 13C NMR 
(50 MHz, DMSO-d6)  20.5 (t), 21.2 (t), 22.4 (2 × t), 26.8 (t), 45.4 (t), 52.0 (2 × t), 55.2 (t), 107.1 
(d), 109.5 (s), 109.9 (s), 113.0 (d), 113.7 (s), 116.1 (d), 117.2 (s), 123.0 (d), 124 7 (d), 125.0 (d), 
126.4 (s), 128.7 (d), 130.9 (d), 135.1 (s), 142.9 (d), 148.4 (s), 149.8 (s), 161.1 (s); Anal. Calculated 
for C27H29Br2N5S (MW: 615.43) : C, 52.69; H, 4.75; N, 11.38%. Found: C, 52.53; H, 5.02; N, 
11.27%. 
3-{2-[5-Bromo-1-(4-piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (61d)  
N
CH2
CH2
CH2
CH2
N
N
S
N
N
HBr
Br
CH3
 
Conditions: 30 minutes at reflux. Yield: 83%, yellow solid; mp: 254-255 °C; IR: 2957 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6)  1.29-1.87 (10H, m, 5 × CH2), 2.76-3.19 (4H, m, 2 × CH2), 3.38-
3.41 (2H, m, CH2), 3.94 (3H, s, CH3), 4.36 (2H, t, J = 6.5 Hz, CH2), 7.26 (1H, dd, J = 7.9, 4.7 Hz, 
H-5’’), 7.47 (1H, dd, J = 8.7, 1.9 Hz, H-6’), 7.68-7.74 (2H, m, H-2’ and H-7’), 8.15 (1H, s, H-2’’), 
8.34-8.39 (2H, m, H-5 and H-6’’), 8.55 (1H, d, J = 1.9 Hz, H-4’), 8.64 (1H, dd, J = 7.9, 1,4 Hz, H-
4’’), 9.02 (1H, bs, NH+); 13C NMR (50 MHz, DMSO-d6)  20.5 (t), 21.2 (t), 22.4 (2 × t), 26.8 (t), 
31.0 (q), 45.4 (t), 52.0 (2 × t), 55.2 (t), 107.2 (d), 108.8 (s), 109.5 (s), 113.0 (d), 113.8 (s), 116.1 (d), 
117.4 (s), 122.9 (d), 125.0 (d), 126.3 (s), 128.5 (d), 128.7 (d), 130.9 (d), 135.1 (s), 142.9 (d), 147.5 
(s), 149.6 (s), 161.2 (s); Anal. Calculated for C28H31Br2N5S (MW: 629.45) : C, 53.43; H, 4.96; N, 
11.13%. Found: C, 53.73; H, 4.86; N, 10.93%. 
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3-{2-[5-Fluoro-1-(4-piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (61e)  
N
CH2
CH2
CH2
CH2
N
N
S
N
H
N
HBr
F
 
Conditions: 30 minutes at reflux. Yield: 70%, yellow solid; mp: 240-241 °C; IR: 3132 (NH), 2970 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.32-1.87 (10H, m, 5 × CH2), 2.80-3.07 (4H, m, 2 × 
CH2), 3.35-3.41 (2H, m, CH2), 4.35 (2H, t, J = 6.3 Hz, CH2), 7.14-7.27 (2H, m, H5’’ and H-6’), 
7.69-7.74 (2H, m, H-2’ and H-7’), 8.07 (1H, dd, J = 9.9, 2.4 Hz, H-4’),8.14 (1H, d, J = 2.3 Hz, H-
2’’), 8.32-8.38 (2H, m, H-5 and H-6’’), 8.63 (1H, d, J = 7.1 Hz, H-4’’), 9.37 (1H, bs, NH+), 12.03 
(1H, bs, NH); 13C NMR (50 MHz, DMSO-d6)  20.5 (t), 21.3 (t), 22.3 (2 × t), 26.8 (t), 45.5 (t), 
51.9 (2 × t), 55.2 (t), 105.5 (d, JC4’-F = 24.4 Hz), 106.9 (d), 109.9 (s), 110.0 (d, JC7a-F = 4.5 Hz), 
110.7 (d, JC6’-F = 26.1 Hz), 112.2 (d, JC7’-F = 9.9 Hz), 116.1 (d), 117.2 (s), 124.9 (d), 125.0 (d, JC3a-F 
= 10.5 Hz), 128.6 (d), 131.3 (d), 133.0 (s), 142.9 (d), 148.5 (s), 149.8 (s), 158.1 (d, JC5’-F = 234.2 
Hz), 161.3 (s); Anal. Calculated for C27H29BrFN5S (MW: 554.52) : C, 58.48; H, 5.27; N, 12.63%. 
Found: C, 58.21; H, 5.39; N, 12.78%. 
3-{2-[5-Fluoro-1-(4-piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (61f)  
N
CH2
CH2
CH2
CH2
N
N
S
N
N
HBr
F
CH3
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Conditions: 30 minutes at reflux. Yield: 57%, yellow solid; mp: 194-195 °C; IR: 2971 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6)  1.39-1.87 (10H, m, 5 × CH2), 2.80-3.07 (4H, m, 2 × CH2), 3.49-
3.52 (2H, m, CH2), 3.94 (3H, s, CH3),4.35 (2H, t, J = 6.5 Hz, CH2), 7.14-7.30 (2H, m, H5’’ and H-
6’), 7.69-7.75 (2H, m, H-2’ and H-7’), 8.09 (1H, dd, J = 9.8, 2.5 Hz, H-4’), 8.21 (1H, s, H-2’’), 
8.36-8.38 (2H, m, H-5 and H-6’’), 8.61 (1H, d, J = 7.9 Hz, H-4’’), 9.30 (1H, bs, NH+); 13C NMR 
(50 MHz, DMSO-d6)  20.5 (t), 21.3 (t), 22.3 (2 × t), 26.8 (t), 31.1 (q), 45.5 (t), 51.9 (2 × t), 55.2 
(t), 105.6 (d, JC4’-F = 24.7 Hz), 107.0 (d), 108.9 (s), 109.9 (d, JC7a-F = 4.4 Hz), 110.7 (d, JC6’-F = 26.1 
Hz), 112.2 (d, JC7’-F = 9.6 Hz), 116.2 (d), 117.4 (s), 125.0 (d, JC3a-F = 11.0 Hz), 128.8 (d), 128.9 (d), 
131.4 (d), 133.0 (s), 142.6 (d), 147.4 (s), 149.4 (s), 158.2 (d, JC5’-F = 234.6 Hz), 161.5 (s); Anal. 
Calculated for C28H31BrFN5S (MW: 568.55) : C, 59.15; H, 5.50; N, 12.32%. Found: C, 59.50; H, 
5.28; N, 12.19%. 
3-{2-[5-Methoxy-1-(4-piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1H-pyrrolo[2,3-
b]pyridine hydrobromide (61g)  
N
CH2
CH2
CH2
CH2
N
N
S
N
H
N
HBr
H3CO
 
Conditions: 30 minutes at reflux. Yield: 74%, yellow solid; mp: 247-248 °C; IR: 3137 (NH), 2971 
(NH+) cm-1; 1H NMR (200 MHz, DMSO-d6)  1.32-1.86 (10H, m, 5 × CH2), 2.76-3.07 (4H, m, 2 × 
CH2), 3.35-3.39 (2H, m, CH2),3.91 (3H, s, CH3),4.31 (2H, t, J = 6.0 Hz, CH2), 6.95 (1H, dd, J = 
8.9, 2.4 Hz, H-6’), 7.26 (1H, dd, J = 7.9, 4.8 Hz, H-5’’), 7.58 (1H, d, J = 8.9 Hz, H-7’), 7.73 (1H, s, 
H-2’), 7.93 (1H, d, J = 2.4 Hz, H-4’), 8.15 (1H, d, J = 2.2 Hz, H-2’’), 8.24 (1H, s, H-5), 8.35 (1H, 
dd, J = 4.8, 1.1 Hz, H-6’’), 8.80 (1H, d, J = 7.9 Hz, H-4’’), 9.34 (1H, bs, NH+), 12.11 (1H, bs, NH); 
13C NMR (50 MHz, DMSO-d6)  20.5 (t), 21.3 (t), 22.3 (2 × t), 26.8 (t), 45.4 (t), 51.9 (2 × t), 55.2 
(t + q), 102.1 (d), 106.6 (d), 109.6 (s), 110.2 (s), 111.7 (d), 112.6 (d), 116.0 (d), 117.8 (s), 124.8 (d), 
125.3 (s), 129.6 (d), 129.9 (d), 131.4 (s), 142.2 (d), 147.7 (s), 149.6 (s), 154.9 (s), 162.0 (s); Anal. 
Calculated for C28H32BrN5OS (MW: 566.56) : C, 59.36; H, 5.69; N, 12.36%. Found: C, 59.12; H, 
5.56; N, 12.73%.
145 
 
3-{2-[5-Methoxy-1-(4-piperidin-1-yl-butyl)-1H-indol-3-yl]-thiazol-4-yl}-1-methyl-1H-
pyrrolo[2,3-b]pyridine hydrobromide (61h)  
N
CH2
CH2
CH2
CH2
N
N
S
N
N
HBr
H3CO
CH3
 
Conditions: 30 minutes at reflux. Yield: 76%, yellow solid; mp: 253-254 °C; IR: 2953 (NH+) cm-1; 
1H NMR (200 MHz, DMSO-d6)  1.32-1.86 (10H, m, 5 × CH2), 2.75-3.12 (4H, m, 2 × CH2), 3.43-
3.46 (2H, m, CH2),3.92 (3H, s, CH3), 3.93 (3H, s, CH3),4.32 (2H, t, J = 6.6 Hz, CH2), 6.97 (1H, 
dd, J = 9.0, 2.5 Hz, H-6’), 7.24 (1H, dd, J = 7.9, 4.7 Hz, H-5’’), 7.59 (1H, d, J = 9.0 Hz, H-7’), 7.68 
(1H, s, H-2’), 7.92 (1H, d, J = 2.5 Hz, H-4’), 8.15 (1H, s, H-2’’), 8.21 (1H, s, H-5), 8.37 (1H, dd, J = 
4.7, 1.4 Hz, H-6’’), 8.72 (1H, dd, J = 7.9, 1.5 Hz, H-4’’), 9.05 (1H, bs, NH+); 13C NMR (50 MHz, 
DMSO-d6)  20.6 (t), 21.2 (t), 22.4 (2 × t), 26.8 (t), 31.0 (q), 45.4 (t), 52.0 (2 × t), 55.2 (t), 55.3 (q), 
102.3 (d), 106.4 (d), 108.9 (s), 109.6 (s), 111.7 (d), 112.5 (d), 116.0 (d), 117.5 (s), 125.3 (s), 128.3 
(d), 129.0 (d), 129.9 (d), 131.4 (s), 142.8 (d), 147.5 (s), 149.5 (s), 154.9 (s), 162.0 (s); Anal. 
Calculated for C29H34BrN5OS (MW: 580.58) : C, 59.99; H, 5.90; N, 12.06%. Found: C, 59.67; H, 
6.06; N, 12.22%. 
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DOCKING STUDIES 
Protein Preparation 
The Uniprot database (http://www.uniprot.org) was used to collect available GSK-3β structures, 
PDB files were downloaded from the RCSB Protein Data Bank (http://www.rcsb.org). 
Schrödinger's Protein Preparation Wizard of the Prime module was used for protein structure 
refinements (Prime, 4.1 version, Schrödinger, LLC, New York, NY, 2015). In the preprocess phase, 
hydrogen atoms were added and bond orders were assigned, missing loops were filled (if needed) 
according to the amino acid sequence. In the refinement phase the hydrogen bond (H-bond) 
network was restored using the H-bond assignment option, which was followed by a restrained 
minimization (converged heavy atoms to RMSD: 0.3 Å) with OPLS_2005 force field. 
Schrödinger’s Maestro was used to visualize interactions between binding site and inhibitors 
(Maestro, 10.3 version, Schrödinger, LLC, New York, NY, 2015). 
Ligand preparation  
Structures were drawn manually, 2D structures were optimized with Schrödinger’s LigPrep module 
with standard settings using the OPLS_2005 forcefield (LigPrep, 3.5 version, Schrödinger, LLC, 
New York, NY, 2015). For compounds 56a-h, 57a-h, 58a-h, 59a-h, 60a-h, 61a-h only their 
protonated forms were used.  
Docking studies 
All docking studies were performed with Schrödinger’s Glide software package (Glide, 6.8 version, 
Schrödinger, LLC, New York, NY, 2015). In the grid generation phase, the position of the grid box 
was determined by the co-crystallized ligand: the center of the docking box was fixed on the center 
of the inhibitor. The size of the boxes was 20x20x20 Å (the inner box was 10x10x10 Å). Standard 
settings (Van der Waals Radius and Charge Scaling) were used. Flexible docking on XP (extra 
precision) level was used, which in terms of glide means that the enzyme was rigid during the 
conformation of the ligands evaluation. The complementarity of ligand-receptor interactions was 
examined using the empirical ChemScore function. The active comformer (‘pose’) of each ligand 
with the highest score was selected as a result. In case of the re-dockings, scores were also 
calculated for the co-crystallized poses (score-in-place-protocol). 


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